var title_f42_38_43616="Large plaque parapsoriasis 2";
var content_f42_38_43616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Irregularly shaped, erythematous patches, some of which larger than 10 cm in diameter, are characteristic of large plaque parapsoriasis.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43616=[""].join("\n");
var outline_f42_38_43616=null;
var title_f42_38_43617="Fluorescein angiogram";
var content_f42_38_43617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Fluorescein angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Color fundus photograph and B) fluorescein angiogram showing early detection of significant neovascularization elsewhere (NVE) by angiography that is barely visible in the color photograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43617=[""].join("\n");
var outline_f42_38_43617=null;
var title_f42_38_43618="Foot care in diabetes mellitus";
var content_f42_38_43618=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?42/38/43618/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43618/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?42/38/43618/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43618/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?42/38/43618/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43618/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/38/43618?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Foot problems are a common complication in people with diabetes. Fortunately, most of these complications can be prevented with careful foot care. If complications do occur, daily attention will ensure that they are detected before they become serious. It may take time and effort to build good foot care habits, but self-care is essential. In fact, when it comes to foot care, the patient is a vital member of the medical team.",
"    </p>",
"    <p>",
"     This topic review presents a general overview of diabetic foot complications and guidelines for good foot care.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DIABETES AND FOOT COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Diabetes can lead to many different types of foot complications, including athlete's foot (a fungal infection), calluses, bunions and other foot deformities, or ulcers that can range from a surface wound to a deep infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Poor circulation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Longstanding high blood sugar can damage blood vessels, decreasing blood flow to the foot. This poor circulation can weaken the skin, contribute to the formation of ulcers, and impair wound healing. Some bacteria and fungi thrive on high levels of sugar in the bloodstream, and bacterial and fungal infections can break down the skin and complicate ulcers.",
"    </p>",
"    <p>",
"     More serious complications include deep skin and bone infections. Gangrene (death and decay of tissue) is a very serious complication that may include infection; widespread gangrene may require foot amputation. Approximately 5 percent of men and women with diabetes eventually require amputation of a toe or foot. This tragic consequence can be prevented in most patients by managing blood sugar levels and daily foot care.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Nerve damage (neuropathy)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Elevated blood glucose levels over time can damage the nerves of the foot, decreasing a person's ability to notice pain and pressure. Without these sensations, it is easy to develop callused pressure spots and accidentally injure the skin, soft tissue, bones, and joints. Over time, bone and joint damage can dramatically alter the shape of the foot. Nerve damage, also called neuropathy, can also weaken certain foot muscles, further contributing to foot deformities. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/5/21587?source=see_link\">",
"      \"Patient information: Diabetic neuropathy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Patients who have had a previous foot ulcer are more likely to have future foot complications. Nerve damage, poor circulation, and chronically high blood sugar levels also increase the likelihood of foot complications.",
"    </p>",
"    <p>",
"     It is important to wear shoes that fit well. Shoes that are too tight can cause pressure ulcers. Going barefoot, even in the home, should be avoided as this increases the risk of injury to the foot.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      FOOT EXAMINATION",
"     </span>",
"    </p>",
"    <p>",
"     People with type 1 diabetes for at least five years should have their feet examined at least once a year. People with type 2 diabetes should have their feet examined once per year.",
"    </p>",
"    <p>",
"     During a foot exam, a healthcare provider checks for poor circulation, nerve damage, skin changes, and deformities. Patients should mention any problems they have noticed in their feet. An exam may reveal decreased or absent reflexes or decreased ability to sense pressure, vibration, pin pricks, and changes in temperature.",
"    </p>",
"    <p>",
"     Special devices, including a monofilament or tuning fork, can help determine the extent of nerve damage. A monofilament is a very thin, flexible thread that is used to determine if a patient can sense pressure in various areas of the foot. A tuning fork is used to determine if a patient can sense vibration in various areas, especially the foot and toe joints.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Possible foot problems",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Poor circulation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some simple clues can point to circulatory problems. Poor pulses, cold feet, thin or blue skin, and lack of hair signal that the feet are not getting enough blood.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Nerve damage",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nerve damage may lead to unusual sensations in the feet and legs, including pain, burning, numbness, tingling, and fatigue. Patients should describe these symptoms if they occur, including the timing, if the feet, ankles, or calves are affected, and what measures relieve the symptoms.",
"    </p>",
"    <p>",
"     Nerve damage may cause no symptoms as the foot and leg slowly lose sensation and become numb. This can be very dangerous because the person may be unaware that they have improperly fit shoes, a rock or other irritant in a shoe, or other problems that could cause damage. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/5/21587?source=see_link\">",
"      \"Patient information: Diabetic neuropathy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Skin changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Excessive skin dryness, scaling, and cracking may indicate that circulation to the skin is compromised. Other skin changes may include healed or new ulcers, calluses, and broken skin between the toes (",
"     <a class=\"graphic graphic_picture graphicRef64087 \" href=\"mobipreview.htm?35/29/36319\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Deformities",
"     </span>",
"     &nbsp;&mdash;&nbsp;The structure and appearance of the feet and foot joints can indicate diabetic complications. Nerve damage can lead to joint and other foot deformities. The toes may have a peculiar \"claw toe\" appearance, and the foot arch and other bones may appear collapsed. This destruction of the bones and joints is called Charcot arthropathy (",
"     <a class=\"graphic graphic_picture graphicRef50500 \" href=\"mobipreview.htm?26/33/27167\">",
"      picture 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      PREVENTING FOOT PROBLEMS IN DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Controlling blood sugar levels can reduce the blood vessel and nerve damage that often lead to diabetic foot complications. If a foot wound or ulcer does occur, blood sugar control reduces the risk of requiring amputation. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Foot care is important, although patients should also continue to follow other general guidelines for managing diabetes.",
"    </p>",
"    <p>",
"     The following strategies can reduce the chances of developing foot problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Quit smoking",
"     </span>",
"     &nbsp;&mdash;&nbsp;Smoking can worsen heart and vascular problems and reduce circulation to the feet. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"      \"Patient information: Quitting smoking (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Avoid activities that can injure the feet",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some activities increase the risk of foot injury and are not recommended, including walking barefoot, using a heating pad or hot water bottle on the feet, and stepping into the bathtub before testing the temperature.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Use care when trimming the nails",
"     </span>",
"     &nbsp;&mdash;&nbsp;Trim the toe nails along the shape of the toe and file the nails to remove any sharp edges (",
"     <a class=\"graphic graphic_figure graphicRef80053 \" href=\"mobipreview.htm?41/51/42814\">",
"      figure 1",
"     </a>",
"     ). Never cut (or allow a manicurist to cut) the cuticles. Do not open blisters, try to free ingrown toenails, or otherwise break the skin on the feet. See a healthcare provider or podiatrist for even minor procedures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Wash and check the feet daily",
"     </span>",
"     &nbsp;&mdash;&nbsp;Use lukewarm water and mild soap to clean the feet. Gently pat your feet dry and apply a moisturizing cream or lotion.",
"    </p>",
"    <p>",
"     Check the entire surface of both feet for skin breaks, blisters, swelling, or redness, including between and underneath the toes where damage may be hidden. Use a mirror if it is difficult to see all parts of the feet or ask a family member or caregiver to help.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Choose socks and shoes carefully",
"     </span>",
"     &nbsp;&mdash;&nbsp;Select cotton socks that fit loosely, and change the socks every day. Select shoes that are snug but not tight, and break new shoes in slowly to prevent any blisters (",
"     <a class=\"graphic graphic_figure graphicRef79305 \" href=\"mobipreview.htm?24/41/25245\">",
"      figure 2",
"     </a>",
"     ). Ask about customized shoes if the feet are misshapen or have ulcers; specialized shoes can reduce the chances of developing foot ulcers in the future. Shoe inserts may also help cushion the step and decrease pressure on the soles of the feet.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Ask for foot exams",
"     </span>",
"     &nbsp;&mdash;&nbsp;Screening for foot complications should be a routine part of most medical visits, but is sometimes overlooked. Don't hesitate to ask the healthcare provider for a foot check at least once a year, and more frequently if there are foot changes.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      TREATMENT OF FOOT PROBLEMS WITH DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of foot problems depends upon the presence and severity of foot ulcers.",
"    </p>",
"    <p>",
"     Treatment of superficial ulcers (involving only the top layers of skin) usually includes cleaning the ulcer and removing dead skin and tissue (debridement) by a healthcare provider (",
"     <a class=\"graphic graphic_picture graphicRef52333 \" href=\"mobipreview.htm?24/21/24912\">",
"      picture 3",
"     </a>",
"     ). There are a number of debridement techniques available.",
"    </p>",
"    <p>",
"     If the foot is infected, antibiotics are generally prescribed. The patient (or someone in his or her household) should clean the ulcer and apply a clean dressing twice daily. The patient should keep weight off the foot ulcer as much as possible, meaning that they should not walk with the affected foot. The foot should be elevated when sitting or lying down. The ulcer should be checked by a healthcare provider at least once per week to make sure that the ulcer is improving.",
"    </p>",
"    <p>",
"     Ulcers that extend into the deeper layers of the foot, involving muscle and bone, usually require hospitalization (",
"     <a class=\"graphic graphic_picture graphicRef75848 \" href=\"mobipreview.htm?27/17/27922\">",
"      picture 4",
"     </a>",
"     ). More extensive laboratory testing and x-rays may be done, and intravenous antibiotics are often necessary. Surgery may be necessary to remove infected bone or to place a cast on the foot to take pressure off the ulcer.",
"    </p>",
"    <p>",
"     If part of the toes or foot become severely damaged, causing areas of dead tissue (gangrene), partial or complete amputation may be required. Amputation is reserved for patients who do not heal despite aggressive treatment, or whose health is threatened by the gangrene. Untreated gangrene can be life-threatening.",
"    </p>",
"    <p>",
"     Some patients with severe foot ulcers and peripheral vascular disease (poor circulation) may require a procedure to restore blood flow to the foot. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/35/14900?source=see_link\">",
"      \"Patient information: Peripheral artery disease and claudication (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      NEW TREATMENTS",
"     </span>",
"    </p>",
"    <p>",
"     Several experimental approaches are being evaluated for the treatment of diabetic foot complications. New options include synthetic wound dressings, skin grown in a laboratory, substances that stimulate healing and support the growth of infection-fighting cells, electrical stimulation, and exposure to elevated oxygen levels.",
"    </p>",
"    <p>",
"     For people with diabetes, foot complications are an ever-present risk. However, it is possible to design a plan for keeping the feet as healthy as possible. It is important to learn as much as possible about diabetic foot care and to take an active role in medical decisions and care. While routine medical exams are important, everyday foot care plays the biggest role in preventing foot complications before they start.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H211\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H254458\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/47/20208?source=see_link\">",
"      Patient information: Nerve damage caused by diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/40/22144?source=see_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/13/210?source=see_link\">",
"      Patient information: Gangrene (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/52/20292?source=see_link\">",
"      Patient information: Diabetes and infections (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H254473\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/60/6083?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/63/4083?source=see_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/1/40980?source=see_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/5/21587?source=see_link\">",
"      Patient information: Diabetic neuropathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/35/14900?source=see_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18551?source=see_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11464?source=see_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/28/37321?source=see_link\">",
"      Management of diabetic foot lesions",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Endocrine Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.endo-society.org/\">",
"      www.endo-society.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?42/38/43618/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/38/43618?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43618/abstract/1\">",
"      Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43618/abstract/2\">",
"      Mayfield JA, Reiber GE, Sanders LJ, et al. Preventive foot care in diabetes. Diabetes Care 2004; 27 Suppl 1:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43618/abstract/3\">",
"      Pham H, Armstrong DG, Harvey C, et al. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 2000; 23:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43618/abstract/4\">",
"      Litzelman DK, Marriott DJ, Vinicor F. The role of footwear in the prevention of foot lesions in patients with NIDDM. Conventional wisdom or evidence-based practice? Diabetes Care 1997; 20:156.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f42_38_43618=[""].join("\n");
var outline_f42_38_43618=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DIABETES AND FOOT COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           FOOT EXAMINATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           PREVENTING FOOT PROBLEMS IN DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           TREATMENT OF FOOT PROBLEMS WITH DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           NEW TREATMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/51/42814\" title=\"figure 1\">",
"           Trim toenails PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/41/25245\" title=\"figure 2\">",
"           Shoe shape PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/29/36319\" title=\"picture 1\">",
"           Diabetic foot ulcer 2 PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/33/27167\" title=\"picture 2\">",
"           Charcot foot PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/21/24912\" title=\"picture 3\">",
"           Diabetic foot ulcer 1 PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/17/27922\" title=\"picture 4\">",
"           Diabetic foot ulcer 3 PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f42_38_43619="Follow-up testing in histo";
var content_f42_38_43619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Follow-up to evaluate for suspected relapse in patients with disseminated histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 590px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43619=[""].join("\n");
var outline_f42_38_43619=null;
var title_f42_38_43620="Primary disorders of phagocytic function: An overview";
var content_f42_38_43620=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary disorders of phagocytic function: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43620/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43620/contributors\">",
"     Robert L Roberts, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43620/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43620/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43620/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43620/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43620/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/38/43620/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility to infection from phagocytic dysfunction ranges from mild recurrent skin infections to overwhelming, fatal systemic infection. Affected patients are more susceptible to bacterial and fungal infections, but have a normal resistance to viral infections. Most are diagnosed in infancy due to the severity of the infection or the unusual presentation of the organism, but some escape diagnosis until adulthood.",
"   </p>",
"   <p>",
"    This topic review provides a brief overview of the types of defects and typical presentation of primary phagocytic disorders. The major disorders resulting from defects of phagocytic function are also briefly discussed. (Detailed discussions of these disorders are presented separately. See links in respective sections below.)",
"   </p>",
"   <p>",
"    A detailed discussion of methods used in the evaluation of immune system function is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phagocytic disorders may be divided into extrinsic and intrinsic defects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extrinsic defects include opsonic abnormalities secondary to deficiencies of antibody and complement factors. Extrinsic factors may lead to neutropenia by suppression of granulocyte production, or cause a decrease in the number of circulating neutrophils via leukocyte autoantibodies or isoantibodies directed against neutrophil antigens.",
"     </li>",
"     <li>",
"      Intrinsic disorders of granulocytes may be divided into those that result from defects in granulocyte development or exit into the circulation (primary neutropenias), granulocyte killing ability, or chemotaxis (cell movement). Intrinsic disorders of phagocytic killing ability include chronic granulomatous disease, glycogen storage disease type Ib, Chediak-Higashi syndrome, and specific granule deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43620/abstract/1\">",
"       1",
"      </a>",
"      ]. Intrinsic disorders of chemotaxis include hyper-IgE syndrome, leukocyte adhesion defects, Shwachman-Diamond syndrome, and syndromes with periodontitis. Defects of phagocytic movement may also occur secondary to diabetes mellitus, metabolic storage disease, malnutrition, immaturity, and burns.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18781392\">",
"    <span class=\"h1\">",
"     TYPICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary phagocytic deficiencies characteristically lead to recurrent and severe fungal (eg, Candida and Aspergillus) and bacterial (eg, Staphylococcus aureus, Pseudomonas aeruginosa, Nocardia asteroides, Salmonella typhi) infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43620/abstract/2\">",
"     2",
"    </a>",
"    ]. Response to nontuberculous mycobacteria may also be abnormal, particularly in patients with chronic granulomatous disease. The most common sites of infection are the respiratory tract and skin. Tissue and organ abscesses also occur. Other frequent manifestations include abnormal wound healing,",
"    <span class=\"nowrap\">",
"     dermatitis/eczema,",
"    </span>",
"    and stomatitis. Many patients have growth failure. Other findings are unique to each disorder, including granuloma formation with chronic granulomatous disease, heart defects and neurologic deficits with certain mutations causing severe congenital neutropenia, and oculocutaneous albinism with Chediak-Higashi syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEUTROPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia (eg, circulating neutrophils &lt;1500",
"    <span class=\"nowrap\">",
"     cells/mm)",
"    </span>",
"    is associated with a number of primary disorders. These include infantile agranulocytosis (Kostmann's syndrome), cyclic neutropenia, glycogen storage disease type Ib, and myelokathexis or failure of release of neutrophils from the marrow. Neutropenia is also common in several primary immunodeficiencies, including X-linked hyper-IgM, X-linked agammaglobulinemia, and reticular dysgenesis. Acquired autoimmune and isoimmune neutropenias result from antibodies directed against neutrophils. Increased neutrophil destruction is also common in chronic splenomegaly from any cause and certain autoimmune diseases (eg, Felty's syndrome, lupus erythematosus).",
"   </p>",
"   <p>",
"    Further discussion of neutropenia appears separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24614?source=see_link\">",
"     \"Laboratory evaluation of neutropenia and neutrophil dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42966?source=see_link\">",
"     \"Cyclic neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42520?source=see_link\">",
"     \"Immune neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10473?source=see_link\">",
"     \"Infectious causes of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHRONIC GRANULOMATOUS DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic granulomatous disease (CGD) is a genetically heterogeneous condition, with both X-linked and autosomal recessive forms. It is characterized by recurrent life-threatening bacterial and fungal infections and granulomata formation. CGD is caused by defects in phagocyte NADPH oxidase (phox). These genetic defects result in the inability of phagocytes (neutrophils, monocytes, and macrophages) to destroy microbial organisms once phagocytosed. The diagnosis is made by neutrophil function testing and mutation analysis. The cornerstones of CGD management are early diagnosis of infections, antimicrobial and immunomodulatory prophylaxis, and aggressive management of infectious complications. Survival of patients with CGD has dramatically improved, with many now living well into middle age.",
"   </p>",
"   <p>",
"    CGD is discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10826?source=see_link\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11465?source=see_link\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LEUKOCYTE ADHESION DEFICIENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocyte adhesion deficiency (LAD) type I results from an inability of neutrophils to leave the circulation in response to infection due to abnormal leukocyte integrins. Patients may present with delayed separation of the umbilical cord, recurrent bacterial sinopulmonary and skin infections, and poor wound healing. Circulating neutrophils may reach levels as high as",
"    <span class=\"nowrap\">",
"     100,000/mm3",
"    </span>",
"    during infections.",
"   </p>",
"   <p>",
"    LAD type II results from an inability to appropriately glycosylate another leukocyte adhesion molecule. Patients with LAD type II have small stature, abnormal facies, and severe cognitive impairment. Recurrent bacterial sinopulmonary and skin infections are characteristic, although less severe than that observed with type 1 disease.",
"   </p>",
"   <p>",
"    A few other LAD deficiencies have also been identified. These disorders are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22953?source=see_link\">",
"     \"Leukocyte adhesion deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HYPERIMMUNOGLOBULIN E SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyper-IgE syndrome (HIE, Job's syndrome) is characterized by recurrent infections (principally bacterial), dermatitis, and elevated serum IgE (generally &gt;2000",
"    <span class=\"nowrap\">",
"     IU/mL).",
"    </span>",
"    HIE is often caused by dominant-negative mutations in the DNA-binding domain of STAT3. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=see_link\">",
"     \"Hyperimmunoglobulin E syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MYELOPEROXIDASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloperoxidase is an enzyme found in the azurophilic granules of neutrophils and monocytes. It catalyzes the production of microbicidal hypohalous acid in the presence of halide ions and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    . The overwhelming majority of patients with myeloperoxidase (MPO) deficiency are clinically normal, even though this enzyme drives an important cytotoxic system capable of killing bacteria, fungi, parasites, and tumor cells. This disorder is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14280?source=see_link\">",
"     \"Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHEDIAK-HIGASHI SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chediak-Higashi Syndrome (CHS) is a rare autosomal recessive disorder with severe congenital neutropenia that is characterized by recurrent pyogenic infections, partial oculocutaneous albinism, progressive neurologic abnormalities, mild coagulation defects, and a lymphoma-like accelerated phase. The defective gene, called",
"    <span class=\"nowrap\">",
"     CHS1/LYST,",
"    </span>",
"    is part of the BEACH family of vesicle trafficking regulatory proteins. This syndrome is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42278?source=see_link\">",
"     \"Chediak-Higashi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NEUTROPHIL-SPECIFIC GRANULE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophil-specific granule deficiency (SGD) is a rare congenital disorder characterized by increased susceptibility to pyogenic infections, especially of the skin, lungs, ears, and lymph nodes. At least one defective gene has been identified, the",
"    <span class=\"nowrap\">",
"     CCAAT/enhancer",
"    </span>",
"    binding protein epsilon",
"    <span class=\"nowrap\">",
"     (C/EBP-epsilon)",
"    </span>",
"    gene. The diagnosis is made by examining neutrophils in a peripheral blood smear for the pathognomonic laboratory findings of paucity or absence of specific granules and predominantly bilobed nuclei (pseudo Pelger-Huet anomaly). This syndrome is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10838?source=see_link\">",
"     \"Neutrophil-specific granule deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SHWACHMAN-DIAMOND SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shwachman-Diamond syndrome (SDS) is a rare autosomal recessive disorder with severe congenital neutropenia. Most patients have a mutation in the Shwachman-Bodian-Diamond syndrome (SBDS) gene. Patients with SDS have pancreatic insufficiency, malabsorption, dyschondroplasia, eczema, and recurrent infection due to both decreased neutrophil chemotaxis and neutropenia. This syndrome is discussed in greater detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33400?source=see_link\">",
"     \"Shwachman-Diamond syndrome\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PERIODONTITIS SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several syndromes of severe periodontitis with chemotactic defects have been described, including localized juvenile periodontitis, rapidly progressive periodontitis, acute necrotizing ulcerative gingivitis, and Papillon-Lef&egrave;vre syndrome (early-onset periodontitis with palmar-plantar hyperkeratosis). Each syndrome has a characteristic oral location, bacterial flora, and hereditary pattern. Oral antibiotics and intensive dental hygiene may aid some patients, but most experience loss of all teeth at an early age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/60/8137?source=see_link\">",
"     \"Systemic conditions associated with periodontal disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/19/8498?source=see_link\">",
"       \"Patient information: Chronic granulomatous disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18781435\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with primary phagocytic disorders are more susceptible to bacterial and fungal infections, but have a normal resistance to viral infections. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Phagocytic disorders can be caused by extrinsic or intrinsic defects. Extrinsic defects include opsonic abnormalities secondary to deficiencies of antibody and complement factors, suppression of granulocyte production, and leukocyte autoantibodies or isoantibodies that decrease the number of circulating neutrophils. Intrinsic disorders of granulocytes may be divided into those that result from defects in granulocyte development, killing ability, or chemotaxis (cell movement). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of defects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common sites of infection are the respiratory tract and skin. Other frequent manifestations include abnormal wound healing,",
"      <span class=\"nowrap\">",
"       dermatitis/eczema,",
"      </span>",
"      and stomatitis. (See",
"      <a class=\"local\" href=\"#H18781392\">",
"       'Typical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fungal infections are primarily Candida and Aspergillus species. The most common bacterial infections are Staphylococcus aureus, Pseudomonas aeruginosa, Nocardia asteroides, and Salmonella typhi. (See",
"      <a class=\"local\" href=\"#H18781392\">",
"       'Typical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43620/abstract/1\">",
"      Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000; 343:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43620/abstract/2\">",
"      Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125:S182.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3913 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43620=[""].join("\n");
var outline_f42_38_43620=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18781435\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18781392\">",
"      TYPICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEUTROPENIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHRONIC GRANULOMATOUS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LEUKOCYTE ADHESION DEFICIENCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HYPERIMMUNOGLOBULIN E SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MYELOPEROXIDASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHEDIAK-HIGASHI SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NEUTROPHIL-SPECIFIC GRANULE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SHWACHMAN-DIAMOND SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PERIODONTITIS SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18781435\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42278?source=related_link\">",
"      Chediak-Higashi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11465?source=related_link\">",
"      Chronic granulomatous disease: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42520?source=related_link\">",
"      Immune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10473?source=related_link\">",
"      Infectious causes of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24614?source=related_link\">",
"      Laboratory evaluation of neutropenia and neutrophil dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22953?source=related_link\">",
"      Leukocyte adhesion deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14280?source=related_link\">",
"      Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10838?source=related_link\">",
"      Neutrophil-specific granule deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/19/8498?source=related_link\">",
"      Patient information: Chronic granulomatous disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33400?source=related_link\">",
"      Shwachman-Diamond syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/60/8137?source=related_link\">",
"      Systemic conditions associated with periodontal disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_38_43621="Secondary causes of dyslipidemia";
var content_f42_38_43621=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondary causes of dyslipidemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43621/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43621/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43621/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43621/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43621/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43621/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43621/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/38/43621/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many patients hyperlipidemia is caused by some underlying \"non-lipid\" etiology rather than a primary disorder of lipid metabolism. The secondary causes of dyslipidemia will be reviewed briefly here; many of these are discussed in more detail elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type 2 diabetes mellitus",
"     </li>",
"     <li>",
"      Excessive alcohol consumption",
"     </li>",
"     <li>",
"      Cholestatic liver diseases",
"     </li>",
"     <li>",
"      Nephrotic syndrome",
"     </li>",
"     <li>",
"      Chronic renal failure",
"     </li>",
"     <li>",
"      Hypothyroidism",
"     </li>",
"     <li>",
"      Cigarette smoking",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a cohort of 824 new patients referred to a lipid clinic at an academic medical center in the United States, 28 percent had one or more potential causes of secondary dyslipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/1\">",
"     1",
"    </a>",
"    ]. The most common conditions that were felt to be contributing to dyslipidemia were excessive alcohol intake (10 percent) and uncontrolled diabetes mellitus (8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPE 2 DIABETES MELLITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia in association with insulin resistance is common in patients with type 2 diabetes mellitus (DM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Insulin resistance and the ensuing hyperinsulinemia are associated with hypertriglyceridemia and low serum high-density lipoprotein (HDL) cholesterol concentrations.",
"   </p>",
"   <p>",
"    The lipoprotein abnormalities are related to the severity of the insulin resistance. A study that measured insulin sensitivity using a euglycemic clamp in patients with and without type 2 DM found that greater insulin resistance was associated with larger very low density lipoprotein (VLDL) particle size, smaller low density lipoprotein (LDL) particle size, and smaller HDL particle size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/4\">",
"     4",
"    </a>",
"    ]. Additionally, the number of VLDL, intermediate density lipoprotein (IDL), and LDL particles increase with increasing insulin resistance, while HDL particle concentration decreases.",
"   </p>",
"   <p>",
"    Hypertriglyceridemia results both from increased substrate availability (glucose and free fatty acids) and from decreased lipolysis of VLDL triglyceride. Nicotinic acid can partially correct these disturbances but at the potential expense of increased insulin resistance and worse glycemic control. In one study, for example, nicotinic acid administration led to a 21 percent rise in hemoglobin A1c values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169063316\">",
"    <span class=\"h1\">",
"     EXCESSIVE ALCOHOL CONSUMPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While moderate alcohol consumption generally has favorable effects on lipids (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    ), excessive alcohol consumption can raise triglyceride levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This is particular concern in patients with severe hypertriglyceridemia at baseline. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link&amp;anchor=H300298#H300298\">",
"     \"Approach to the patient with hypertriglyceridemia\", section on 'Severe hypertriglyceridemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHOLESTATIC LIVER DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary biliary cirrhosis and similar disorders may be accompanied by marked hypercholesterolemia that results from an accumulation of lipoprotein-X. Clinical stigmata include xanthomata striata palmare that may appear when the serum cholesterol concentration is 1400",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (36",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or higher. Xanthomata appear on the extremities as well. Marked elevations in lipoprotein X has been associated with the hyperviscosity syndrome, but no clear association with coronary heart disease (CHD) has been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18149?source=see_link\">",
"     \"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NEPHROTIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marked hyperlipidemia can occur in the nephrotic syndrome due primarily to high serum total and low-density lipoprotein (LDL) cholesterol concentrations. Increased hepatic production of lipoproteins (induced in part by the fall in plasma oncotic pressure) is the major abnormality, but diminished lipid catabolism may play a contributory role. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyslipidemia is less prominent in chronic kidney disease (CKD), but CKD is associated with elevations in LDL cholesterol and triglycerides, and low levels of HDL cholesterol; hypertriglyceridemia (type IV hyperlipoproteinemia) occurs in 30 to 50 percent of cases of CKD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=see_link\">",
"     \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HYPOTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism is frequently associated with and is a common cause of hyperlipidemia. The relationship between hypothyroidism and hyperlipidemia can be illustrated by the following findings (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28550?source=see_link\">",
"     \"Lipid abnormalities in thyroid disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 268 patients with primary hypothyroidism, hypercholesterolemia (type IIa hyperlipoproteinemia) was present in 56 percent, hypercholesterolemia and hypertriglyceridemia (type IIb) in 34 percent, and hypertriglyceridemia (type IV) in 1.5 percent; only 8.5 percent had a normal lipid profile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The severity of the lipid abnormalities increases in a graded fashion with the severity of the hypothyroidism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a survey of 248 patients referred to a lipid disorders clinic, 2.8 percent had overt hypothyroidism and 4.4 percent had subclinical hypothyroidism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, serum thyrotropin should be measured in all patients with dyslipidemia (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    ). Reversal of the hypothyroidism with thyroid hormone replacement leads to correction of the hyperlipidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CIGARETTE SMOKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking modestly lowers the serum HDL cholesterol concentrations and may induce insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In the screening phase of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12933?source=see_link\">",
"     Bezafibrate",
"    </a>",
"    Infarction Prevention Study Group, for example, the mean serum HDL cholesterol concentration was 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in nonsmokers, 37",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in former smokers, and 35",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in current smokers with an intake of two packs per day or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/12\">",
"     12",
"    </a>",
"    ]. Another report found that the effect of smoking was more prominent if adjusted for concomitant alcohol intake; in such patients, smoking was associated with a 5 to 9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.1 to 0.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    decline in serum HDL cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/13\">",
"     13",
"    </a>",
"    ]. These effects are reversible within one to two months after smoking cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is associated with a number of deleterious changes in lipid metabolism, including high serum concentrations of total cholesterol, LDL cholesterol, VLDL cholesterol, and triglycerides, and a reduction in serum HDL cholesterol concentration of about 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/17\">",
"     17",
"    </a>",
"    ]. Loss of body fat can reverse the hypercholesterolemia and hypertriglyceridemia. However, improvement in serum total and HDL cholesterol, HDL2-cholesterol, and apolipoprotein A-I is primarily limited to patients with LDL subclass A; improvement occurs in only one-third of patients with LDL subclass B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some medications, including thiazide diuretics, beta blockers, and oral estrogens can cause modest changes in serum lipid concentrations (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44659?source=see_link\">",
"     \"Antihypertensive drugs and lipids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    ). Some of the atypical antipsychotic agents, in particular,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , have been associated with weight gain, obesity, hypertriglyceridemia, and development of diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43621/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. The mechanism(s) by which they cause the metabolic syndrome have not been defined.",
"   </p>",
"   <p>",
"    Antiretroviral regimens used for HIV infection, and in particular the protease inhibitors, have been associated with abnormalities in lipids and glucose metabolism often as part of a lipodystrophy syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23352?source=see_link&amp;anchor=H25#H25\">",
"     \"Lipodystrophic syndromes\", section on 'Lipodystrophy associated with HIV therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link&amp;anchor=H33#H33\">",
"     \"HIV protease inhibitors\", section on 'Class-related adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/1/40980?source=see_link\">",
"       \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"       \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/6/43108?source=see_link\">",
"       \"Patient information: High cholesterol treatment options (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H655288727\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many patients, hyperlipidemia may be caused by some &ldquo;non-lipid&rdquo; etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with type 2 diabetes mellitus, hyperlipidemia occurs in association with insulin resistance and frequently involves increased triglycerides and low serum high-density lipoprotein (HDL) cholesterol. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Type 2 diabetes mellitus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excessive alcohol consumption can raise triglyceride levels. (See",
"      <a class=\"local\" href=\"#H169063316\">",
"       'Excessive alcohol consumption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis and similar disorders may be accompanied by marked hypercholesterolemia that results from an accumulation of lipoprotein-X. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cholestatic liver diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Marked hyperlipidemia can occur in the nephrotic syndrome due primarily to high serum total and low-density lipoprotein (LDL) cholesterol concentrations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nephrotic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dyslipidemia is less prominent in chronic kidney disease (CKD), but CKD is associated with elevations in LDL cholesterol and triglycerides, and low levels of HDL cholesterol; hypertriglyceridemia (type IV hyperlipoproteinemia) occurs in 30 to 50 percent of cases of CKD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=see_link\">",
"       \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypothyroidism is a common cause of hyperlipidemia, most typically raising LDL cholesterol, but hypertriglyceridemia can also be seen. We suggest screening for hypothyroidism in all patients with dyslipidemia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hypothyroidism'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=see_link\">",
"       \"Diagnosis of and screening for hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoking modestly lowers the serum HDL cholesterol concentrations. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cigarette smoking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obesity is associated with a number of deleterious changes in lipid metabolism, including high serum concentrations of total cholesterol, LDL cholesterol, VLDL cholesterol, and triglycerides, and a reduction in serum HDL cholesterol concentration. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Obesity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of medications can affect serum lipid concentrations, either directly or through affects on weight or glucose metabolism. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/1\">",
"      Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol 2012; 110:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/2\">",
"      Zavaroni I, Dall'Aglio E, Alpi O, et al. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis 1985; 55:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/3\">",
"      Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/4\">",
"      Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/5\">",
"      Wakabayashi I. Comparison of the relationships of alcohol intake with atherosclerotic risk factors in men with and without diabetes mellitus. Alcohol Alcohol 2011; 46:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/6\">",
"      Park H, Kim K. Association of alcohol consumption with lipid profile in hypertensive men. Alcohol Alcohol 2012; 47:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/7\">",
"      Rosenson RS, Baker AL, Chow MJ, Hay RV. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology 1990; 98:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/8\">",
"      O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/9\">",
"      Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/10\">",
"      Tsimihodimos V, Bairaktari E, Tzallas C, et al. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. Thyroid 1999; 9:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/11\">",
"      Facchini FS, Hollenbeck CB, Jeppesen J, et al. Insulin resistance and cigarette smoking. Lancet 1992; 339:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/12\">",
"      Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation 1992; 86:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/13\">",
"      Criqui MH, Cowan LD, Tyroler HA, et al. Lipoproteins as mediators for the effects of alcohol consumption and cigarette smoking on cardiovascular mortality: results form the Lipid Research Clinics Follow-up Study. Am J Epidemiol 1987; 126:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/14\">",
"      Moffatt RJ. Effects of cessation of smoking on serum lipids and high density lipoprotein-cholesterol. Atherosclerosis 1988; 74:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/15\">",
"      Nilsson P, Lundgren H, S&ouml;derstr&ouml;m M, et al. Effects of smoking cessation on insulin and cardiovascular risk factors--a controlled study of 4 months' duration. J Intern Med 1996; 240:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/16\">",
"      Terres W, Becker P, Rosenberg A. Changes in cardiovascular risk profile during the cessation of smoking. Am J Med 1994; 97:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/17\">",
"      Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/18\">",
"      Katzel LI, Coon PJ, Rogus E, et al. Persistence of low HDL-C levels after weight reduction in older men with small LDL particles. Arterioscler Thromb Vasc Biol 1995; 15:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/19\">",
"      Dursun SM, Szemis A, Andrews H, Reveley MA. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 1999; 24:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/20\">",
"      Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/21\">",
"      Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43621/abstract/22\">",
"      Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001; 62 Suppl 23:39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4568 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43621=[""].join("\n");
var outline_f42_38_43621=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H655288727\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPE 2 DIABETES MELLITUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H169063316\">",
"      EXCESSIVE ALCOHOL CONSUMPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHOLESTATIC LIVER DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NEPHROTIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HYPOTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CIGARETTE SMOKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OBESITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H655288727\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44659?source=related_link\">",
"      Antihypertensive drugs and lipids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18149?source=related_link\">",
"      Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=related_link\">",
"      Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28550?source=related_link\">",
"      Lipid abnormalities in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23352?source=related_link\">",
"      Lipodystrophic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/6/43108?source=related_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_38_43622="CT scan infrarenal aortic aneurysm with thrombus";
var content_f42_38_43622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    CT scan infrarenal aortic aneurysm with thrombus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 4 cm infrarenal AAA is shown on the axial CT images prior to (A) and following administration of intravenous contrast (B). Luminal thrombus (arrowhead) is seen&nbsp;surrounding the flow channel. The coronal CT reconstruction (C) shows the low density circumferential thrombus (arrows) surrounding the contrast-filled lumen.",
"    <div class=\"footnotes\">",
"     CT: computed tomography; AAA: abdominal aortic aneurysm.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43622=[""].join("\n");
var outline_f42_38_43622=null;
var title_f42_38_43623="Irregular heart rate (arrhythmias) in children";
var content_f42_38_43623=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Irregular heart rate (arrhythmias) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43623/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43623/contributors\">",
"     Andrew D Blaufox, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43623/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43623/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43623/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43623/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/38/43623/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with an irregular heart rate is a common problem that has numerous etiologies ranging from normal benign variants to malignant arrhythmias. Determining the underlying cause of an irregular rhythm is important, as it may be a life-threatening or serious condition. In the majority of children, the cause of an irregular heart rate is identified by an in-depth history and physical examination, and electrocardiogram, which can be completed by the primary clinician. In some cases, referral to a pediatric cardiologist is required for further diagnostic work-up and, if necessary, treatment.",
"   </p>",
"   <p>",
"    The etiology and evaluation of an irregular heart rhythm in children will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most likely diagnosis for an irregular heart rate varies with the clinical setting in which the irregularity is first noted. The differential diagnosis and subsequent evaluation differs for an asymptomatic child with an incidental finding of an irregular heart rate compared to a symptomatic child who complains of palpitations or who has an episode of syncope. In general, the asymptomatic child will have a benign condition, whereas the symptomatic child is more likely to have a significant arrhythmia that may require intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Asymptomatic child",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the most common causes of an irregular rhythm in an asymptomatic child, which is usually detected as an incidental finding during a routine physical examination or evaluation for some other issue.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sinus arrhythmia",
"     </li>",
"     <li>",
"      Ventricular premature beats (VPBs)",
"     </li>",
"     <li>",
"      Atrial premature beats (APBs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Sinus arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus arrhythmia is a normal physiologic variant that is characterized by an increased heart rate during inspiration and a decreased heart rate during expiration (",
"    <a class=\"graphic graphic_waveform graphicRef78161 \" href=\"mobipreview.htm?5/11/5311\">",
"     waveform 1",
"    </a>",
"    ). Rhythm variability is caused, in part, by changes in parasympathetic input to the heart, which is mediated by the vagus nerve. Vagal tone, in turn, is modulated by the respiratory cycle. During expiration, enhanced vagal tone lowers the heart rate, and during inspiration, vagal withdrawal increases the heart rate. During active exercise, vagal tone is decreased and the sympathetic tone is increased, which results in an increased heart rate.",
"   </p>",
"   <p>",
"    Sinus arrhythmia is a benign condition, even in individuals (eg, physically trained athletes) in whom this",
"    <span class=\"nowrap\">",
"     vagal/respiratory",
"    </span>",
"    heart rate pattern is markedly pronounced. The diagnosis is made by electrocardiogram. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Electrocardiogram'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Ventricular premature beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs), also referred to as premature ventricular contractions (PVCs), are premature depolarizations of the ventricles leading to early systolic contraction of the ventricles (",
"    <a class=\"graphic graphic_waveform graphicRef57511 \" href=\"mobipreview.htm?25/6/25704\">",
"     waveform 2",
"    </a>",
"    ). VPBs are usually followed by a pause and occur without regularity, resulting in an irregular heart rate. VPBs also may on occasion occur in an irregular pattern (eg, every other beat: bigeminy, (",
"    <a class=\"graphic graphic_waveform graphicRef51529 \" href=\"mobipreview.htm?12/44/13002\">",
"     waveform 3",
"    </a>",
"    ), or every third beat: trigeminy, (",
"    <a class=\"graphic graphic_waveform graphicRef64181 \" href=\"mobipreview.htm?42/34/43559\">",
"     waveform 4",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    In an asymptomatic healthy child, VPBs that occur in isolation are generally benign and produce few or no symptoms. VPBs commonly occur in infancy, decline in incidence in early childhood, and become increasingly common again in adolescence and adulthood.",
"   </p>",
"   <p>",
"    VPBs rarely cause true hemodynamic compromise except in patients with frequent VPBs and severely depressed left ventricular function, or when they are concurrent with bradycardia. In these patients, VPBs may be associated with an increased risk of a malignant arrhythmia, such as sustained ventricular tachycardia. Frequent or polymorphic VPB's also may be a harbinger of a more malignant arrhythmia, such as catecholaminergic polymorphic ventricular tachycardia (CPVT) and arrhythmogenic right ventricular dysplasia (ARVD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15897?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of wide QRS complex tachycardia in children\", section on 'Ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical significance and evaluation of VPBs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/36/36424?source=see_link\">",
"     \"Clinical significance and treatment of ventricular premature beats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=see_link\">",
"     \"Prevalence and evaluation of ventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Atrial premature beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial premature beats (APBs), also known as premature atrial contractions (PACs), are early depolarizations of atrial myocardium that lead to propagation of electrical impulses through the atrium and to the ventricle via the atrioventricular (AV) node. These electrical impulses result in early systolic ventricular contraction (",
"    <a class=\"graphic graphic_waveform graphicRef66489 \" href=\"mobipreview.htm?13/0/13312\">",
"     waveform 5",
"    </a>",
"    ). Although APBs occur most commonly in isolation in infants and young children, they can occur throughout childhood. In asymptomatic children, APBs are benign and are unlikely to be associated with sustained tachyarrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/441?source=see_link&amp;anchor=H2#H2\">",
"     \"Supraventricular premature beats\", section on 'Atrial premature beats'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Symptomatic child",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a symptomatic child with an irregular heart rate, there is an increased likelihood that the underlying etiology is due to a sustained tachyarrhythmia. These tachyarrhythmias may be paroxysmal in nature, and often present with episodes of palpitations, syncope,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest pain. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal and multifocal atrial tachycardia &mdash; Focal atrial tachycardia (FAT), also referred to as ectopic atrial tachycardia, is caused by rapid depolarizations from a single atrial focus outside the sinoatrial node (",
"      <a class=\"graphic graphic_waveform graphicRef70215 \" href=\"mobipreview.htm?29/51/30518\">",
"       waveform 6",
"      </a>",
"      ). Clinical presentation varies from mild symptoms of palpitations and dizziness associated with sporadic episodes of tachycardia to heart failure with sustained tachycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43623/abstract/1\">",
"       1",
"      </a>",
"      ]. FAT is an uncommon condition that is seen more frequently in infants and young children in whom spontaneously resolution is likely. In contrast, FAT in children beyond three years of age is likely to be a chronic condition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43623/abstract/2\">",
"       2",
"      </a>",
"      ]. Multifocal atrial tachycardia is a rare disorder that is caused by multiple foci of enhanced atrial automaticity, which presents in a similar manner to FAT. The variability of the timing in the firing of these foci, as well as the variability in conduction through the AV node during these arrhythmias account for the irregular heart rate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=see_link\">",
"       \"Focal atrial tachycardia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38216?source=see_link&amp;anchor=H11#H11\">",
"       \"Multifocal atrial tachycardia\", section on 'MAT in children and young adults'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reentrant supraventricular tachycardia &mdash; In reentrant supraventricular tachycardia (SVT), an electrical impulse cycles repetitively through a circuit from the atria to the ventricles and back again, which results in rapid, regular ventricular contractions. Common clinical manifestations of reentrant SVT are palpitations, chest pain, fatigue, and lightheadedness ( due to the hypotension associated with the rapid heart rate). Most children tolerate short episodes of tachycardia well. Although prolonged episodes can precipitate heart failure, this is uncommon because other symptoms (eg, palpitations) prompt patients to seek medical attention before this occurs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43623/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Certain forms of SVT, such as atrioventricular reentrant tachycardia (AVRT), may be associated with Wolff-Parkinson-White (WPW) syndrome (",
"      <a class=\"graphic graphic_waveform graphicRef76226 \" href=\"mobipreview.htm?35/41/36506\">",
"       waveform 7",
"      </a>",
"      ). WPW is associated with an increased risk of sudden cardiac death. These patients are referred to a pediatric cardiologist for further diagnostic evaluation and management. Two forms of reentrant SVT, AVRT including the WPW syndrome and atrioventricular nodal reentrant tachycardia (AVNRT), are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=see_link\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular tachycardia &mdash; In children with normal hearts, ventricular tachycardia (VT) is relatively uncommon and is usually benign. Common forms of pediatric VT include right ventricular outflow tract tachycardia and posterior fascicular ventricular tachycardia arising from the left ventricle. Common clinical manifestations include palpitations and syncope, although some children may be asymptomatic and present because of an incidental finding on routine physical examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children with congenital and acquired heart disease, the risk of VT increases, and there is a high risk of mortality and serious morbidity. Causes, evaluation, and management of ventricular tachycardia in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15897?source=see_link\">",
"     \"Causes of wide QRS complex tachycardia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22152?source=see_link\">",
"     \"Management and evaluation of wide QRS complex tachycardia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have bradycardia and an irregular heart rate may be asymptomatic and present because of an incidental finding on routine physical examination, or present with symptoms such as fatigue, dizziness, and syncope. The causes of bradycardia and an irregular heart rate include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus node dysfunction &mdash; In sinus node dysfunction, there is inappropriate sinus bradycardia or chronotropic incompetence (failure to appropriately elevate the heart rate in response to physiologic stress). This results in a slow heart rate and potential irregularity because of variations in the length of pauses in sinus activation and compensatory escape beats arising from other parts of the atrium, AV node, or ventricle.",
"      <br/>",
"      <br/>",
"      Sinus node dysfunction is uncommon in patients with structurally normal hearts. In contrast, it is a common complication in patients with complex congenital heart disease, and it can be associated with inflammatory diseases such as myocarditis, Kawasaki disease, or rheumatic heart disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33161?source=see_link&amp;anchor=H21#H21\">",
"       \"Bradycardia in children\", section on 'Sinus node dysfunction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Second-degree heart block &mdash; Children who have second degree AV block, in whom the organized atrial impulse fails to be conducted to the ventricle in a 1:1 ratio, may have a regularly irregular or irregularly irregular slow heart rate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33161?source=see_link&amp;anchor=H26#H26\">",
"       \"Bradycardia in children\", section on 'Second-degree AV block'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with Mobitz type 1 block (also referred to as Wenckebach block), the PR interval progressively lengthens until a sinus beat is not conducted through the AV node in a consistent pattern of timing, resulting in a regularly irregular heart rate (",
"      <a class=\"graphic graphic_waveform graphicRef73051 \" href=\"mobipreview.htm?42/35/43573\">",
"       waveform 8",
"      </a>",
"      ). These patients are generally asymptomatic, and treatment is generally not indicated unless there is evidence for more significant conduction system dysfunction.",
"     </li>",
"     <li>",
"      In patients with Mobitz type 2 block, a P wave suddenly fails to conduct without any change in PR interval. This rhythm may be a regularly irregular or irregularly irregular heart rate (",
"      <a class=\"graphic graphic_waveform graphicRef79539 \" href=\"mobipreview.htm?28/37/29270\">",
"       waveform 9",
"      </a>",
"      ). This condition may progress to complete heart block and is sometimes associated with congenital heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation begins with a comprehensive history and physical examination regardless of the setting in which the irregular heart rate is first noted. The cause of an irregular heart rate is often diagnosed by an electrocardiogram, which should be obtained if the history and physical examination have not completely confirmed that the irregularity is due to a benign etiology (",
"    <a class=\"graphic graphic_algorithm graphicRef71674 \" href=\"mobipreview.htm?22/52/23360\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should focus on determining whether there are other signs of heart disease, and begins to differentiate among the various causes of an irregular heart rate. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Important elements of the history include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43623/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpitations &mdash; The presence of palpitations (awareness of the beating of the heart) may represent an abnormality in heart rate or rhythm. Palpitations can be manifestations of a single beat (eg, ventricular premature beats), nonsustained tachycardias, or a sustained tachycardia. An accurate description may be useful in identifying the underlying arrhythmia. For example, palpitations due to sinus tachycardia usually have a gradual onset and termination, and are associated with anxiety or activity. In contrast, patients with reentrant tachyarrhythmia typically have a sudden onset and ending of palpitations that correlate with the opening and closing of the circuit responsible for the arrhythmia.",
"     </li>",
"     <li>",
"      Syncope &mdash; Although the range of causes of syncope (defined as sudden, brief loss of consciousness associated with loss of postural tone from which recovery is spontaneous) is broad (",
"      <a class=\"graphic graphic_table graphicRef60014 \" href=\"mobipreview.htm?36/49/37660\">",
"       table 1",
"      </a>",
"      ), a history of syncope increases the risk for an underlying serious cardiac disease and the potential for a life-threatening cardiac arrhythmia. As a result, an electrocardiogram is recommended as part of the initial evaluation for any child with a syncopal episode (",
"      <a class=\"graphic graphic_algorithm graphicRef53383 \" href=\"mobipreview.htm?0/49/784\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36007?source=see_link\">",
"       \"Causes of syncope in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11432?source=see_link\">",
"       \"Emergent evaluation of syncope in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest pain &mdash; Cardiac arrhythmias with an irregular heart rate are rare cases of chest pain in children, which include supraventricular tachycardia with or without underlying Wolff-Parkinson-White syndrome ventricular premature beats. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27241?source=see_link&amp;anchor=H17#H17\">",
"       \"Approach to chest pain in children\", section on 'Cardiac conditions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Family history &mdash; Familial sudden unexpected death has been associated with Wolff-Parkinson-White (WPW) syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT) and arrhythmogenic right ventricular dysplasia (ARVD), which may be preceded by frequent spontaneous premature beats. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15559?source=see_link&amp;anchor=H599199#H599199\">",
"       \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Familial SCD'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If any of these historical elements is suggestive of an underlying cardiac disorder, an electrocardiogram should be obtained as an initial part of the evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include a complete description of the irregular heart rate, because several conditions have characteristic findings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory cycle &mdash; Any consistent change of the heart rate in relation to the respiratory cycle should be noted. It is helpful in a cooperative child to have the patient take large inspiration and hold it prior to exhaling while the rhythm is being assessed. Patients with sinus arrhythmia have a characteristic increased heart rate during inspiration that decreases with expiration. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sinus arrhythmia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated ectopy &mdash; An irregular early heart beat followed by a pause in the midst of an otherwise regular rhythm is suggestive of ventricular or atrial premature beats. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ventricular premature beats'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Atrial premature beats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bradycardia &mdash; In patients with bradycardia and an irregular regular rhythm, an irregular heart beat that arises from a pause in an otherwise regular rhythm is suggestive of sinus node dysfunction or second degree atrioventricular (AV) block. Patients with irregularly irregular bradycardia may have Mobitz type 2 AV block. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bradycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tachycardia &mdash; Several tachyarrhythmias may be associated with an irregular heart rate, especially in a symptomatic child, including focal and multifocal atrial tachycardia, reentrant supraventricular tachycardia, and ventricular tachycardia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Symptomatic child'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other elements of the cardiac examination include inspection, palpation (apical impulse, heave, thrill), and auscultation of the heart to assess the heart sounds and detect the presence of a gallop or murmur. Any abnormality of the cardiac examination increases the likelihood of a significant cardiac disorder, and an electrocardiogram should be obtained as an initial part of the evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38471?source=see_link&amp;anchor=H6#H6\">",
"     \"The pediatric physical examination: Chest and abdomen\", section on 'Heart'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the history and physical examination have not confirmed that the irregularity is due to a benign etiology, the next step in the evaluation is the performance of an electrocardiogram (ECG). A 12 lead ECG with a 30 second \"rhythm strip\" often provides a diagnosis of the underlying cause of an irregular heart rate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus arrhythmia (",
"      <a class=\"graphic graphic_waveform graphicRef78161 \" href=\"mobipreview.htm?5/11/5311\">",
"       waveform 1",
"      </a>",
"      ) &mdash; The heart rate varies with the respiratory cycle. During the ECG, the child can be asked to hold",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      breath during inspiration, which is correlated with an increase in heart rate. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sinus arrhythmia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular and atrial premature beats may be found during a rhythm strip depending upon their frequency (",
"      <a class=\"graphic graphic_waveform graphicRef57511 \" href=\"mobipreview.htm?25/6/25704\">",
"       waveform 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef51529 \" href=\"mobipreview.htm?12/44/13002\">",
"       waveform 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef64181 \" href=\"mobipreview.htm?42/34/43559\">",
"       waveform 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef66489 \" href=\"mobipreview.htm?13/0/13312\">",
"       waveform 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ventricular premature beats'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Atrial premature beats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Second degree atrioventricular block is identified by ECG (",
"      <a class=\"graphic graphic_waveform graphicRef73051 \" href=\"mobipreview.htm?42/35/43573\">",
"       waveform 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef79539 \" href=\"mobipreview.htm?28/37/29270\">",
"       waveform 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33161?source=see_link&amp;anchor=H26#H26\">",
"       \"Bradycardia in children\", section on 'Second-degree AV block'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although tachyarrhythmias are usually paroxysmal and may not be seen on ECG, there may be findings suggestive of an underlying tachyarrhythmia. For example, the presence of a short PR interval and a delta wave with a wide QRS confirms the diagnosis of Wolff-Parkinson-White (WPW) syndrome (",
"      <a class=\"graphic graphic_waveform graphicRef76226 \" href=\"mobipreview.htm?35/41/36506\">",
"       waveform 7",
"      </a>",
"      ), and patients with arrhythmogenic right ventricular dysplasia (ARVD) have characteristic ECG findings that include incomplete right bundle branch block, T wave inversion in leads V3 and V4, and epsilon waves. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=see_link\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15897?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of wide QRS complex tachycardia in children\", section on 'Ventricular tachycardia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CARDIAC REFERRAL AND FURTHER EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A referral to a pediatric cardiologist is made when the initial evaluation does not result in a diagnosis, the patient is symptomatic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the ECG demonstrates a significant abnormality. Consultation should be obtained more quickly in patients who are symptomatic because of the increased risk of significant cardiac disease. Further testing is dependent upon the findings of the preceding evaluation, the setting in which the irregularity is first noted, and, if present, the frequency and duration of symptoms (",
"    <a class=\"graphic graphic_algorithm graphicRef71674 \" href=\"mobipreview.htm?22/52/23360\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Holter monitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;A holter monitor provides a continuous rhythm recording from adhesive electrodes for a minimum of 24 or 48 hours. It uses a small, lightweight, battery operated electromagnetic tape recorder or digital recorder that records two or three channels of electrocardiographic data that provides the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimum, average, and maximum heart rate",
"     </li>",
"     <li>",
"      Longest pause in heart rate",
"     </li>",
"     <li>",
"      Number of ventricular and atrial premature beats",
"     </li>",
"     <li>",
"      The number of supraventricular tachyarrhythmias (SVT) runs, the duration of the longest SVT run, the rate of the fastest SVT run",
"     </li>",
"     <li>",
"      The number of ventricular tachycardia (VT) runs, the duration of the longest VT run, the rate of the fastest VT run",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Holter monitoring is useful in the assessment of an asymptomatic child when an irregular heart rate is noted on routine examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ECG, or in a patient with symptoms that occur daily or more frequently. In the symptomatic child, the",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    should maintain a written diary of symptoms to correlate symptoms with the rhythm recording, which will help determine whether the symptoms are due to arrhythmias. It is also used to determine the frequency and severity of abnormalities detected on ECG, such as ventricular premature beats, sinus node dysfunction, or second degree AV block.",
"   </p>",
"   <p>",
"    It is not generally necessary to perform a holter monitor in an asymptomatic child with APBs or sinus arrhythmia already documented by ECG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Event monitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with intermittent or infrequent symptoms, event monitoring using a transtelephonic device is the preferred diagnostic test to determine whether symptoms are due to an underlying cardiac arrhythmia, as they can be used for 30 to 60 days. In particular, transtelephonic monitoring is most useful in trying to determine whether supraventricular or ventricular tachycardia is present or not. Transtelephonic monitor provides a rhythm recording, which can either be stored or transmitted by telephone to a health care provider. There are two basic types of transtelephonic monitors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation by the patient &mdash; The event monitor is activated by the patient at the onset of symptoms. The most common monitors are relatively small hand-held devices with electrodes that can record rhythm strips after an activation button is pressed. The strips can be transmitted via telephone lines to a computer system where the data is analyzed, and the rhythm strips can be printed.",
"     </li>",
"     <li>",
"      Continuous monitor &mdash; Loop monitors continuously monitor the rhythm. At activation, the preactivation rhythm of 5 to 10 seconds is also captured. These monitors can be set up to record automatically based on a preset heart rate criteria, so that they may be used to capture asymptomatic events or events that occur in young children who are not capable of activating the monitor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One major impediment to these devices is that it may be difficult for a child to wear the leads for an extended period of time, as the prolonged application of the leads can cause skin irritation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of exercise testing is to observe the effect of enhanced sympathetic drive upon the rhythm status in a child found to have an ECG or holter monitor abnormality. It permits an assessment of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus node function &mdash; Exercise testing evaluates the ability of the sinus node to respond to stress by comparing the heart rate to normative data. Patients with sinus node dysfunction have chronotropic incompetence (failure to appropriately elevate the heart rate in response to physiologic stress). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bradycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intracardiac conduction &mdash; For patients with AV block, exercise may demonstrate changes in conduction pattern, escape rates, or the development of ventricular ectopy. Results from exercise testing may assist in determining whether pacemaker placement is indicated. AV conduction that improves with exercise in patients is a reassuring sign.",
"     </li>",
"     <li>",
"      Wolff-Parkinson-White (WPW) syndrome &mdash; The disappearance of the delta wave during exercise suggests that these patients are at low risk from sudden death. These results indicate that the accessory pathway is not rapidly conducted from the atrium to the ventricle so that the resulting heart rate during an atrial arrhythmia would not be excessively fast and irregular. In contrast, patients in whom the ECG findings of WPW persist during exercise may still be at risk for sudden death and require further assessment with electrophysiology study (",
"      <a class=\"graphic graphic_algorithm graphicRef71674 \" href=\"mobipreview.htm?22/52/23360\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Electrophysiology study'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Ventricular premature beats (VPBs) and risk of VT &mdash; An exercise test is performed to help determine if patients with frequent isolated VPBs are at risk for developing more complex and potentially dangerous ventricular tachycardia (VT). If, during exercise, ventricular ectopy is suppressed, the VPBs are determined to be benign. However, if ventricular ectopy worsens and the patient develops nonsustained or sustained ventricular tachycardia, further invasive evaluation and management (ie, electrophysiology study) is required. If VPBs remain and there is no complex ectopy, the result of the exercise testing is equivocal. An equivocal exercise test does not help in the clinical evaluation of the patient, so the decision to proceed with further testing should be based upon the patient's history, physical, and other testing results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiogram is performed when there is an increased likelihood for structural heart disease as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspicion of structural heart disease based upon clinical findings other than the irregular heart rate.",
"     </li>",
"     <li>",
"      Sinus node dysfunction, because this condition is uncommon in patients who have a structurally normal heart.",
"     </li>",
"     <li>",
"      AV block from acquired inflammatory diseases (eg, Lyme Disease or autoimmune diseases contracted later in life) because there may be valvar or pericardial injury. An echocardiogram should also be performed in patients with AV block associated with myocarditis because of the increased risk of ventricular dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43623/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe chronic bradycardia, either due to sinus node dysfunction or AV block, because of the increased risk of ventricular dilation associated with prolonged bradycardia.",
"     </li>",
"     <li>",
"      Frequent ventricular premature beats (VPBs) and ventricular tachycardia may be associated with structural problems, such as intracardiac tumors, cardiomyopathies, or congenital heart disease.",
"     </li>",
"     <li>",
"      Supraventricular tachycardia (SVT) &mdash; SVT may be associated with congenital heart disease (CHD), and patients with SVT are at increased risk for developing myocardial dysfunction and heart failure (HF). An echocardiogram should be performed after the initial presentation to detect the presence of CHD and should be repeated if the patient has a prolonged episode of tachycardia associated with signs or symptoms of HF to determine whether a tachycardia-induced cardiomyopathy is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Electrophysiology study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with irregular heart rate may require an invasive electrophysiology study (EPS) to provide a more definitive etiology and assessment of the severity of the arrhythmia, as well as an assessment of the risk of an associated malignant arrhythmia and sudden cardiac death (",
"    <a class=\"graphic graphic_table graphicRef52417 \" href=\"mobipreview.htm?41/15/42235\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    EPS is a cardiac catheterization procedure during which the heart is stimulated and responses to these stimulations are assessed. This technique permits a detailed analysis of the mechanism underlying the cardiac arrhythmia, and the precise location of the site of origin of the arrhythmia. The main risks of EPS are due to sedation, vascular complications, and bleeding.",
"   </p>",
"   <p>",
"    Following the diagnostic EPS, mapping and ablation can be performed in patients with SVT or VT (",
"    <a class=\"graphic graphic_table graphicRef78003 \" href=\"mobipreview.htm?42/28/43468\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of cardiac EPS, and discussions on the use of EPS for specific arrhythmias are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12326?source=see_link\">",
"     \"Overview of invasive cardiac electrophysiology studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22328?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Bradyarrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of irregular heart rate depends on multiple factors, including the cause of the irregularity and whether it poses significant risk to the patient, the severity and frequency of associated symptoms, whether the arrhythmia is amenable to medical therapy, and the family's preference regarding treatment options (medical therapy versus catheter ablation).",
"   </p>",
"   <p>",
"    Sinus arrhythmia and isolated atrial premature beats do not require intervention.",
"   </p>",
"   <p>",
"    The management for other specific conditions that are associated with irregular heart rate is presented separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sinus node dysfunction (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37576?source=see_link\">",
"       \"Treatment of the sick sinus syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Second degree AV block (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33161?source=see_link&amp;anchor=H24#H24\">",
"       \"Bradycardia in children\", section on 'AV Heart block'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Supraventricular tachycardia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15514?source=see_link\">",
"       \"Management of supraventricular tachycardia in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ventricular tachycardia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22152?source=see_link\">",
"       \"Management and evaluation of wide QRS complex tachycardia in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Focal atrial tachycardia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=see_link\">",
"       \"Focal atrial tachycardia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Multifocal atrial tachycardia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38216?source=see_link\">",
"       \"Multifocal atrial tachycardia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An irregular heart rate is a common pediatric problem that has numerous etiologies that range from normal benign variants to malignant arrhythmias. In general, an asymptomatic child with an incidental finding of an irregular heart rate will have a benign condition, whereas a symptomatic child (palpitations, syncope, or chest pain) is more likely to have a significant arrhythmia that may require intervention. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determining the underlying cause of an irregular rhythm is important, as it may be a life-threatening or serious condition. In the majority of children, the cause of an irregular heart rate is identified by an in-depth history and physical examination, and electrocardiography, which can be completed by the primary care physician (",
"      <a class=\"graphic graphic_algorithm graphicRef71674 \" href=\"mobipreview.htm?22/52/23360\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A referral to a pediatric cardiologist is made when the initial evaluation does not result in a diagnosis, the patient is symptomatic,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the ECG demonstrates a significant abnormality. Further testing is dependent upon the findings of the preceding evaluation, the setting in which the irregularity is first noted, and, if present, the frequency and duration of symptoms (",
"      <a class=\"graphic graphic_algorithm graphicRef71674 \" href=\"mobipreview.htm?22/52/23360\">",
"       algorithm 1",
"      </a>",
"      ). Testing includes holter monitoring, event monitoring, exercise testing, echocardiogram, and electrophysiology study. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cardiac referral and further evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of irregular heart rate depends upon multiple factors, including the cause of the irregularity and whether it poses significant risk to the patient, the severity and frequency of associated symptoms, whether the arrhythmia is amenable to medical therapy, and the family's preference regarding treatment options (medical therapy versus catheter ablation). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43623/abstract/1\">",
"      Fishberger SB, Colan SD, Saul JP, et al. Myocardial mechanics before and after ablation of chronic tachycardia. Pacing Clin Electrophysiol 1996; 19:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43623/abstract/2\">",
"      Salerno JC, Kertesz NJ, Friedman RA, Fenrich AL Jr. Clinical course of atrial ectopic tachycardia is age-dependent: results and treatment in children &lt; 3 or &gt; or =3 years of age. J Am Coll Cardiol 2004; 43:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43623/abstract/3\">",
"      Deal BJ, Keane JF, Gillette PC, Garson A Jr. Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: management and follow-up. J Am Coll Cardiol 1985; 5:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43623/abstract/4\">",
"      Giardina AC, Ehlers KH, Engle MA. Wolff-Parkinson-White syndrome in infants and children. A long-term follow-up study. Br Heart J 1972; 34:839.",
"     </a>",
"    </li>",
"    <li>",
"     Geggel, RL and Flyer, DC. History, growth, nutrition, physical examination, and routine laboratory studies. In Nadas' Pediatric Cardiology, 2nd ed, Keane, JF, Lock, JE, Flyer, DC (Eds), Saunders Elsevier, Philadelphia, 2006. p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43623/abstract/6\">",
"      Seferovi PM, Risti AD, Maksimovi R, et al. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology (Oxford) 2006; 45 Suppl 4:iv39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5766 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43623=[""].join("\n");
var outline_f42_38_43623=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Asymptomatic child",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Sinus arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Atrial premature beats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Symptomatic child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CARDIAC REFERRAL AND FURTHER EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Holter monitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Event monitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Electrophysiology study",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5766\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5766|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/52/23360\" title=\"algorithm 1\">",
"      Eval irreg heart rate child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?0/49/784\" title=\"algorithm 2\">",
"      Emergent evaluation of pediatric syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5766|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/49/37660\" title=\"table 1\">",
"      Causes of syncope children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/15/42235\" title=\"table 2\">",
"      Indications electrophys study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/28/43468\" title=\"table 3\">",
"      Indications for RF ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5766|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?5/11/5311\" title=\"waveform 1\">",
"      Sinus arrhythmia child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?25/6/25704\" title=\"waveform 2\">",
"      Ventric premature beat tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?12/44/13002\" title=\"waveform 3\">",
"      Ventricular bigeminy tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/34/43559\" title=\"waveform 4\">",
"      Ventricular trigeminy tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?13/0/13312\" title=\"waveform 5\">",
"      ECG APB noncompensatory pause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?29/51/30518\" title=\"waveform 6\">",
"      Repetitive automatic AT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?35/41/36506\" title=\"waveform 7\">",
"      ECG sinus rhythm WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/35/43573\" title=\"waveform 8\">",
"      ECG Mobitz type I AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?28/37/29270\" title=\"waveform 9\">",
"      ECG Mobitz type II AV block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27241?source=related_link\">",
"      Approach to chest pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33161?source=related_link\">",
"      Bradycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36007?source=related_link\">",
"      Causes of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15897?source=related_link\">",
"      Causes of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11432?source=related_link\">",
"      Emergent evaluation of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22328?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Bradyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22152?source=related_link\">",
"      Management and evaluation of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38216?source=related_link\">",
"      Multifocal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=related_link\">",
"      Prevalence and evaluation of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/441?source=related_link\">",
"      Supraventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38471?source=related_link\">",
"      The pediatric physical examination: Chest and abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37576?source=related_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_38_43624="Comprehensive geriatric assessment";
var content_f42_38_43624=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Comprehensive geriatric assessment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43624/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43624/contributors\">",
"     Katherine T Ward, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43624/contributors\">",
"     David B Reuben, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43624/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43624/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43624/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43624/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/38/43624/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geriatric conditions such as functional impairment and dementia are common and frequently unrecognized or inadequately addressed in older adults. Identifying geriatric conditions by performing a geriatric assessment can help clinicians manage these conditions and prevent or delay their complications.",
"   </p>",
"   <p>",
"    Although the geriatric assessment is a diagnostic process, the term is often used to include both evaluation and management. Geriatric assessment is sometimes used to refer to evaluation by the individual clinician (usually a primary care clinician or a geriatrician) and at other times is used to refer to a more intensive multidisciplinary program, also known as a comprehensive geriatric assessment (CGA).",
"   </p>",
"   <p>",
"    This topic will review the indications for CGA, as well as its major components and evidence of its efficacy. General issues of geriatric health maintenance and the assessment of specific geriatric populations are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38186?source=see_link\">",
"     \"Geriatric health maintenance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34215?source=see_link\">",
"     \"Failure to thrive in elderly adults: Evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional limitations of a frail older person in order to develop a coordinated plan to maximize overall health with aging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The health care of an older adult extends beyond the traditional medical management of illness. It requires evaluation of multiple issues including physical, cognitive, affective, social, financial, environmental, and spiritual components that influence an older adult's health. CGA is based on the premise that a systematic evaluation of frail, older persons by a team of health professionals may identify a variety of treatable health problems and lead to better health outcomes.",
"   </p>",
"   <p>",
"    CGA programs are usually initiated through a referral by the primary care clinician or by a clinician caring for a patient in the hospital setting. The content of the assessment varies depending on different settings of care (eg, home, clinic, hospital, nursing home). CGA is not available in all settings, due to issues related to the time required for evaluation, need for coordination of multidisciplinary specialties, and lack of reimbursement for some components (eg, outpatient social work, pharmacy, and nutrition).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best evidence for comprehensive geriatric assessment (CGA) is based on identifying appropriate patients (ie, excluding patients who are either too well or are too sick to derive benefit). No criteria have been validated to readily identify patients who are likely to benefit from CGA. Specific criteria used by CGA programs to identify patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Medical comorbidities such as heart failure or cancer",
"     </li>",
"     <li>",
"      Psychosocial disorders such as depression or isolation",
"     </li>",
"     <li>",
"      Specific geriatric conditions such as dementia, falls, or functional disability",
"     </li>",
"     <li>",
"      Previous or predicted high health care utilization",
"     </li>",
"     <li>",
"      Consideration of change in living situation (eg, from independent living to assisted living, nursing home, or in-home caregivers)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One outpatient approach would be to refer patients for CGA who are found to have problems in multiple areas during geriatric assessment screens. Major illnesses (eg, those requiring hospitalization or increased home resources to manage medical and functional needs) should also prompt referral for CGA, particularly for functional status, fall risk, cognitive problems, and mood disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38186?source=see_link\">",
"     \"Geriatric health maintenance\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Major components'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An inpatient approach would be to refer older patients admitted for a specific medical or surgical reason (eg, fractures, failure to thrive, recurrent pneumonia, pressure sores). Another approach would be to have all patients above a certain age (eg, 85 years) receive preliminary screening to determine whether a full multidisciplinary evaluation is needed.",
"   </p>",
"   <p>",
"    Most outpatient CGA programs exclude patients who are unlikely to benefit because of terminal illness, severe dementia, complete functional dependence, and inevitable nursing home placement. Exclusionary criteria have also included identifying older persons who are \"too healthy\" to benefit, such as those who are completely functional without any medical comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSESSMENT TEAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of health care professionals working in the assessment team varies based on the services provided by individual comprehensive geriatric assessment (CGA) programs. In many settings, the CGA process relies on a core team consisting of a physician, nurse, and social worker and, when appropriate, draws upon an extended team of physical and occupational therapists, nutritionists, pharmacists, psychiatrists, psychologists, dentists, audiologists, podiatrists, and opticians. Although these professionals are usually on staff in the hospital setting and are also available in the community, access to and reimbursement for these services have limited the availability of CGA programs. Increasingly, CGA programs are moving towards a \"virtual team\" concept in which members are included as needed, assessments are conducted at different locations on different days, and team communication is completed via telephone or electronically.",
"   </p>",
"   <p>",
"    Traditionally, the various components of the evaluation are completed by different members of the team, with considerable variability in the assessments. The medical assessment of older persons may be conducted by a physician (usually a geriatrician), nurse practitioner, or physician's assistant. The core team (geriatrician, nurse, social worker) may conduct only brief initial assessments or screens for some dimensions. These may be subsequently augmented with more in-depth evaluations by additional professionals. As an example, a dietitian may be needed to assess dietary intake and provide recommendations on optimizing nutrition, or an audiologist may need to conduct a more extensive assessment of hearing loss and evaluate an older person for a hearing aid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONDUCTING THE ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Framework",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conceptually, comprehensive geriatric assessment (CGA) involves several processes of care that are shared over several providers in the assessment team. The overall care rendered by CGA teams can be divided into six steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Data gathering",
"     </li>",
"     <li>",
"      Discussion among the team",
"     </li>",
"     <li>",
"      Development of a treatment plan",
"     </li>",
"     <li>",
"      Implementation of the treatment plan",
"     </li>",
"     <li>",
"      Monitoring response to the treatment plan",
"     </li>",
"     <li>",
"      Revising the treatment plan",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these steps is essential if the process is to be successful at achieving maximal health and functional benefits.",
"   </p>",
"   <p>",
"    Several different models for CGA have been implemented in various health care settings. An increasing number of CGA programs are relying on post-discharge assessment due to the decrease in length of hospital stay. Furthermore, while most of the early CGA programs focused on restorative or rehabilitative goals (tertiary prevention), many newer programs are aimed at primary and secondary prevention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38186?source=see_link&amp;anchor=H2#H2\">",
"     \"Geriatric health maintenance\", section on 'Classification of preventive measures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Assessment tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the amount of potentially important information may seem overwhelming, formal assessment tools and shortcuts can reduce this burden on the clinician performing the initial CGA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/3\">",
"     3",
"    </a>",
"    ]. A pre-visit questionnaire sent to the patient or caregiver prior to the initial assessment can be a timesaving method to gather a large amount of information (",
"    <a class=\"graphic graphic_table graphicRef64158 \" href=\"mobipreview.htm?12/20/12622\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These questionnaires can be used to gather information about general history (eg, past medical history, medications, social history, review of systems), as well as gather information specific to CGA, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ability to perform functional tasks and need for assistance",
"     </li>",
"     <li>",
"      Fall history",
"     </li>",
"     <li>",
"      Sources of social support, particularly family or friends",
"     </li>",
"     <li>",
"      Depressive symptoms",
"     </li>",
"     <li>",
"      Vision or hearing difficulties",
"     </li>",
"     <li>",
"      Whether the patient has specified a durable power of attorney",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Office staff can be trained to administer screening instruments to both save time and help the clinician to hone in on specific disabilities that need more detailed evaluation (",
"    <a class=\"graphic graphic_table graphicRef64158 \" href=\"mobipreview.htm?12/20/12622\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MAJOR COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Core components of comprehensive geriatric assessment (CGA) that should be evaluated during the assessment process are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Functional capacity",
"     </li>",
"     <li>",
"      Fall risk",
"     </li>",
"     <li>",
"      Cognition",
"     </li>",
"     <li>",
"      Mood",
"     </li>",
"     <li>",
"      Polypharmacy",
"     </li>",
"     <li>",
"      Social support",
"     </li>",
"     <li>",
"      Financial concerns",
"     </li>",
"     <li>",
"      Advanced care preferences",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional components may also include evaluation of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Nutrition/weight",
"      </span>",
"      change",
"     </li>",
"     <li>",
"      Urinary continence",
"     </li>",
"     <li>",
"      Sexual function",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Vision/hearing",
"      </span>",
"     </li>",
"     <li>",
"      Dentition",
"     </li>",
"     <li>",
"      Living situation",
"     </li>",
"     <li>",
"      Spirituality",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This section will focus on the core components of CGA. Although other aspects of the geriatric assessment are usually addressed during the CGA (eg,",
"    <span class=\"nowrap\">",
"     vision/hearing,",
"    </span>",
"    nutrition), these components are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38186?source=see_link\">",
"     \"Geriatric health maintenance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Functional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional status refers to the ability to perform activities necessary or desirable in daily life. Functional status is directly influenced by health conditions, particularly in the context of an elder's environment and social support network. Changes in functional status (eg, not being able to bathe independently) should prompt further diagnostic evaluation and intervention. Measurement of functional status can be valuable in monitoring response to treatment and can provide prognostic information that assists in long-term care planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Activities of daily living",
"    </span>",
"    &nbsp;&mdash;&nbsp;An older adult's functional status can be assessed at three levels: basic activities of daily living (BADLs), instrumental or intermediate activities of daily living (IADLs), and advanced activities of daily living (AADLs).",
"   </p>",
"   <p>",
"    BADLs refer to self-care tasks which include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bathing",
"     </li>",
"     <li>",
"      Dressing",
"     </li>",
"     <li>",
"      Toileting",
"     </li>",
"     <li>",
"      Maintaining continence",
"     </li>",
"     <li>",
"      Grooming",
"     </li>",
"     <li>",
"      Feeding",
"     </li>",
"     <li>",
"      Transferring",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IADLs refer to the ability to maintain an independent household which include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Shopping for groceries",
"     </li>",
"     <li>",
"      Driving or using public transportation",
"     </li>",
"     <li>",
"      Using the telephone",
"     </li>",
"     <li>",
"      Performing housework",
"     </li>",
"     <li>",
"      Doing home repair",
"     </li>",
"     <li>",
"      Preparing meals",
"     </li>",
"     <li>",
"      Doing laundry",
"     </li>",
"     <li>",
"      Taking medications",
"     </li>",
"     <li>",
"      Handling finances",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AADLs vary considerably from individual to individual. These advanced activities include the ability to fulfill societal, community, and family roles as well as participate in recreational or occupational tasks.",
"   </p>",
"   <p>",
"    Scales that measure functional status at each of these levels have been developed and validated. The Vulnerable Elders Scale-13 (VES-13) is a 13-item screening tool that is based upon age, self-rated health, and the ability to perform functional and physical activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. It identifies populations of community-dwelling elders at increased risk for functional decline or death over a five year period (",
"    <a class=\"graphic graphic_table graphicRef73154 \" href=\"mobipreview.htm?18/14/18668\">",
"     table 2",
"    </a>",
"    ). The VES-13 can be self-administered or administered by nonmedical personnel over the telephone or at an office visit in less than five minutes.",
"   </p>",
"   <p>",
"    Questions that ask about specific BADL and IADL functions have also been incorporated into a variety of more generic, health-related quality-of-life instruments (eg, the Medical Outcomes Study Short-form and its shorter version, the SF-12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. Some AADLs (eg, exercise and leisure time physical activity) can be ascertained by using standardized instruments. However, given the broad nature of AADLs, open-ended questions asking how one's day is spent might provide a better assessment of function in healthier older persons.",
"   </p>",
"   <p>",
"    Adults over age 70 are more likely to have motor vehicle accidents, as well as increased associated mortality. The patient's ability and safety to drive a car should also be evaluated in the functional assessment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3385?source=see_link\">",
"     \"Approach to the evaluation of older drivers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24768708\">",
"    <span class=\"h3\">",
"     Gait speed",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to measures of ADLs, gait speed alone predicts functional decline and early mortality in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/11\">",
"     11",
"    </a>",
"    ].&nbsp;Assessing gait speed in clinical practice may identify patients who need further evaluation, such as those at increased risk of falls. Additionally, assessing gait speed may help identify frail patients who might not benefit from treatment of chronic asymptomatic diseases such as hypertension. For example, elevated blood pressure in individuals age 65 and older was associated with increased mortality only in individuals with a walking speed &ge;0.8",
"    <span class=\"nowrap\">",
"     meters/second",
"    </span>",
"    (measured over 6 meters or 20 feet) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Falls/imbalance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of community-dwelling persons age 65 years and one-half of those over 80 years of age fall each year. Patients who have fallen or have a gait or balance problem are at higher risk of having a subsequent fall and losing independence. An assessment of fall risk should be integrated into the history and physical examination of all geriatric patients (",
"    <a class=\"graphic graphic_algorithm graphicRef69682 \" href=\"mobipreview.htm?29/50/30496\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=see_link&amp;anchor=H21#H21\">",
"     \"Falls in older persons: Risk factors and patient evaluation\", section on 'Falls risk assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/12/9417?source=see_link\">",
"     \"Gait disorders of elderly patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cognition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of dementia increases with age, particularly among those over 85 years, yet many patients with cognitive impairment remain undiagnosed. The value of making an early diagnosis includes the possibility of uncovering treatable conditions. The evaluation of cognitive function can include a thorough history, brief cognition screens, a detailed mental status examination, neuropsychologic testing, tests to evaluate medical conditions that may contribute to cognitive impairment (eg, B12, TSH), depression assessment,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic imaging (CT or MRI). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mood disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressive illness in the elder population is a serious health concern leading to unnecessary suffering, impaired functional status, increased mortality, and excessive use of health care resources. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link\">",
"     \"Diagnosis and management of late-life depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Late-life depression remains underdiagnosed and inadequately treated. Depression in the elderly may present atypically, and may be masked in patients with cognitive impairment. A two question screener is easily administered and likely to identify patients at risk if both questions are answered affirmatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/13\">",
"     13",
"    </a>",
"    ]. The questions are:",
"   </p>",
"   <p>",
"    &nbsp;\"During the past month, have you been bothered by feeling down, depressed or hopeless?\"",
"   </p>",
"   <p>",
"    &nbsp;\"During the past month, have you been bothered by little interest or pleasure in doing things?\"",
"   </p>",
"   <p>",
"    This two-question screen is sensitive, but not specific (",
"    <a class=\"graphic graphic_table graphicRef59906 \" href=\"mobipreview.htm?41/16/42251\">",
"     table 3",
"    </a>",
"    ). Thus, a positive screen should be supplemented with seven additional questions to complete the Patient Health Questionnaire-9 (PHQ-9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/14\">",
"     14",
"    </a>",
"    ]. The PHQ-9 has increasingly been used to detect and monitor depression symptoms among elder adults (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"mobipreview.htm?14/12/14541\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/15\">",
"     15",
"    </a>",
"    ]. The PHQ-9 provides a reliable and valid measure of depression severity.",
"   </p>",
"   <p>",
"    A variety of other screens for depression are available and each has its advantages and disadvantages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Polypharmacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older persons are often prescribed multiple medications by different health care providers, putting them at increased risk for drug-drug interactions and adverse drug events. The clinician should review the patient's medications at each visit. The best method of detecting potential problems with polypharmacy is to have patients bring in all of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    medications (prescription and nonprescription) in their bottles. Entering the medication list electronically can help to detect potential medication errors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=see_link\">",
"     \"Drug prescribing for older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42138?source=see_link&amp;anchor=H6972875#H6972875\">",
"     \"Medical care of the nursing home patient in the United States\", section on 'Prevention of adverse drug events'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elder patients should also be asked about alternative medical therapy. As an example, asking about herb use can be done with: \"What prescription medications, over the counter medicines, vitamins, herbs, or supplements do you use?\" (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Social and financial support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The existence of a strong social support network in an elder's life can frequently be the determining factor of whether the patient can remain at home or needs placement in an institution. A brief screen of social support includes taking a social history and determining who would be available to the elder to help if he or she becomes ill. Early identification of problems with social support can help planning and timely development of resource referrals. For patients with functional impairment, the clinician should ascertain who the person has available to help with activities of daily living. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Activities of daily living'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Caregivers should be screened periodically for symptoms of depression or caregiver burnout and, if present, referred for counseling or support groups. Elder mistreatment should be considered in any geriatric assessment, particularly if the patient presents with contusions, burns, bite marks, genital or rectal trauma, pressure ulcers, or malnutrition with no clinical explanation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17850?source=see_link\">",
"     \"Elder mistreatment: Abuse, neglect, and financial exploitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The financial situation of a functionally impaired older adult is important to assess. Elders may qualify for state or local benefits, depending upon their income. Older patients occasionally have other benefits such as long-term care insurance or veteran's benefits that can help in paying for caregivers or prevent the need for institutionalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Advanced care preferences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should begin discussions with all patients about preferences for specific treatments while the patient still has the cognitive capacity to make these decisions. These discussions should include preparation for in-the-moment decision-making [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/17\">",
"     17",
"    </a>",
"    ], which includes choosing an appropriate decision-maker (ie, appointing a durable power of attorney, also known as a health care proxy, to serve as a surrogate in the event of personal incapacity), clarifying and articulating patients&rsquo; values over time, and thinking about factors other than the patient&rsquo;s stated preferences in surrogate decision-making. As an example, patients who want to extend their life as long as possible might be asked about what should be done if the patient&rsquo;s health status changes and doctors recommend against further treatment, or if it becomes too hard for loved ones to keep them at home. Advance directives help guide therapy if a patient is unable to speak for him or herself and are vital to caring optimally for the geriatric population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most meta-analyses have found that comprehensive geriatric assessment (CGA) leads to improved detection and documentation of geriatric problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/1,18-22\">",
"     1,18-22",
"    </a>",
"    ]. However, the ability of CGA to improve outcomes (eg, decreased hospitalization, nursing home admission, and mortality) depends on specific CGA models and the settings where they have been implemented.",
"   </p>",
"   <p>",
"    Several meta-analyses of randomized trials have evaluated five models of CGA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/1,18-22\">",
"     1,18-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Home geriatric assessment",
"     </li>",
"     <li>",
"      Acute geriatric care units",
"     </li>",
"     <li>",
"      Post-hospital discharge",
"     </li>",
"     <li>",
"      Outpatient consultation",
"     </li>",
"     <li>",
"      Inpatient consultation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Home geriatric assessment and acute geriatric care units have been shown to be consistently beneficial for several health outcomes. In contrast, the data are conflicting for post-hospital discharge, outpatient geriatric consultation, and inpatient geriatric consultation services.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Home assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Home geriatric assessment programs focus primarily on preventive rather than rehabilitative services. Although home assessment programs vary, most programs include a visiting nurse trained in geriatric care, as well as a physical therapist, social worker, psychologist, and specialty referrals when appropriate. In addition to home visits, telephone follow-up is routinely performed. Patients assessed at home are usually followed for at least one year.",
"   </p>",
"   <p>",
"    Multiple meta-analyses have found home assessments to be consistently effective in reducing functional decline as well as overall mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/1,19-21\">",
"     1,19-21",
"    </a>",
"    ]. As an example, a meta-analysis of 21 randomized trials found that multidimensional home visit programs were effective in reducing functional decline if a clinical examination was conducted (OR 0.64, CI 0.48-0.87) and in reducing mortality in patients age &le;77 years old (OR 0.74, 95% CI 0.58-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the home visits did not significantly prevent nursing home admissions (OR 0.86, CI 0.68-1.10). Like other meta-analyses for home assessments, this study was limited by heterogeneity across studies for all outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute geriatric care units",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several inpatient geriatric unit approaches have been developed in a variety of clinical settings. Within the Department of Veterans Affairs Hospitals, these are usually referred to as Geriatric Evaluation and Management Units (GEMUs). In academic and private sector hospitals, they are usually labeled Acute Care of the Elderly (ACE) units. ACE units initially included structural modifications to promote mobility and simulate living conditions at home in preparation for a return to independence. More recently, however, ACE units are located on conventional hospital wards as designated geriatric units and tend to focus exclusively on processes of care.",
"   </p>",
"   <p>",
"    GEMUs are hospital wards that care for frail elderly patients through the multidisciplinary team approach. GEMUs have two main advantages over inpatient CGA consultation models. First, physicians staffing the unit generally assume primary care of the patient, thus facilitating the implementation of recommendations. Second, the availability and experience of a dedicated team of providers (eg, nurses and therapists) increase the consistency and geriatric orientation of hospital care.",
"   </p>",
"   <p>",
"    One meta-analysis of 17 randomized trials evaluating geriatric rehabilitative units (within an acute care hospital or a rehabilitation hospital) found that inpatient multidisciplinary programs were associated with improvement in all outcomes at discharge, including better functional status (OR 1.75, 95% CI 1.31-2.35), decreased nursing home admission (RR 0.64, 0.51-0.81), and reduced mortality (RR 0.72, 0.55-0.95) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/22\">",
"     22",
"    </a>",
"    ]. A subsequent meta-analysis of 22 randomized trials of inpatient comprehensive geriatric assessment by mobile teams or in designated wards found that patients who received CGA were more likely to be alive and in their own homes at the end of the scheduled follow-up (OR 1.1, 95% CI 1.05-1.28) and less likely to be living in residential care (OR 0.78, 95% CI 0.69-0.88), compared with usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/23\">",
"     23",
"    </a>",
"    ]. There was also a reduction in the combined outcome of death or functional decline (OR 0.76, 95% CI 0.64- 0.90). Wards appeared to be more effective than mobile units. These meta-analyses were limited by wide variability in interventions across studies. Moreover, due to length of stay (up to three months), such rehabilitative units are rarely available in the United States outside the Department of Veterans Affairs hospitals.",
"   </p>",
"   <p>",
"    ACE units in acute care hospitals promote mobility and include processes to provide patient-centered care with nursing-initiated protocols. ACE units involve more intensive discharge planning and more detailed education to improve medication compliance, in comparison to usual hospital care. In clinical trials, care in ACE units was associated with greater independence in ADLs at discharge, less frequent discharge to a nursing home, shorter and less expensive hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/24\">",
"     24",
"    </a>",
"    ], as well as higher satisfaction rates among patients, family members, physicians, and nurses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the logistical barriers of having dedicated geriatric inpatient units (eg, unfilled beds when the census is light, overflow to other units when the unit is full), some programs have attempted to recreate the core elements of ACE units for hospitalized older persons who are not located on a single unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/26\">",
"     26",
"    </a>",
"    ]. Whether these \"virtual\" units are as effective as ACE units is unknown. The lack of a consistent nursing staff that is trained in the care of older persons may diminish the effectiveness of this model.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Post-hospital discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key elements of post-hospital discharge geriatric assessment include targeting criteria to identify vulnerable patients, a program of multidimensional assessment, comprehensive discharge planning, and home follow-up with nurses with specialized geriatrics training who visit the patients during the hospitalization and at least twice during the weeks following discharge. This intervention usually is initiated one to two days prior to hospital discharge. Similar to the home assessments discussed above, the post-discharge home visits are supplemented by telephone calls and additional visits by physical therapy, occupational therapy, social work,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    home nursing services when indicated. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Home assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Studies of CGA have found inconsistent benefit for post-hospital discharge programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/1,27-30\">",
"     1,27-30",
"    </a>",
"    ]. As an example, in a randomized trial of post-hospitalization CGA conducted in the home versus usual care, there was no difference between treatment and control arms in reducing functional decline, readmission rates, or mortality after 60 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/27\">",
"     27",
"    </a>",
"    ]. In another randomized trial of comprehensive discharge planning with home follow-up versus usual care, there was no difference in functional status, post-discharge acute care visits, depression, or patient satisfaction after 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/28\">",
"     28",
"    </a>",
"    ]. However, those randomly assigned to the intervention were less likely to be readmitted to the hospital compared to the control group (20 versus 37 percent, respectively). The intervention was also associated with a reduction in cost. Subsequent studies of similar discharge management programs with in-home follow-up have also found a reduction in readmission rates, for up to 12 months in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/30\">",
"     30",
"    </a>",
"    ]. A systematic review found that many of the components of CGA were parts of care transition interventions that were effective in reducing rehospitalizations and emergency department visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CGA programs for patients discharged to home from the emergency department were found to be effective at reducing emergency room visits and hospital admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Outpatient consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although meta-analyses have not shown benefit of outpatient CGA consultation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/1,18\">",
"     1,18",
"    </a>",
"    ], more complex CGA programs that address adherence to program recommendations and treat patients at higher risk of hospitalization have led to improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first meta-analysis to evaluate CGA included four randomized trials and did not demonstrate benefit from outpatient CGA consultation in terms of hospital admission, nursing home placement, or",
"    <span class=\"nowrap\">",
"     physical/cognitive",
"    </span>",
"    function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/1\">",
"     1",
"    </a>",
"    ]. However, one trial from this meta-analysis did not address whether recommendations from CGA were implemented and another trial included patients with poor prognoses, which may limit the generalizability of these data.",
"   </p>",
"   <p>",
"    Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/32-35\">",
"     32-35",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/36\">",
"     36",
"    </a>",
"    ], of the subsequent randomized trials have shown some efficacy of outpatient CGA. Representative trials include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CGA coupled with an adherence intervention designed to empower the patient and prompt the primary care physician to adhere to CGA recommendations was evaluated in a randomized trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/32\">",
"       32",
"      </a>",
"      ]. Among community-dwelling older persons with functional disability, urinary incontinence, falls, or depressive symptoms, those randomly assigned to CGA with adherence intervention had less functional decline, less fatigue, and better social functioning over a 15-month period compared to the control group.",
"     </li>",
"     <li>",
"      In a randomized trial evaluating CGA followed by six months of interdisciplinary primary care versus usual primary care in a population at risk for high health care utilization, those randomly assigned to treatment had reduced functional decline, depression, and use of home health services compared to the control group over 15 to 18 months following randomization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, in a large, cluster-randomized trial of multidimensional geriatric assessment followed by either geriatric team management or the primary care clinician alone, there were no differences between the groups in hospitalization, admission to other institutions, and quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a meta-analysis of nine randomized controlled trials (n = 3750) evaluating mortality, there was no benefit of outpatient CGA on survival (RR 0.95, 95% CI 0.82-1.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/18\">",
"     18",
"    </a>",
"    ]. Tests for heterogeneity showed consistency between trial data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Specialized team management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches to outpatient CGA have used some of the more successful components of older models and adapted them to programs within primary care practices:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Geriatric Resources for Assessment and Care of Elders (GRACE) includes home-based CGA and long-term care management by a nurse practitioner and social worker who collaborate with the primary care clinician and a geriatrics interdisciplinary team. In a randomized trial of low income elderly patients, those randomly assigned to the GRACE intervention had better health-related quality-of-life and fewer emergency department visits compared to those assigned to usual care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/37\">",
"       37",
"      </a>",
"      ]. Patients at high risk of hospitalization also had fewer admissions by the second year.",
"     </li>",
"     <li>",
"      Guided Care integrates an intensively trained nurse into primary care practices to provide geriatric assessment and chronic care management to high-risk patients. In a randomized trial of chronically-ill older patients, those randomly assigned to Guided Care reported improved satisfaction rates and had less health care utilization with lower costs of care compared to those randomly assigned to usual care at eight months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/38,39\">",
"       38,39",
"      </a>",
"      ], but by 20 months of follow-up, the only significant reduction of health care was fewer episodes of home health care in the intervention group (OR",
"      <sup>",
"      </sup>",
"      0.70, 95% CI&nbsp;0.53-0.93). Among health maintenance organization (HMO) patients, the intervention also reduced the number of skilled nursing facility admissions (OR 0.53, CI 0.31-0.89) and days of hospitalization (OR 0.48, CI 0.28-0.84) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Practice redesign approaches (screening, structured visit notes, delegation to office staff, outreach to community resources) focus on specific geriatric conditions for assessment and management by physicians or nurse practitioners. In two trials of patients in community-based practices, patients randomly assigned to practice-based interventions received better quality of care for falls and incontinence compared to those randomly assigned to usual care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/34\">",
"       34",
"      </a>",
"      ]. In a study within an academic geriatrics practice, this model of comanagement for five geriatric conditions resulted in improvements in quality of care for dementia, falls, and urinary incontinence when compared to a wait list control group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Inpatient consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two meta-analyses of randomized trials of inpatient consultation found little benefit of inpatient consultation for comprehensive geriatric assessment (CGA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/1,42\">",
"     1,42",
"    </a>",
"    ]. Inpatient consultation for CGA has largely been abandoned except in teaching settings.",
"   </p>",
"   <p>",
"    In contrast, co-management with a geriatrician may be beneficial for hip fracture patients in reducing complications, mortality, readmissions, and delirium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43624/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging. CGA is based on the premise that a systematic evaluation of frail older persons by a team of health professionals may identify a variety of treatable health problems and lead to better health outcomes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No standard criteria are available to readily identify patients who are likely to benefit from CGA. Specific criteria used by CGA programs to identify patients include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Medical comorbidities",
"     </li>",
"     <li>",
"      Psychosocial problems",
"     </li>",
"     <li>",
"      Specific geriatric conditions such as functional disability",
"     </li>",
"     <li>",
"      Previous or predicted high healthcare utilization",
"     </li>",
"     <li>",
"      Consideration of change in living situation (eg, from independent living to assisted living, nursing home, or in-home caregivers)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Community-dwelling older patients with functional disability, increased fall risk, cognitive decline, depression, or those at high risk for high healthcare utilization are appropriate candidates for CGA. Follow-up support is needed to ensure implementation of the findings of the CGA. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inpatients admitted with fractures, failure to thrive, recurrent pneumonia, and pressure sores may benefit from hospitalization on a geriatric unit that provides CGA. Patients age &ge;85 years who have geriatric conditions such as dementia or immobility should also be considered for care on these units. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The assessment team usually consists of a physician, nurse, and social worker. Depending on the patient's condition, the team may also include physical and occupational therapists, nutritionists, pharmacists, psychiatrists, psychologists, dentists, audiologists, podiatrists, and opticians. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Assessment team'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several components of CGA that should be evaluated, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Functional capacity",
"     </li>",
"     <li>",
"      Fall risk",
"     </li>",
"     <li>",
"      Cognition",
"     </li>",
"     <li>",
"      Mood",
"     </li>",
"     <li>",
"      Polypharmacy",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Nutrition/weight",
"      </span>",
"      change",
"     </li>",
"     <li>",
"      Urinary incontinence",
"     </li>",
"     <li>",
"      Sexual function",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Vision/hearing",
"      </span>",
"     </li>",
"     <li>",
"      Dentition",
"     </li>",
"     <li>",
"      Living situation",
"     </li>",
"     <li>",
"      Social support",
"     </li>",
"     <li>",
"      Financial concerns",
"     </li>",
"     <li>",
"      Spirituality",
"     </li>",
"     <li>",
"      Advanced care preferences",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Major components'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Home geriatric assessment has been shown to be effective in improving functional status, preventing institutionalization, and reducing mortality. CGA performed in the hospital, especially in dedicated units, also has benefit on survival. Most programs of hospital discharge management with in-home follow-up have reduced readmission rates. However, studies of CGA have found inconsistent benefit for outpatient and inpatient geriatric consultation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/1\">",
"      Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993; 342:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/2\">",
"      Devons CA. Comprehensive geriatric assessment: making the most of the aging years. Curr Opin Clin Nutr Metab Care 2002; 5:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/3\">",
"      Elsawy B, Higgins KE. The geriatric assessment. Am Fam Physician 2011; 83:48.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.geronet.ucla.edu/images/stories/docs/professionals/Geri_Pre-visit_Questionnaire.pdf (Accessed on November 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/5\">",
"      Reuben DB. Medical care for the final years of life: \"When you're 83, it's not going to be 20 years\". JAMA 2009; 302:2686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/6\">",
"      Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001; 49:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/7\">",
"      Min L, Yoon W, Mariano J, et al. The vulnerable elders-13 survey predicts 5-year functional decline and mortality outcomes in older ambulatory care patients. J Am Geriatr Soc 2009; 57:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/8\">",
"      Min LC, Elliott MN, Wenger NS, Saliba D. Higher vulnerable elders survey scores predict death and functional decline in vulnerable older people. J Am Geriatr Soc 2006; 54:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/9\">",
"      Reuben DB, Borok GM, Wolde-Tsadik G, et al. A randomized trial of comprehensive geriatric assessment in the care of hospitalized patients. N Engl J Med 1995; 332:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/10\">",
"      Ware JE, et al. SF12: an even shorter health survey. Med Outcomes Trust Bull 1996; 4:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/11\">",
"      Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA 2011; 305:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/12\">",
"      Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med 2012; 172:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/13\">",
"      Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ 2003; 327:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/14\">",
"      Rinaldi P, Mecocci P, Benedetti C, et al. Validation of the five-item geriatric depression scale in elderly subjects in three different settings. J Am Geriatr Soc 2003; 51:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/15\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/16\">",
"      Hoyl MT, Alessi CA, Harker JO, et al. Development and testing of a five-item version of the Geriatric Depression Scale. J Am Geriatr Soc 1999; 47:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/17\">",
"      Sudore RL, Fried TR. Redefining the \"planning\" in advance care planning: preparing for end-of-life decision making. Ann Intern Med 2010; 153:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/18\">",
"      Kuo HK, Scandrett KG, Dave J, Mitchell SL. The influence of outpatient comprehensive geriatric assessment on survival: a meta-analysis. Arch Gerontol Geriatr 2004; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/19\">",
"      Stuck AE, Egger M, Hammer A, et al. Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. JAMA 2002; 287:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/20\">",
"      Elkan R, Kendrick D, Dewey M, et al. Effectiveness of home based support for older people: systematic review and meta-analysis. BMJ 2001; 323:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/21\">",
"      Huss A, Stuck AE, Rubenstein LZ, et al. Multidimensional preventive home visit programs for community-dwelling older adults: a systematic review and meta-analysis of randomized controlled trials. J Gerontol A Biol Sci Med Sci 2008; 63:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/22\">",
"      Bachmann S, Finger C, Huss A, et al. Inpatient rehabilitation specifically designed for geriatric patients: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 340:c1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/23\">",
"      Ellis G, Whitehead MA, Robinson D, et al. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ 2011; 343:d6553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/24\">",
"      Landefeld CS, Palmer RM, Kresevic DM, et al. A randomized trial of care in a hospital medical unit especially designed to improve the functional outcomes of acutely ill older patients. N Engl J Med 1995; 332:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/25\">",
"      Counsell SR, Holder CM, Liebenauer LL, et al. Effects of a multicomponent intervention on functional outcomes and process of care in hospitalized older patients: a randomized controlled trial of Acute Care for Elders (ACE) in a community hospital. J Am Geriatr Soc 2000; 48:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/26\">",
"      Arbaje AI, Maron DD, Yu Q, et al. The geriatric floating interdisciplinary transition team. J Am Geriatr Soc 2010; 58:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/27\">",
"      Siu AL, Kravitz RL, Keeler E, et al. Postdischarge geriatric assessment of hospitalized frail elderly patients. Arch Intern Med 1996; 156:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/28\">",
"      Naylor MD, Brooten D, Campbell R, et al. Comprehensive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial. JAMA 1999; 281:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/29\">",
"      Caplan GA, Williams AJ, Daly B, Abraham K. A randomized, controlled trial of comprehensive geriatric assessment and multidisciplinary intervention after discharge of elderly from the emergency department--the DEED II study. J Am Geriatr Soc 2004; 52:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/30\">",
"      Naylor MD, Aiken LH, Kurtzman ET, et al. The care span: The importance of transitional care in achieving health reform. Health Aff (Millwood) 2011; 30:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/31\">",
"      Hesselink G, Schoonhoven L, Barach P, et al. Improving patient handovers from hospital to primary care: a systematic review. Ann Intern Med 2012; 157:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/32\">",
"      Reuben DB, Frank JC, Hirsch SH, et al. A randomized clinical trial of outpatient comprehensive geriatric assessment coupled with an intervention to increase adherence to recommendations. J Am Geriatr Soc 1999; 47:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/33\">",
"      Boult C, Boult LB, Morishita L, et al. A randomized clinical trial of outpatient geriatric evaluation and management. J Am Geriatr Soc 2001; 49:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/34\">",
"      Wenger NS, Roth CP, Shekelle PG, et al. A practice-based intervention to improve primary care for falls, urinary incontinence, and dementia. J Am Geriatr Soc 2009; 57:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/35\">",
"      Burns R, Nichols LO, Martindale-Adams J, Graney MJ. Interdisciplinary geriatric primary care evaluation and management: two-year outcomes. J Am Geriatr Soc 2000; 48:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/36\">",
"      Fletcher AE, Price GM, Ng ES, et al. Population-based multidimensional assessment of older people in UK general practice: a cluster-randomised factorial trial. Lancet 2004; 364:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/37\">",
"      Counsell SR, Callahan CM, Clark DO, et al. Geriatric care management for low-income seniors: a randomized controlled trial. JAMA 2007; 298:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/38\">",
"      Boult C, Reider L, Frey K, et al. Early effects of \"Guided Care\" on the quality of health care for multimorbid older persons: a cluster-randomized controlled trial. J Gerontol A Biol Sci Med Sci 2008; 63:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/39\">",
"      Leff B, Reider L, Frick KD, et al. Guided care and the cost of complex healthcare: a preliminary report. Am J Manag Care 2009; 15:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/40\">",
"      Boult C, Reider L, Leff B, et al. The effect of guided care teams on the use of health services: results from a cluster-randomized controlled trial. Arch Intern Med 2011; 171:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/41\">",
"      Ganz DA, Koretz BK, Bail JK, et al. Nurse practitioner comanagement for patients in an academic geriatric practice. Am J Manag Care 2010; 16:e343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/42\">",
"      Ellis G, Whitehead MA, O'Neill D, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2011; :CD006211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/43\">",
"      Fisher AA, Davis MW, Rubenach SE, et al. Outcomes for older patients with hip fractures: the impact of orthopedic and geriatric medicine cocare. J Orthop Trauma 2006; 20:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43624/abstract/44\">",
"      Marcantonio ER, Flacker JM, Wright RJ, Resnick NM. Reducing delirium after hip fracture: a randomized trial. J Am Geriatr Soc 2001; 49:516.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3009 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43624=[""].join("\n");
var outline_f42_38_43624=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSESSMENT TEAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONDUCTING THE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Framework",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Assessment tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MAJOR COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Functional status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Activities of daily living",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24768708\">",
"      - Gait speed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Falls/imbalance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cognition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mood disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Polypharmacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Social and financial support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Advanced care preferences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Home assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute geriatric care units",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Post-hospital discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Outpatient consultation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Specialized team management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Inpatient consultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/3009\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3009|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?29/50/30496\" title=\"algorithm 1\">",
"      Prevention falls algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3009|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/20/12622\" title=\"table 1\">",
"      Screening frail older patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/14/18668\" title=\"table 2\">",
"      Vulnerable elders surv 13 scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/16/42251\" title=\"table 3\">",
"      Screening tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/12/14541\" title=\"table 4\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3385?source=related_link\">",
"      Approach to the evaluation of older drivers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17850?source=related_link\">",
"      Elder mistreatment: Abuse, neglect, and financial exploitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34215?source=related_link\">",
"      Failure to thrive in elderly adults: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/12/9417?source=related_link\">",
"      Gait disorders of elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38186?source=related_link\">",
"      Geriatric health maintenance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42138?source=related_link\">",
"      Medical care of the nursing home patient in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_38_43625="Treatment of visceral leishmaniasis";
var content_f42_38_43625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of visceral leishmaniasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43625/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43625/contributors\">",
"     Caryn Bern, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43625/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43625/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43625/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43625/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/38/43625/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral leishmaniasis (VL; also known as kala-azar) is caused by parasites of the Leishmania donovani complex. These parasites may be divided taxonomically and geographically into two groups: L. donovani (South Asia and East Africa) and L. infantum (Mediterranean basin, western Asia from the Middle East to Pakistan, Brazil and other parts of the New World) (",
"    <a class=\"graphic graphic_table graphicRef58861 \" href=\"mobipreview.htm?13/56/14221\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. L. chagasi is synonymous with L. infantum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to treatment of VL will be reviewed here. Issues related to epidemiology, clinical manifestations, and prevention of visceral leishmaniasis are discussed separately, as are issues related to cutaneous leishmaniasis. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of treatment, the case fatality rate of fully manifest clinical VL (kala-azar) without treatment is &gt;90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Mortality is often due to hemorrhagic or infectious complications. Treatment consists of antileishmanial therapy; the main constraints on the choice of antileishmanial drug are cost and availability. Drug resistance must also be considered, especially for VL originating in the Indian subcontinent. Supportive therapy to address nutritional status, concomitant anemia, hemorrhagic complications, and secondary infections is also essential to optimize treatment outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Therapeutic approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with VL should be evaluated for HIV coinfection; if found, HIV should be treated aggressively. In the absence of effective immune reconstitution, treatment response is poor in HIV-VL-coinfected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'HIV coinfection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THERAPEUTIC APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents with efficacy against visceral leishmaniasis (VL) include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , pentavalent antimonial drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    (a parenteral aminoglycoside), and miltefosine (the first oral drug for treatment of VL) (",
"    <a class=\"graphic graphic_table graphicRef80899 \" href=\"mobipreview.htm?18/33/18972\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     Liposomal amphotericin B",
"    </a>",
"    is the drug with the highest therapeutic efficacy and the most favorable safety profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The pentavalent antimonial drugs, sodium stibogluconate (SSG) and meglumine antimoniate, remain the most widely used antileishmanial agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. Conventional amphotericin B deoxycholate has high antileishmanial efficacy but is associated with high risk of renal toxicity and other side effects. In the past decade, two new drugs have been added to the armamentarium: paromomycin and miltefosine; neither is readily available in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. Pentamidine isethionate was previously a second-line alternative treatment but is rarely used due to suboptimal efficacy and toxicity (with particular risk of irreversible insulin-dependent diabetes mellitus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensitivity to specific drugs varies by region. High level resistance to antimonial drugs is common in India and Nepal; in these regions conventional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate has replaced SSG as the first-line treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/9,12,14,15\">",
"     9,12,14,15",
"    </a>",
"    ]. In South Asia, L. donovani appears to respond to lower doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    than L. infantum or East African L. donovani [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. However, species identification is not usually critical to treatment decisions for VL (in contrast to cutaneous leishmaniasis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate binds to parasite ergosterol precursors such as lanosterol, causing disruption of the parasite membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Conventional",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate should be administered as a slow intravenous infusion over 4 hours. Effective regimens include 0.75 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for 15 to 20 days or 0.75 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day for 30 to 40 days. Alternate day dosing and pretreatment saline loading may decrease risk of renal toxicity and other adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal function should be monitored carefully;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    can cause renal abnormalities such as distal renal tubular acidosis, nephrogenic diabetes insipidus and renal potassium wasting. These are usually reversible with discontinuation of the drug, although dose-related acute renal insufficiency can be progressive and incompletely reversible.",
"   </p>",
"   <p>",
"    Fever and rigors are also common, especially at the beginning of infusion; pretreatment antipyretics may decrease severity. Other adverse effects include malaise, anorexia, bone marrow suppression, myalgia, arthralgia, and rash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Liposomal",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     Liposomal amphotericin B",
"    </a>",
"    (AmBisome, Gilead) consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    packaged with cholesterol and other phospholipids within a small unilamellar liposome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/19\">",
"     19",
"    </a>",
"    ]. The characteristics of this specialized formulation facilitate improved antimicrobial efficacy with reduced systemic toxicity. The liposomal drug formulation has improved stability in blood, macrophages, and tissues, permitting more effective tissue penetration with sustained tissue drug levels, especially in the liver and spleen. This formulation has increased affinity for ergosterol and its precursors with excellent antimicrobial efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, the presence of cholesterol in the formulation minimizes interaction with mammalian cell membranes, thereby reducing toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     Liposomal amphotericin B",
"    </a>",
"    is the only drug with US Food and Drug Administration (FDA) approval for treatment of VL in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/21\">",
"     21",
"    </a>",
"    ]. Four European trials including a total of 348 patients treated with total cumulative doses &gt;18",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    demonstrated cure rates of 98 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Two African studies including a total of 74 patients treated with total doses ranging from 10 to 24",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    demonstrated cure rates of 88 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Three Indian trials including a total of 144 patients treated with total doses of 14 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    demonstrated cure rates of 96 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. An expert panel convened by the WHO in 2005 concluded that a total cumulative dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is adequate to achieve high cure rates in immunocompetent VL patients in all regions of the world, regardless of the specific dosing schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The wide variation in successful dosing schedules may reflect the fact that the drug accumulates in viscera and the active drug is then slowly released. Pharmacokinetic studies suggest that optimal tissue levels may be achieved if the initial dose is at least 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/19\">",
"     19",
"    </a>",
"    ], although the FDA recommends 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on days 1 to 5, 14, and 21 for a total dose of 21",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/21\">",
"     21",
"    </a>",
"    ]. In New Zealand, the recommended regimen is 1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for 21 days, or 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for 10 days. In Italy, the standard regimen consists of 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    days 1 to 5 and 10, for a total dose of 18",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/31\">",
"     31",
"    </a>",
"    ]. Many European pediatricians favor a regimen of 10",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    on two consecutive days, obviating the need for longer hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In VL-endemic areas in Asia, Africa, and Latin America, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    has been constrained by the high cost of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/10\">",
"     10",
"    </a>",
"    ]. Liposomal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is available through the World Health Organization at preferential pricing for non-profit and public sectors in low and selected moderate income VL-endemic countries; nonetheless, the total cost of a treatment course is substantially higher than generic SSG or conventional amphotericin B deoxycholate.",
"   </p>",
"   <p>",
"    Because cost is the limiting factor for use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    , many different regimens have been evaluated in India in an attempt to find the lowest total dose with acceptable efficacy. Among 203 patients in one study, a single dose of 7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    gave a 90 percent cure rate at 6 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/33\">",
"     33",
"    </a>",
"    ]. Among 84 patients with VL in another study, total doses of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in various schedules gave cure rates &gt;95 percent, while a single dose of 3.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    led to a cure rate of 89 percent in a limited number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/28\">",
"     28",
"    </a>",
"    ]. A third trial including 304 patients compared a single dose of liposomal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    with conventional amphotericin B deoxycholate (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    total dose; 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day for 15 doses); efficacy was equivalent (96 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/34\">",
"     34",
"    </a>",
"    ]. Although the use of single dose therapy (10",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is under consideration in the Indian VL control program, total doses below 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    are not currently considered adequate as monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     Liposomal amphotericin B",
"    </a>",
"    causes substantially less toxicity than conventional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate because of differences in cell penetration, pharmacokinetic properties, and interactions with lipoproteins and host cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/17\">",
"     17",
"    </a>",
"    ]. Infusion-related reactions are less common and less severe than with conventional amphotericin B or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/11\">",
"     11",
"    </a>",
"    ]. Although transient rises in creatinine can occur, acute and chronic toxicity from liposomal amphotericin B is low, even when 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is administered as a single dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    appears to be rare, although resistant parasites have been generated in culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics and in vitro and in vivo activity profiles differ with different lipid delivery vehicles, although the mechanism of action for all formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is the same [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trial data are limited for lipid associated amphotericin preparations other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    , and optimum dosing schedules are not established. For",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    colloidal dispersion, studies in Italy and India have demonstrated efficacy &gt;95 percent for regimens totaling 7.5 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over six to seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In India efficacy has been demonstrated for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    (short courses totaling 5 to 15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    and amphotericin B lipid emulsion (15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/11,39\">",
"     11,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=see_link\">",
"     Amphotericin B lipid complex",
"    </a>",
"    has a side effect profile intermediate between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    and conventional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/11,29\">",
"     11,29",
"    </a>",
"    ]. At higher doses, amphotericin B colloidal dispersion has been associated with severe back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pentavalent antimonial compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pentavalent antimonial drugs have been used for the treatment of VL since the 1940s. Sodium stibogluconate (SSG, brand name Pentostam [GSK]; also generic versions from many manufacturers) and meglumine antimoniate (brand name Glucantime [Aventis]) remain the most widely used antileishmanial agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no trials comparing the efficacy and toxicity of SSG with meglumine antimoniate for VL; the two drugs are considered largely interchangeable and the choice between them is governed by availability and historical usage patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/9\">",
"     9",
"    </a>",
"    ]. There have been several double-blind controlled comparisons of Pentostam and generic SSG from one specific manufacturer demonstrating equivalent efficacy and toxicity profiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. However, generic SSG from other manufacturers has not been tested, and the efficacy and toxicity of these preparations are considered unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/9\">",
"     9",
"    </a>",
"    ]. In India and Nepal, clusters of patients with severe toxicity and fatal outcomes have raised concern about the use of untested generic SSG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action of pentavalent antimonial drugs is uncertain; in vivo conversion to trivalent antimony compounds may be involved in both antileishmanial activity and drug toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/46\">",
"     46",
"    </a>",
"    ]. Other studies suggest that antileishmanial activity may occur via inhibition of parasite ADP phosphorylation, DNA I topoisomerase,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    trypanothione reductase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/17,47\">",
"     17,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxicity is usually related to the cumulative dose. The most serious adverse effects are cardiotoxicity and clinical pancreatitis, either of which can lead to death. Other side effects are frequent and include myalgia and arthralgia, nausea, vomiting, abdominal pain, headache, fatigue, rash, electrocardiographic abnormalities, elevated liver function tests, elevated lipase and amylase levels, and decreased hemoglobin, white blood cell, and platelet counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimony can lead to non-specific EKG changes, including flattening or inversion of the T waves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/49\">",
"     49",
"    </a>",
"    ]. Prolongation of the corrected QT interval (measured QT interval divided by the square root of the preceding RR interval) to &gt;0.5 seconds or development of T wave inversion with concave ST segments are considered signs of serious cardiotoxicity and should prompt immediate cessation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/48\">",
"     48",
"    </a>",
"    ]. Pre-existing cardiac disease is thought to increase the risk of cardiotoxicity and is a contraindication to use of antimonial drugs.",
"   </p>",
"   <p>",
"    The standard dosing regimen consists of 20",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of antimony for 28 to 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/48\">",
"     48",
"    </a>",
"    ]. Administration is intravenous or intramuscular. Intramuscular injections are frequently used in regions with limited health infrastructure, but are very painful as the volume is large and the compound is a tissue irritant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/40\">",
"     40",
"    </a>",
"    ]. Sterile abscesses can result from intramuscular injection and phlebitis is a common complication of intravenous administration.",
"   </p>",
"   <p>",
"    Prior to and during therapy, clinical monitoring as well as electrocardiogram (EKG), complete blood count, creatinine, transaminase, lipase, and amylase levels should be performed weekly. Asymptomatic elevations of amylase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lipase levels occur in the majority of patients and do not require cessation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/50\">",
"     50",
"    </a>",
"    ]. However, clinical pancreatitis is an indication for suspending treatment, as are EKG findings as described above.",
"   </p>",
"   <p>",
"    Accurate in vitro testing for antimonial resistance requires the use of amastigotes in a macrophage cellular system (not promastigote-based assays) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/51\">",
"     51",
"    </a>",
"    ]. High level resistance to antimonial drugs is common in Bihar State, India, especially north of the river Ganges, and in southeastern Nepal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/14,15,52\">",
"     14,15,52",
"    </a>",
"    ]. In these regions, conventional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate has replaced SSG as the first-line treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/9,12,14,15\">",
"     9,12,14,15",
"    </a>",
"    ]. Outside of these regions, efficacy of antimonial drugs is generally &gt;95 percent.",
"   </p>",
"   <p>",
"    Pentavalent antimonial compounds are not licensed in the United States, but Pentostam is available under an investigational new drug (IND) protocol from the United States Centers for Disease Control and Prevention (CDC) Drug Service for civilians and the Walter Reed Army Medical Center for United States military personnel. Consultations about diagnostic testing, management, and drug requests should be addressed to the Division of Parasitic Diseases Public Inquiries line (404-718-4745; email",
"    <a class=\"external\" href=\"mailto:parasites@cdc.gov\">",
"     parasites@cdc.gov",
"    </a>",
"    ), CDC Drug Service (404-639-3670), or for emergencies outside of business hours, CDC Emergency Operations Center (770-488-7100).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Miltefosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miltefosine (hexadecylphosphocholine, Impavido, Paladin Labs Inc.) is the only oral agent for treatment of VL. Miltefosine is licensed in Germany, India, and Colombia, but not in the United States. The United States distributor for miltefosine is Caligor Rx Inc, Professional Medical Suppliers, 1226 Lexington Ave, New York NY 10028, (212-369-4034). Its use necessitates an individual compassionate use investigational new drug (IND) protocol from the FDA.",
"   </p>",
"   <p>",
"    The mechanism of action of miltefosine is not fully understood. The drug is a phosphocholine analogue thought to interfere with cell-signaling pathways, and there is some evidence that it targets parasite lipid biosynthetic enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Miltefosine is an effective drug for treatment of VL. In a study including 398 patients with VL in India, 299 received treatment with miltefosine (50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if &lt;25 kg and 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if &gt;25 kg) and 99 received treatment with conventional amphotericin deoxycholate (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day; total 15 infusions); cure rates at six months were 94 and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/53\">",
"     53",
"    </a>",
"    ]. Among children miltefosine is safe and approximately 90 percent effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/54\">",
"     54",
"    </a>",
"    ]. Evaluation of outpatient miltefosine therapy is also encouraging; among 1132 adult and pediatric VL patients in northern India, six-month cure rates were 82 percent by intention to treat analysis and 94 percent by per protocol analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standard regimen is 2.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    orally for 28 days. Miltefosine is teratogenic in experimental models; if miltefosine therapy is planned for women of reproductive age, a negative pregnancy test and effective contraception during and for at least two months after therapy are required.",
"   </p>",
"   <p>",
"    Vomiting may occur in up to 65 percent of patients and diarrhea in 5 to 20 percent of patients, but these adverse effects rarely require suspension of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/56\">",
"     56",
"    </a>",
"    ]. Transaminase elevations occur in 15 to 30 percent of patients, which may require suspension of therapy if severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/57\">",
"     57",
"    </a>",
"    ]. If the patient cannot tolerate miltefosine due to side effects, an alternative drug should be used.",
"   </p>",
"   <p>",
"    The long half-life of miltefosine and the potential for poor compliance with oral therapy administered without clinician supervision has raised concern regarding potential for emergence of resistance. Clinical resistance to miltefosine has not been reported, although clinical failure rates of 8 to 30 percent have been reported in miltefosine treatment programs (compared with 3 to 4 percent in Phase III trials) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/56,58\">",
"     56,58",
"    </a>",
"    ]. Relapse of VL following miltefosine treatment has been described in 3 to 11 percent of patients treated in clinical trials with at least 6 months of followup; such patients usually respond well to amphotericin B rescue therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/56,59\">",
"     56,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Paromomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     Paromomycin",
"    </a>",
"    (aminosidine) is an aminoglycoside antibiotic with activity against Leishmania as well as bacteria and some enteric protozoa. It binds the 30S ribosomal subunit, causing impaired parasite protein synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/60\">",
"     60",
"    </a>",
"    ]. Parenteral paromomycin was used as an antibiotic until the 1980s when the introduction of newer antibiotics led to cessation of its manufacture. Topical and oral forms of paromomycin have been used for treatment of cutaneous leishmaniasis and intestinal amebiasis, respectively, but availability of these forms in the United States is limited. The parenteral form has received FDA Orphan Drug Status but is not currently available in the United States. Injectable paromomycin is produced in India (Glanda Pharma, Hyderabad) for the non-profit sector [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trials conducted in India have demonstrated good efficacy for doses ranging from 12 to 20",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (intramuscular or intravenous administration) for 21 to 28 days (88 to 95 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. In India the recommended dosing schedule for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    monotherapy is 15",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (equivalent to 11",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    paromomycin base) for 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parasite susceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    appears to be geographically variable. In East Africa, the efficacy of paromomycin monotherapy with the dosing range evaluated in India was &lt;90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Clinical trials are currently underway to determine the optimum paromomycin dosing schedule for African VL. Some non-governmental organizations use paromomycin in combination with antimonial therapy, but optimized dosing schedules have not yet been determined in controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/40,65\">",
"     40,65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Adverse effects are uncommon; they include elevated liver function enzymes (&ge;3 times the upper limit of normal in 6 percent of patients), reversible ototoxicity (2 percent) and renal insufficiency (1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acquisition of resistance during therapy is a theoretical risk (since resistance can be induced in vitro), although thus far no clinically acquired resistance has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/66\">",
"     66",
"    </a>",
"    ]. Given the parenteral administration and relatively short half-life, the risk of inducing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    resistance is likely lower than for miltefosine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a broad consensus among experts that antileishmanial therapy in endemic regions should move toward combination drug regimens to 1) protect the limited armamentarium of antileishmanial agents from development of acquired resistance, and 2) establish shorter treatment courses with high efficacy to improve compliance and decrease treatment costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/40,67\">",
"     40,67",
"    </a>",
"    ]. However, published data are sparse and recommendations for specific combination regimens do not yet exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several small trials or observational studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    (12 to 18",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    combined with SSG (20",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    have demonstrated good parasitological response rates for dosing schedules of 17 to 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/63-65,68\">",
"     63-65,68",
"    </a>",
"    ]. In a dose-finding study in India, regimens that combined single dose liposomal amphotericin (5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    with miltefosine (100 mg daily) for 7, 10, or 14 days showed efficacy rates of 96 to 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent trial among 634 patients in India with non-severe VL demonstrated 97 to 98 percent efficacy for each of three combination regimens: single intravenous infusion of liposomal amphotericin (5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    plus miltefosine (50 mg per day for 7 days), single intravenous infusion of liposomal amphotericin (5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    plus intramuscular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    (11",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 10 days), and miltefosine (50 mg per day for 10 days) plus intramuscular paromomycin (11",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 10 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/70\">",
"     70",
"    </a>",
"    ]. These data are a promising first step in the movement to shift to combination therapy in the future. Further research is needed to validate the efficacy of these regimens in severe VL in India, as well as to ascertain efficacy for other geographical areas where higher doses of paromomycin and liposomal amphotericin monotherapy are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     HIV coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) both target the cellular immune response and exert synergistically detrimental effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/6,71,72\">",
"     6,71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with HIV coinfection may have severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atypical clinical presentations and may respond poorly to treatment in the absence of immune reconstitution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The highest cumulative number of HIV-VL coinfections have been reported from Spain, but this is presumed to reflect better reporting from this region compared to Africa or Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/6,73\">",
"     6,73",
"    </a>",
"    ]. The disease burden is greatest for the Horn of Africa and is increasing in the Indian subcontinent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/6,73\">",
"     6,73",
"    </a>",
"    ]. In treatment facilities on the Ethiopia-Sudan border, more than 30 percent of VL patients are coinfected with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/74\">",
"     74",
"    </a>",
"    ]. In one treatment facility in Bihar, India, the focus with the highest burden of VL in the world, the prevalence of HIV coinfection in VL patients rose from 0.9 to 2.2 percent between 2000 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiparasitic therapy &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       Liposomal amphotericin B",
"      </a>",
"      is currently the treatment of choice for patients with HIV and VL coinfection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/8,10\">",
"       8,10",
"      </a>",
"      ]. Liposomal and lipid complex preparations are significantly better tolerated than conventional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or pentavalent antimony, although these agents have comparable efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/11,23,75-79\">",
"       11,23,75-79",
"      </a>",
"      ]. In VL-endemic areas in Asia, Africa, and Latin America, the use of liposomal amphotericin B has been constrained by the high cost of the drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Liposomal'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients with HIV-VL coinfection require higher total doses of amphotericin B than VL patients without HIV. Because of greater tolerability, higher daily dosing is recommended for liposomal or lipid complex preparations than conventional amphotericin B [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/10,21\">",
"       10,21",
"      </a>",
"      ]. Dosing regimens are as follows [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/10,21,23,76,77,80\">",
"       10,21,23,76,77,80",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Liposomal or lipid complex preparations &mdash; 2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      administered on consecutive days or in an interrupted schedule (eg, 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on days 1 to 5, 10, 17, 24, 31, and 38) to achieve a total cumulative dose of 20 to 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      body weight.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      deoxycholate 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      to achieve a total dose of 1.5 to 2.0 g.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on the use of miltefosine among HIV-VL-coinfected patients are limited; in one series including 25 patients, the initial cure rate was 64 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/81\">",
"     81",
"    </a>",
"    ]. Among 199 Ethiopian VL patients with a high prevalence of HIV-coinfection treated with miltefosine or pentavalent antimony, miltefosine was associated with a lower cure rate at 30 days (70 versus 81 percent), but more favorable mortality rate (6 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/41\">",
"     41",
"    </a>",
"    ]. Among 25 patients with HIV-VL coinfection in Europe, meglumine antimoniate treatment was associated with adverse effects in more than half of cases, including acute pancreatitis, acute renal failure and leukopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/82\">",
"     82",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    There are no data addressing the efficacy of paromomycin for treatment of VL in HIV-coinfected patients.",
"    <br/>",
"    <br/>",
"    There are no data addressing the efficacy of combination regimens in HIV-VL coinfected patients and the optimal regimen is unknown. One review suggests that patients with multiple relapses may be offered a combination of miltefosine plus paromomycin, or miltefosine plus liposomal amphotericin on a compassionate use basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiretroviral therapy &mdash; Among European patients with HIV-VL coinfection not taking antiretroviral therapy (ART), the 12-month risk of VL relapse after initial antileishmanial treatment was 90 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. Highly active antiretroviral therapy has significantly improved the survival of HIV-VL-coinfected patients and can decrease the likelihood of relapse after antileishmanial therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/74,85-87\">",
"       74,85-87",
"      </a>",
"      ]. In a study that included 356 Ethiopian patients, ART decreased VL relapse rates by approximately 50 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/74\">",
"       74",
"      </a>",
"      ]. Antiretroviral therapy should be managed as discussed in detail separately [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36265?source=see_link\">",
"       \"Modifying HIV antiretroviral therapy regimens\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary prophylaxis &mdash; There has been one controlled trial of secondary prophylaxis to prevent relapse after treatment of an initial VL episode; all other available data come from observational studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/88\">",
"       88",
"      </a>",
"      ]. The trial demonstrated lower relapse rates at one year with intermittent administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=see_link\">",
"       amphotericin B lipid complex",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 21 days) compared to no prophylaxis (50 versus 78 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/88\">",
"       88",
"      </a>",
"      ]. Decreased relapse rates have also been observed in retrospective studies of prophylaxis with monthly SSG (850 mg) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (200 to 350 mg) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]. The optimal regimen is uncertain.",
"      <br/>",
"      <br/>",
"      General consensus is that secondary prophylaxis is usually warranted, particularly in the setting of CD4+ counts &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/83-85,88\">",
"       83-85,88",
"      </a>",
"      ]. Although the risk of relapse is much higher when the CD4+ lymphocyte count remains &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      VL relapses can occur even with CD4+ counts &gt;350",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      leading some experts to advise against discontinuation of secondary prophylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/74,89,90\">",
"       74,89,90",
"      </a>",
"      ]. Others favor considering discontinuation if there are no signs of VL and the CD4+ count has remained &gt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      for at least six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/6\">",
"       6",
"      </a>",
"      ]. For HIV-VL coinfected patients with multiple relapses, compassionate use of combination regimens can be considered (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Combination therapy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;VL infection in the setting of pregnancy has been associated with congenital infection and fetal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/91\">",
"     91",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     Liposomal amphotericin B",
"    </a>",
"    is the drug of choice for treatment of VL in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Alternative choices include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate and pentavalent antimony. Good clinical and pregnancy outcomes have been reported for five pregnant women treated with liposomal amphotericin B and three cases treated with meglumine antimoniate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/92-94\">",
"     92-94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Miltefosine is contraindicated in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Post kala-azar dermal leishmaniasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of post kala-azar dermal leishmaniasis (PKDL) requires prolonged treatment; the optimal approach is uncertain and clinical trial data are limited. A frequent approach consists of 60 to 120 daily injections of SSG (20",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/95\">",
"     95",
"    </a>",
"    ]. In an Indian trial performed in 1987 including 108 patients with PKDL, cure rates for those treated with 120 injections of 10",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    were 50, 67, and 92 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate may be superior to antimony treatment in terms of speed of response and cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/97\">",
"     97",
"    </a>",
"    ]. This was evaluated in a study of 22 patients in India in 1997 treated with amphotericin B deoxycholate infusion (1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 20 days with intervening 20 day drug-free intervals) or SSG intramuscular injection (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    day for 20 days with intervening 20-day drug-free intervals) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/97\">",
"     97",
"    </a>",
"    ]. Cure rates for the amphotericin arm and the SSG arm were 100 percent",
"    <span class=\"nowrap\">",
"     (11/11)",
"    </span>",
"    and 64 percent",
"    <span class=\"nowrap\">",
"     (7/11),",
"    </span>",
"    respectively. The decrease in the cure rate with SSG from 1987 to 1997 may also reflect the increasing SSG resistance in Bihar observed over that period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case report described resolution of PKDL with oral miltefosine (100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 12 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/98\">",
"     98",
"    </a>",
"    ]. A clinical trial of miltefosine for PKDL is underway in India.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ASSESSING RESPONSE TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to treatment is generally assessed clinically, based on resolution of fever, decrease in spleen size, and weight gain. Serological tests are not useful tests of cure as they remain positive for months to years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. The urine KAtex assay detects parasite antigen in urine and becomes negative more rapidly than serologic assays, but has poor sensitivity for diagnosis and is not widely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43625/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients whose clinical response is equivocal (eg, no decrease in spleen size within a month of treatment initiation, continued fever) or are suspected to have relapse, bone marrow, or splenic aspirate should be performed to confirm the diagnosis of VL",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to evaluate for alternative diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Agents with activity against visceral leishmaniasis (VL) include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , pentavalent antimonial drugs,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      (a parenteral aminoglycoside) and miltefosine (the first oral drug for treatment of VL) (",
"      <a class=\"graphic graphic_table graphicRef80899 \" href=\"mobipreview.htm?18/33/18972\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Therapeutic approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend liposomal amphotericin for treatment of VL in circumstances when this agent is available (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ); it has the highest therapeutic efficacy and the most favorable safety profile. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Liposomal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For circumstances in which liposomal amphotericin is not available, we suggest either conventional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate or pentavalent antimonial drugs (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Both require close monitoring for toxicity. Pentavalent antimonial drugs should not be used for patients who acquired VL in northern India or Nepal because of the high rate of primary drug resistance in this region. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Conventional'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Pentavalent antimonial compounds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Miltefosine and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      are antileishmanial drugs with high efficacy and good safety profiles, but neither is readily available in the United States. These are also acceptable second line therapies. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Miltefosine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Paromomycin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinial trials are planned or underway for a variety of antileishmanial drug combinations. Thus far the efficacy and safety of combination regimens have not been established. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with VL should be evaluated for HIV co-infection; if found, HIV-VL coinfection should be treated aggressively with antiparasitic therapy and antiretroviral therapy. We suggest antiparasitic therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ); a higher cumulative dose is required than for VL patients without HIV coinfection. Following therapy, we suggest secondary prophylaxis to prevent relapses (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In the absence of effective immune reconstitution, treatment response is poor in HIV-VL-coinfected patients. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'HIV coinfection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VL infection in the setting of pregnancy has been associated with congenital infection and fetal death. We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      for treatment of VL in pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternative choices include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate and pentavalent antimony. Miltefosine is contraindicated in pregnancy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Response to treatment is generally assessed clinically, based on resolution of fever, decrease in spleen size, and weight gain. Serological tests are not useful tests of cure as they remain positive for months to years after treatment. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Assessing response to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of post kala-azar dermal leishmaniasis (PKDL) requires prolonged treatment; the optimal approach is uncertain and clinical trial data are limited. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Post kala-azar dermal leishmaniasis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jeronimo, SMB, de Queiroz Sousa, et al. Leishmaniasis. In: Tropical infectious diseases: principles, pathogens and practice, Guerrant, RL, Walker, DH, Weller, PF (Eds), Churchill Livingstone Elsevier, Edinburgh, Scotland 2006. p.1095-1113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/2\">",
"      Kuhls K, Keilonat L, Ochsenreither S, et al. Multilocus microsatellite typing (MLMT) reveals genetically isolated populations between and within the main endemic regions of visceral leishmaniasis. Microbes Infect 2007; 9:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/3\">",
"      Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996; 14:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/4\">",
"      Sen Gupta, PC. History of kala-azar in India. Indian Medical Gazette 1947; 82:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/5\">",
"      Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004; 38:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/6\">",
"      Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/7\">",
"      Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97 Suppl 1:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/8\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/9\">",
"      Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006; 61:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/10\">",
"      Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006; 43:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/11\">",
"      Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004; 38:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/12\">",
"      Murray HW. Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 2004; 71:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/13\">",
"      Das VN, Siddiqui NA, Pandey K, et al. A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India. Ther Clin Risk Manag 2009; 5:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/14\">",
"      Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/15\">",
"      Rijal S, Chappuis F, Singh R, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 2003; 97:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/16\">",
"      den Boer ML, Alvar J, Davidson RN, et al. Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs 2009; 14:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/17\">",
"      Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des 2002; 8:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/18\">",
"      Sundar S, Chakravarty J, Rai VK, et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 2007; 45:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/19\">",
"      Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49 Suppl 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/20\">",
"      Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003; 4:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/21\">",
"      Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/22\">",
"      Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/23\">",
"      Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/24\">",
"      di Martino L, Davidson RN, Giacchino R, et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997; 131:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/25\">",
"      Syriopoulou V, Daikos GL, Theodoridou M, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003; 36:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/26\">",
"      Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998; 76:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/27\">",
"      Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996; 124:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/28\">",
"      Sundar S, Jha TK, Thakur CP, et al. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002; 66:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/29\">",
"      Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001; 17:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/30\">",
"      Thakur CP, Pandey AK, Sinha GP, et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/31\">",
"      Gradoni L, Gramiccia M, Scalone A. Visceral leishmaniasis treatment, Italy. Emerg Infect Dis 2003; 9:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/32\">",
"      Kafetzis DA, Velissariou IM, Stabouli S, et al. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds? Int J Antimicrob Agents 2005; 25:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/33\">",
"      Sundar S, Jha TK, Thakur CP, et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/34\">",
"      Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362:504.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Report of a WHO Informal Consultation on Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis, Rome, Italy, April 2005. WHO/CDS/NTD/IDM/2007.4 Geneva: WHO, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/36\">",
"      Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45:3487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/37\">",
"      Gaeta GB, Maisto A, Di Caprio D, et al. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients. Scand J Infect Dis 2000; 32:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/38\">",
"      Sundar S, Mehta H, Chhabra A, et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis 2006; 42:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/39\">",
"      Sundar S, Singh A, Agarwal D, et al. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am J Trop Med Hyg 2009; 80:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/40\">",
"      den Boer M, Davidson RN. Treatment options for visceral leishmaniasis. Expert Rev Anti Infect Ther 2006; 4:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/41\">",
"      Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/42\">",
"      Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000; 5:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/43\">",
"      Moore E, O'Flaherty D, Heuvelmans H, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001; 79:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/44\">",
"      Rijal S, Chappuis F, Singh R, et al. Sodium stibogluconate cardiotoxicity and safety of generics. Trans R Soc Trop Med Hyg 2003; 97:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/45\">",
"      Sundar S, Sinha PR, Agrawal NK, et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 1998; 59:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/46\">",
"      Fr&eacute;zard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules 2009; 14:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/47\">",
"      Baiocco P, Colotti G, Franceschini S, Ilari A. Molecular basis of antimony treatment in leishmaniasis. J Med Chem 2009; 52:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/48\">",
"      Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/49\">",
"      Chulay JD, Spencer HC, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985; 34:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/50\">",
"      Gasser RA Jr, Magill AJ, Oster CN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/51\">",
"      Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/52\">",
"      Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/53\">",
"      Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/54\">",
"      Sundar S, Jha TK, Sindermann H, et al. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003; 22:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/55\">",
"      Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007; 196:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/56\">",
"      Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012; 55:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/57\">",
"      Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/58\">",
"      Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005; 83:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/59\">",
"      Pandey BD, Pandey K, Kaneko O, et al. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am J Trop Med Hyg 2009; 80:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/60\">",
"      Davidson RN, den Boer M, Ritmeijer K. Paromomycin. Trans R Soc Trop Med Hyg 2009; 103:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/61\">",
"      Jha TK, Olliaro P, Thakur CP, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998; 316:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/62\">",
"      Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med 2007; 356:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/63\">",
"      Thakur CP, Kanyok TP, Pandey AK, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/64\">",
"      Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990; 84:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/65\">",
"      Melaku Y, Collin SM, Keus K, et al. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007; 77:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/66\">",
"      Jhingran A, Chawla B, Saxena S, et al. Paromomycin: uptake and resistance in Leishmania donovani. Mol Biochem Parasitol 2009; 164:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/67\">",
"      Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/68\">",
"      Seaman J, Pryce D, Sondorp HE, et al. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993; 168:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/69\">",
"      Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008; 47:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/70\">",
"      Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011; 377:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/71\">",
"      Olivier M, Badar&oacute; R, Medrano FJ, Moreno J. The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol 2003; 97 Suppl 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/72\">",
"      Tremblay M, Olivier M, Bernier R. Leishmania and the pathogenesis of HIV infection. Parasitol Today 1996; 12:257.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization, 2007. Report of the 5th Consultative Meeting on Leishmania/HIV Coinfection. WHO Technical Report Series WHO/CDS/NTD/IDM/2007.5.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/74\">",
"      ter Horst R, Collin SM, Ritmeijer K, et al. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/75\">",
"      Laguna F, L&oacute;pez-V&eacute;lez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999; 13:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/76\">",
"      Laguna F, Videla S, Jim&eacute;nez-Mej&iacute;as ME, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 2003; 52:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/77\">",
"      Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996; 32:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/78\">",
"      Lazanas MC, Tsekes GA, Papandreou S, et al. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 1993; 7:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/79\">",
"      Torre-Cisneros J, Villanueva JL, Kindelan JM, et al. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis 1993; 17:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/80\">",
"      Laguna F, Torre-Cisneros J, Moreno V, et al. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/81\">",
"      Sindermann H, Engel KR, Fischer C, et al. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004; 39:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/82\">",
"      Delgado J, Mac&iacute;as J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg 1999; 61:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/83\">",
"      Alvar J, Ca&ntilde;avate C, Guti&eacute;rrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/84\">",
"      Ribera E, Oca&ntilde;a I, de Otero J, et al. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996; 100:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/85\">",
"      Pintado V, Mart&iacute;n-Rabad&aacute;n P, Rivera ML, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001; 80:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/86\">",
"      de la Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001; 32:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/87\">",
"      Tortajada C, P&eacute;rez-Cuevas B, Moreno A, et al. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/88\">",
"      L&oacute;pez-V&eacute;lez R, Videla S, M&aacute;rquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/89\">",
"      Mira JA, Corzo JE, Rivero A, et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 2004; 70:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/90\">",
"      Casado JL, Lopez-Velez R, Pintado V, et al. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001; 20:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/91\">",
"      Meinecke CK, Schottelius J, Oskam L, Fleischer B. Congenital transmission of visceral leishmaniasis (Kala Azar) from an asymptomatic mother to her child. Pediatrics 1999; 104:e65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/92\">",
"      Gradoni L, Gaeta GB, Pellizzer G, et al. Mediterranean visceral leishmaniasis in pregnancy. Scand J Infect Dis 1994; 26:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/93\">",
"      Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/94\">",
"      Utili R, Rambaldi A, Tripodi MF, Andreana A. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate. Infection 1995; 23:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/95\">",
"      Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003; 3:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/96\">",
"      Thakur CP, Kumar K, Sinha PK, et al. Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate. Br Med J (Clin Res Ed) 1987; 295:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/97\">",
"      Thakur CP, Narain S, Kumar N, et al. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol 1997; 91:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/98\">",
"      Sundar S, Kumar K, Chakravarty J, et al. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg 2006; 100:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/99\">",
"      Bern C, Haque R, Chowdhury R, et al. The epidemiology of visceral leishmaniasis and asymptomatic leishmanial infection in a highly endemic Bangladeshi village. Am J Trop Med Hyg 2007; 76:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/100\">",
"      Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002; 9:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43625/abstract/101\">",
"      Boelaert M, El-Safi S, Hailu A, et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg 2008; 102:32.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5710 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AD134220F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43625=[""].join("\n");
var outline_f42_38_43625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THERAPEUTIC APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Conventional",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Liposomal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pentavalent antimonial compounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Miltefosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Paromomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HIV coinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Post kala-azar dermal leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ASSESSING RESPONSE TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5710\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5710|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/56/14221\" title=\"table 1\">",
"      Visceral leishmaniasis species",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/33/18972\" title=\"table 2\">",
"      Treatment of visceral leishmaniasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_38_43626="Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents";
var content_f42_38_43626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43626/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43626/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43626/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43626/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/38/43626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/38/43626/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/38/43626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preeminent role of LDL-cholesterol in the pathogenesis and perpetuation of atherosclerotic vascular disease has emerged from many sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The Lipid Research Clinics Prevalence Study, for example, evaluated the influence of lipids on 10-year cumulative coronary heart disease (CHD) death rates in patients with and without CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/2\">",
"     2",
"    </a>",
"    ]. The CHD death rate increased at higher plasma concentrations of total and LDL-cholesterol for both cohorts, but the impact of elevated lipid levels was significantly greater in subjects with preexisting CHD (",
"    <a class=\"graphic graphic_figure graphicRef50334 \" href=\"mobipreview.htm?33/19/34109\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The major clinical trials that have addressed cholesterol lowering for the secondary prevention of coronary events are reviewed here, including trials in patients with coronary risk equivalents. Coronary risk equivalents include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Symptomatic carotid artery disease",
"     </li>",
"     <li>",
"      Peripheral artery disease",
"     </li>",
"     <li>",
"      Abdominal aortic aneurysm",
"     </li>",
"     <li>",
"      Chronic kidney disease",
"     </li>",
"     <li>",
"      Multiple risk factors that confer a 10-year risk of CHD &gt;20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of cholesterol lowering in primary prevention (ie, in patients without known CHD) and recommendations for clinical practice are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIFESTYLE MODIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies with conventional dietary modification (National Cholesterol Education Program [NCEP] Step 1 or Step 2 diet) showed little benefit on established coronary atherosclerosis, especially when compared with drug therapy (",
"    <a class=\"graphic graphic_table graphicRef64360 \" href=\"mobipreview.htm?0/20/333\">",
"     table 1",
"    </a>",
"    ). However, more positive results have been reported in trials that investigated more aggressive dietary therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/5-7\">",
"     5-7",
"    </a>",
"    ] or in combination with exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These studies have employed various regimens directed at lowering the consumption of dietary fat, saturated fat, and cholesterol.",
"   </p>",
"   <p>",
"    The St. Thomas' Atheroma Regression Study (STARS) randomized men with CHD and total cholesterol levels exceeding 232",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.02",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to conventional care or a low-fat diet (with a target cholesterol intake of 100 to 120",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    well below the normal level of approximately 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/6\">",
"     6",
"    </a>",
"    ]. Overweight patients were also provided a weight reduction diet and a suitable level of daily exercise was recommended. (This study contained a third arm of diet plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    ; the effect of drug therapy is considered separately below.)",
"   </p>",
"   <p>",
"    At three years, the following benefits on coronary atherosclerosis were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The progression rate was slowed in the diet-treated group compared with conventional care (15 versus 46 percent, p&lt;0.02) and the frequency of regression was increased.",
"     </li>",
"     <li>",
"      Severe lesions (&gt;50 percent stenosis) exhibited the largest changes in diameter.",
"     </li>",
"     <li>",
"      Angina pectoris severity was lessened.",
"     </li>",
"     <li>",
"      More patients in the diet intervention group had regression than progression despite an end trial LDL-cholesterol level of 162",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Angiographic improvement was more common when the LDL cholesterol was below 115 to 135",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.0 to 3.5",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Lifestyle Heart Trial was a smaller study (53 enrolled, 41 follow-up arteriograms) that evaluated the efficacy of an aggressive vegetarian diet therapy (in which cholesterol intake was reduced from 213 to 5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in conjunction with exercise and relaxation techniques; the control group was treated with conventional dietary therapy (NCEP Step 2 diet) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/8\">",
"     8",
"    </a>",
"    ]. Over a 12 month period, the combined therapy group showed a decrease in the diameter of atherosclerotic lesions (from 61.1 to 55.8 percent diameter stenosis in lesions with more than a 50 percent stenosis) versus an increase in the control group (from 61.7 to 64.4 percent). The aggressive treatment groups also had reduced symptoms of ischemic heart disease.",
"   </p>",
"   <p>",
"    There was a further regression of atherosclerosis among 20 patients who maintained the above comprehensive lifestyle changes for five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/10\">",
"     10",
"    </a>",
"    ]. There were fewer cardiac events in the treated compared to the control patients (0.89 versus 2.25 events per patient).",
"   </p>",
"   <p>",
"    This trial, however, is less generally applicable than the STARS study. It suffers from a small sample size and from selection bias because it consisted of a highly motivated group of patients and an artificial environment in which gourmet chefs prepared all meals. Nevertheless, both studies found that clinical and arteriographic improvement induced by dietary intervention was more likely to occur with aggressive reductions in LDL cholesterol.",
"   </p>",
"   <p>",
"    The Lyon Diet Heart Study evaluated the effects of a Mediterranean diet, rich in alpha-linolenic acid, with that of a \"prudent\" diet in 605 patients after a first myocardial infarction. An intermediate analysis, performed after a 27 month follow-up, showed that patients eating the Mediterranean diet had lower rates of the major primary (death and myocardial infarction) and secondary endpoints (unstable angina, stroke, heart failure, pulmonary or peripheral embolism) (22.5 versus 34.3 percent, p&lt;0.005) (",
"    <a class=\"graphic graphic_figure graphicRef67586 \" href=\"mobipreview.htm?10/27/10686\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/11\">",
"     11",
"    </a>",
"    ]. The benefit of this diet was maintained for up to four years; those on a Mediterranean diet had a lower rate of the primary end point (1.24 versus 4.07 events per 100 patients per year, risk ratio 0.28) and combined primary and secondary endpoints (2.59 versus 9.03 events per 100 patients per year, risk ratio 0.33) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the major traditional risk factors were still independent predictors of a cardiovascular event, indicating that the Mediterranean diet did not alter the predictive value of these risk factors. It has been suggested that Mediterranean-style step I diet should be implemented in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of LDL-lowering therapy achieved with diet and lipid-altering agents have evaluated cohorts of patients with familial hypercholesterolemia, familial combined hyperlipidemia, and polygenic hypercholesterolemia (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    ). The lipid altering agents employed have included bile acid sequestrants, nicotinic acid, the HMG-CoA reductase inhibitors (statins), and various combinations of these agents.",
"   </p>",
"   <p>",
"    These drugs have a variety of beneficial effects on the lipid profile. They lower total and LDL-cholesterol and triglycerides, raise HDL-cholesterol, improve the LDL phenotype in some patients from the more atherogenic small dense LDL particles to more buoyant, less atherogenic particles, and increase the resistance of LDL and VLDL to oxidation to more atherogenic particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H22#H22\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Small dense LDL (LDL phenotype B)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two types of outcomes were assessed: coronary regression as assessed by arteriography and the incidence of cardiovascular events. Before presenting the evidence that lipid lowering can stabilize or regress coronary atherosclerosis in many patients and that outcomes are likely to be improved, it is useful to review the mechanisms that may be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanisms of improvement with lipid lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of benefit with lipid-lowering are incompletely understood. Regression of atherosclerosis occurs in only a minority of patients after six months of therapy, although one study using magnetic resonance imaging found significant regression of aortic and carotid atherosclerosis after 12 months of therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the benefit of lipid lowering is seen in as little as six months, before significant regression could occur (",
"    <a class=\"graphic graphic_figure graphicRef62070 \" href=\"mobipreview.htm?19/57/20381\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. Thus, other factors must contribute; these include plaque stabilization, reversal of endothelial dysfunction, and decreased thrombogenicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Improvement in atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials have consistently demonstrated that lipid lowering agents are more likely than diet alone to delay progression and induce regression of atherosclerotic lesions both in native vessels and in coronary bypass grafts (",
"    <a class=\"graphic graphic_table graphicRef64360 \" href=\"mobipreview.htm?0/20/333\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52650 \" href=\"mobipreview.htm?22/16/22798\">",
"     figure 4",
"    </a>",
"    ). Some illustrative trials are detailed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     CLAS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cholesterol Lowering Atherosclerosis Study (CLAS) examined the hypothesis that a reduction in LDL-cholesterol and elevation in HDL-cholesterol could prevent progression, or cause regression of atherosclerotic lesions at two and four years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. CLAS included 188 men with previous coronary artery bypass grafts independent of the plasma cholesterol concentration. The patients were randomized to diet plus placebo or diet plus combined therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    (30 g per day) and nicotinic acid (3 to 12 g daily). The participants were preselected to ensure tolerance to nicotinic acid and colestipol. The treated group had a 43 percent reduction in LDL-cholesterol and a 37 percent elevation in HDL-cholesterol. The following treatment benefits were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regression was greater with drug treatment at two years (16.2 versus 2.4 percent) and at four years (18 versus 6 percent).",
"     </li>",
"     <li>",
"      Progression of old lesions and the development of new lesions was significantly less common in both native and grafted vessels.",
"     </li>",
"     <li>",
"      Progression was more common in bypass grafts and lesions proximal to grafts than in native arteries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefit of combined nicotinic acid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    therapy was most prominent in patients with baseline plasma cholesterol levels above 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.2",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     FATS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Familial Atherosclerosis Treatment Study (FATS) examined the effect of lipid altering therapies in men with familial combined hyperlipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/23\">",
"     23",
"    </a>",
"    ]. The study included 146 men with one coronary stenosis of greater than 50 percent or three lesions of greater than 30 percent. Patients were randomized to one of three groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placebo plus low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"       colestipol",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      if the LDL-cholesterol level exceeded 190",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      This regimen lowered LDL-cholesterol by 7 percent and raised HDL-cholesterol by 5 percent.",
"     </li>",
"     <li>",
"      Nicotinic acid (4",
"      <span class=\"nowrap\">",
"       g/day)-",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"        colestipol",
"       </a>",
"      </span>",
"      (30",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      which lowered LDL-cholesterol by 32 percent and raised HDL-cholesterol by 43 percent.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"       Lovastatin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day)-",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"        colestipol",
"       </a>",
"      </span>",
"      (30",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      which lowered LDL-cholesterol by 46 percent and raised HDL-cholesterol by 15 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two aggressive therapy groups were equally effective, being associated with delayed progression (21 and 25 versus 46 percent in the placebo group) and an increased likelihood of regression of coronary lesions (32 and 39 versus 11 percent). Active therapy was also associated with fewer clinical coronary endpoints such as death, myocardial infarction, worsening angina, or coronary revascularization. These endpoints occurred in 10 of 52 patients (19 percent) treated conventionally compared to only 3 of 46 (6.5 percent) assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    and 2 of 48 (4.2 percent) receiving niacin and colestipol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     REGRESS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Regression Growth Evaluation Statin Study (REGRESS) evaluated the influence of cholesterol lowering therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in 885 men with plasma cholesterol levels ranging from 155 to 310",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4 to 8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/24\">",
"     24",
"    </a>",
"    ]. Pravastatin was associated with the following benefits compared with placebo at 24 months:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A delay in progression of coronary artery disease",
"     </li>",
"     <li>",
"      A greater rate of remaining free of clinical cardiovascular events at two years (89 versus 81 percent)",
"     </li>",
"     <li>",
"      A 42 percent reduction in nonfatal myocardial infarction that was not statistically significant",
"     </li>",
"     <li>",
"      Preservation of regional myocardial perfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduction in ischemic episodes quantified by ambulatory ECG monitoring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A lower rate of progression of peripheral (femoral and carotid) atherosclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     LCAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Lipoprotein and Coronary Atherosclerosis Study (LCAS) randomly assigned 429 patients with CHD (documented on angiography) and moderately elevated LDL cholesterol (115 to 190",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.97 to 4.91",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    despite a NCEP Step 1 diet to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/27\">",
"     27",
"    </a>",
"    ]. After a 2.5 year follow-up, fluvastatin reduced the LDL cholesterol level by 24 percent and reduced the rate of lesion progression on repeat angiography compared to placebo. A consistent benefit was seen regardless of the serum LDL concentration above or below 160 or 130",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    A follow-up analysis of the data showed that placebo patients with low HDL cholesterol levels &le;35",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.91",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    had more angiographic progression of disease and the greatest angiographic benefit from fluvastatin (",
"    <a class=\"graphic graphic_figure graphicRef64601 \" href=\"mobipreview.htm?17/22/17773\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/28\">",
"     28",
"    </a>",
"    ]. Event-free survival was significantly improved by fluvastatin in patients with low HDL cholesterol, but not in those with a higher HDL cholesterol concentration (",
"    <a class=\"graphic graphic_figure graphicRef76372 \" href=\"mobipreview.htm?40/45/41693\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     BECAIT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of fibrates was addressed in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12933?source=see_link\">",
"     Bezafibrate",
"    </a>",
"    Coronary Atherosclerosis Intervention Trial (BECAIT), which evaluated whether bezafibrate (200 mg TID) could slow the progression of coronary stenoses in 92 young (&lt;45 years) male survivors of myocardial infarction with fasting serum cholesterol concentration above 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and triglyceride concentration above 141",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.6",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    patients were evaluated two years and five years after randomization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The median change in minimum lumen diameter (primary end point) was less in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12933?source=see_link\">",
"     bezafibrate",
"    </a>",
"    group than in the placebo group (p = 0.049). Bezafibrate had a preferential effect upon slowing the progression of coronary narrowing when the lesion caused &lt;50 percent stenosis at baseline; it had no effect in segments with &ge;50 percent diameter stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/30\">",
"     30",
"    </a>",
"    ]. Associated with these changes was a reduction in the cumulative coronary event rate with bezafibrate therapy (3 versus 11) (",
"    <a class=\"graphic graphic_table graphicRef55863 \" href=\"mobipreview.htm?35/10/36012\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12933?source=see_link\">",
"     bezafibrate",
"    </a>",
"    on the progression of focal coronary artery disease was partly attributed to the increase in HDL and a shift in LDL subclass from small dense particles, which are strongly associated with CHD, to larger particles (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/31\">",
"     31",
"    </a>",
"    ]. The fact that these treatment benefits were independent of LDL-cholesterol suggests that reductions in VLDL-cholesterol and fibrinogen may alter the natural history of coronary disease.",
"   </p>",
"   <p>",
"    Another factor associated with the reduction in disease progression was the levels of insulin-like growth factor (IGF)-I, which were directly related to changes in coronary artery disease; treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12933?source=see_link\">",
"     bezafibrate",
"    </a>",
"    resulted in a significant reduction in IGF-I levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/32\">",
"     32",
"    </a>",
"    ]. The relation between serum IGF-I levels and coronary artery disease progression was independent of the extent of coronary artery disease on baseline angiography, age, body mass index, serum lipoprotein and fibrinogen concentrations, and measures of glucose-insulin homeostasis.",
"   </p>",
"   <p>",
"    However, the implications of this study must be tempered by the small sample size and presumably low statistical power.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     GAIN trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GAIN trial used intracoronary ultrasound to evaluate the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    on atherosclerosis progression in 131 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/33\">",
"     33",
"    </a>",
"    ]. After a 12 month follow-up, atorvastatin reduced the progression of mean plaque volume or thickness (1.2 versus 9.6 mm3 for placebo) and increased the hyperechogenicity of the plaque, indicating a change in plaque composition (from lipid-rich to fibrotic and calcified) that corresponds to increased plaque stability and a reduced tendency for rupture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     HARP and SCAT trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Harvard Atherosclerosis Reversibility Project (HARP) and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"      Simvastatin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"      Enalapril",
"     </a>",
"    </span>",
"    Coronary Atherosclerosis Trial (SCAT) addressed the question of whether intensive pharmacological treatment of normocholesterolemic patients could delay the angiographic progression of coronary atherosclerosis, with conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HARP included patients with a total plasma cholesterol concentration less than 181 to 251",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.7 to 6.5",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/34\">",
"     34",
"    </a>",
"    ]. The goals of therapy were to reduce the total cholesterol concentration below 158",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and to lower the ratio of",
"    <span class=\"nowrap\">",
"     LDL/HDL-cholesterol",
"    </span>",
"    to &le;2.0. Seventy-nine patients were treated for 2.5 years with a stepwise regimen of diet,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/d),",
"    </span>",
"    nicotinic acid,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , with the following effects:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol fell by 28 percent, from 211 to 159",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.47 to 4.12",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      LDL-cholesterol fell by 41 percent, from 137 to 86",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.55 to 2.23",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      HDL-cholesterol rose by 13 percent, from 41 to 47",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.06 to 1.22",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       LDL/HDL-cholesterol",
"      </span>",
"      ratio fell from 3.34 to 1.83.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeat coronary arteriograms were performed. There were no significant differences between the two groups in the following parameters:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coronary obstruction worsened by a mean of 0.14 to 0.15 mm.",
"     </li>",
"     <li>",
"      Progression of coronary stenosis was reported in 23 to 28 percent of lesions and regression occurred in 13 percent of lesions.",
"     </li>",
"     <li>",
"      Regression occurred in 13 percent of lesions from both groups.",
"     </li>",
"     <li>",
"      Clinical cardiac events occurred in 12 patients in the control group versus six in the treated group (p = 0.19).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study concluded that aggressive use of lipid altering therapy does not alter the progression rate of coronary stenoses in normocholesterolemic men. However, the general applicability of these findings is limited by small sample size, short duration of follow-up for a cohort with a slower rate of progression than subjects with hypercholesterolemia, and large variability in angiographic measurements. Furthermore, this lack of benefit has",
"    <strong>",
"     not been confirmed",
"    </strong>",
"    in other trials.",
"   </p>",
"   <p>",
"    As an example, SCAT found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    therapy had a beneficial effect on angiographic coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/2\">",
"     2",
"    </a>",
"    ]. This study included 460 normocholesterolemic patients with average levels of total, LDL, and HDL cholesterol of 200",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    95",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and 38",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.2, 3.36, and 0.99",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    who underwent a double randomization to simvastatin or placebo",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    or placebo. After a follow-up of 48 months, patients receiving simvastatin had less progression of coronary disease compared to those on placebo. The change in mean diameter, minimum diameter, and percent diameter stenosis and need for angioplasty was less with simvastatin. There was no additional benefit seen with enalapril therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     REVERSAL trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The REVERSAL trial randomly assigned patients with CHD to intensive lipid lowering therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or moderate therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and evaluated progression of atherosclerosis by measuring plaque volume with coronary intravascular ultrasound at baseline and after 18 months of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/36\">",
"     36",
"    </a>",
"    ]. There were 654 patients who both underwent randomization and received a study drug, and of these, 502 had an evaluable ultrasound at 18 months.",
"   </p>",
"   <p>",
"    The primary study end point of median percentage change in atheroma volume was significantly lower in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    group than in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    group (-0.4 versus 2.7 percent); the change in the atorvastatin group was not significantly different from zero (% CI -2.35-1.49), while the change in the pravastatin group was positive (CI 0.24 to 4.67) indicating progression from baseline. The authors report, however, that \"many\" patients in both groups had significant progression of atherosclerosis.",
"   </p>",
"   <p>",
"    The mean LDL-C concentration with therapy was lower in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    than in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    group (79 versus 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.0 versus 2.8",
"    <span class=\"nowrap\">",
"     mmol/L]);",
"    </span>",
"    the percentage decrease in LDL-C concentration was also greater (46 versus 25 percent). The percentage decrease in C-reactive protein (CRP) concentration was also much greater with atorvastatin (36 versus 5 percent).",
"   </p>",
"   <p>",
"    In a regression analysis, each 10 percent reduction in LDL-C concentration (15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.39",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    led to an approximately 1 percent reduction in the change in atheroma volume after 18 months. However, at any level of LDL-C reduction, the rate of progression was lower in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    group than in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    group. This suggests that factors other than LDL-C reduction played a role in the improved outcomes seen with the more intensive therapy.",
"   </p>",
"   <p>",
"    A subsequent analysis suggested that one such factor may have been reduction in CRP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/37\">",
"     37",
"    </a>",
"    ]. While there was only a weak correlation between reduction in LDL-C and reduction in CRP, adjusting for CRP partially explained the slower rate of progression in atherosclerosis seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    at a given level of LDL-C. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The study was not intended to be able to detect differences in clinical outcomes, and there did not appear to be any such differences in outcomes or in adverse events.",
"   </p>",
"   <p>",
"    These data appear to confirm the importance of achieving target LDL concentrations of less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in patients with CHD and raise the possibility that lower LDL targets may be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     ARBITER 2 study",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial examined the effects of extended-release (ER) niacin 1000 mg daily in 167 patients with known CHD and an HDL-C concentration below 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.16",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    who were already receiving a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients treated with ER niacin experienced a mean increase in HDL-C of 21 percent from 39",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    at baseline to 47",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.22",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    on treatment (absolute change of 8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.21",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    while patients treated with placebo had no change in HDL-C concentration.",
"   </p>",
"   <p>",
"    Carotid intima-media thickness (CIMT) was assessed by ultrasound. After one year of therapy, mean CIMT increased significantly in the placebo group (0.044 mm, p&lt;0.001), but not in the niacin group (0.014 mm, p = 0.23). The difference between these rates approached being statistically significant (p = 0.08). Cardiovascular events occurred in 3.8 percent of patients receiving niacin and in 9.6 percent of patients receiving placebo (p = 0.20).",
"   </p>",
"   <p>",
"    The paper states that the within group changes in CIMT (which achieved statistical significance) were the primary outcome measure of the study; however, the study appears to have been powered to detect a difference between groups in CIMT, which would be the more standard measure of effect and which did not achieve statistical significance. A post-hoc subset analysis suggested that ER niacin may have had a greater effect in preventing CIMT progression in patients who did not have insulin resistance (diabetes or the metabolic syndrome).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     ASTEROID trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ASTEROID trial was an open-label uncontrolled study of intensive lipid-lowering therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    40 mg daily in 507 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients were required to have undergone coronary angiography and had a greater than 20 percent narrowing of at least one vessel and had a target vessel that would be evaluated by intravascular ultrasound (IVUS) with a narrowing of no more than 50 percent throughout a target segment with a minimum length of 4 cm.",
"   </p>",
"   <p>",
"    IVUS was performed at baseline and at 24 months, and 349 patients had evaluable IVUS examinations. There were 158 patients who were not included in the IVUS analysis including 63 who were withdrawn for adverse events; an additional three patients were not included in the analysis of lipid levels.",
"   </p>",
"   <p>",
"    LDL-C levels decreased by 53 percent from 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    to 61",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.37 to 1.57",
"    <span class=\"nowrap\">",
"     mmol/L];",
"    </span>",
"    HDL-C levels increased by 15 percent from 43 to 49",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.11 to 1.27",
"    <span class=\"nowrap\">",
"     mmol/L].",
"    </span>",
"   </p>",
"   <p>",
"    There were improvements in the two primary measures of efficacy. The median percent atheroma volume decreased by -0.79, and the median atheroma volume in the most diseased 10 mm segment decreased by -9.1 percent. As mentioned, there was no control group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Oxford Niaspan study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Oxford Niaspan study was a randomized trial of extended release nicotinic acid in 71 patients with an HDL-C below 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.03",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and known cardiovascular disease, and who were already taking a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients took an escalating dose of nicotinic acid or placebo up to a dose of 2000 mg daily.",
"   </p>",
"   <p>",
"    The primary outcome was the change in carotid artery wall area as assessed by MRI at 12 months. Patients treated with nicotinic acid had a greater decrease in carotid artery wall area compared with the placebo group (difference -1.6 mm2, 95% CI -3.1 to -0.2 mm2). Clinical end points were not reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H648157811\">",
"    <span class=\"h3\">",
"     SATURN trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SATURN trial was a randomized trial comparing two intensive statin therapy regimens (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg daily and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    40 mg daily) in 1039 patients with known coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/41\">",
"     41",
"    </a>",
"    ]. Compared with atorvastatin, patients treated with rosuvastatin had lower levels of LDL-C (62.6 versus 70.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.62 versus 1.82",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and higher levels of HDL-C (50.4 versus 48.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.30 versus 1.26",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    but there was no statistically-significant difference between the regimens in the primary endpoint of percent atheroma volume, which decreased with both regimens (-1.22 versus -0.99 percent, respectively). Clinical outcomes were similar with the two regimens as were adverse events and discontinuation of treatment, however, more patients treated with rosuvastatin developed proteinuria (3.8 versus 1.7 percent) and fewer developed elevated alanine aminotransferase levels (0.7 versus 2.1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Improvement in clinical outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasing number of clinical trials have shown an improvement in clinical outcome with lipid lowering therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. This includes a reduction in the number of ischemic episodes and decreased mortality. Data from the REGRESS trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/25\">",
"     25",
"    </a>",
"    ] and a smaller study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/44\">",
"     44",
"    </a>",
"    ] showed that when patients with coronary disease were studied by 48 hour ambulatory monitoring, those treated with a statin had a significant reduction in the number of episodes of transient myocardial ischemia (1.23 versus 0.53 episodes) and a significant reduction in the duration of ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/25\">",
"     25",
"    </a>",
"    ], suggesting that the beneficial effect may be related in part to an improvement in endothelial function.",
"   </p>",
"   <p>",
"    Most of the more recent studies have used a statin, although a statistically significant benefit was not always demonstrated. Why this occurred is not clear. Several possible contributing factors are insufficient statistical power, because of a relatively small sample size, and varying antiatherothrombogenic properties of these drugs other than LDL-lowering (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Mechanisms of improvement with lipid lowering'",
"    </a>",
"    above). Nevertheless, most trials have shown at least a trend toward improved outcome; a similar benefit has been demonstrated on carotid atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     4S trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Scandinavian",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     Simvastatin",
"    </a>",
"    Survival Study (4S) evaluated 4444 patients with established CHD (angina or previous myocardial infarction) and baseline plasma total cholesterol levels between 212 and 309",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.5 and 8.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/46\">",
"     46",
"    </a>",
"    ]. The patients were treated with a lipid lowering diet and then randomly assigned to therapy with placebo or with simvastatin (20 to 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in an attempt to reduce the level of total cholesterol below 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    At",
"    the end of 5.4 years, there was a clear reduction in total mortality in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    compared with placebo (8 versus 12 percent) (",
"    <a class=\"graphic graphic_figure graphicRef81991 \" href=\"mobipreview.htm?18/55/19325\">",
"     figure 7",
"    </a>",
"    ). There were also highly statistically significant reductions in major coronary events (19 versus 28 percent), CHD deaths (42 percent reduction), revascularization procedures, and fatal plus nonfatal cerebrovascular events (2.7 versus 4.3 percent). There were no differences between the simvastatin and placebo groups in noncardiovascular deaths, cancers, suicides, homicides, or trauma. The benefit of simvastatin on total mortality was still seen after a median follow-up of 7.4 years (12 versus 16 percent); there was no difference in the incidence of noncardiovascular deaths or cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reduction in major cardiac events was highly correlated with on-treatment serum total cholesterol and LDL concentrations and with changes from baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/48\">",
"     48",
"    </a>",
"    ]. It was estimated that each additional 1 percent reduction in LDL reduced the risk by 1.7 percent (",
"    <a class=\"graphic graphic_figure graphicRef72721 \" href=\"mobipreview.htm?24/34/25134\">",
"     figure 8",
"    </a>",
"    ). There was less of an association with HDL concentrations and no relationship with triglycerides.",
"   </p>",
"   <p>",
"    Based upon these findings, it was calculated that the number needed to treat to prevent one event or death was 159 over one year and 30 over the course of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the above benefits, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    resulted in a significant reduction in new or worsening angina pectoris, intermittent claudication, and in new or worsening carotid bruits (",
"    <a class=\"graphic graphic_figure graphicRef76764 \" href=\"mobipreview.htm?39/54/40814\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above results applied to the entire study population. Additional analyses found that several subsets of patients derived particular benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A statistically significant mortality benefit was demonstrated in the elderly, but not in women, presumably due to smaller sample size [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10760?source=see_link\">",
"       \"Treatment of dyslipidemia in the older adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       Simvastatin",
"      </a>",
"      significantly reduced the risk of a cardiac event (death, infarction, cardiac arrest) in the 3525 patients with a prior myocardial infarction who were at low, medium, or high risk based upon clinical features (hypertension, diabetes, cholesterol levels, smoking); the reduction in relative risk with therapy was 38, 39, and 42 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/51\">",
"       51",
"      </a>",
"      ]. To prevent one cardiac event, the number needed to treat for six years was 13, 11, and 6, respectively. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35658?source=see_link\">",
"       \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with the lowest serum HDL (&lt;39",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and highest serum triglycerides (&gt;159",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.8",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      who were more likely to have other features of the metabolic or insulin resistance syndrome (increased body mass index, hypertension, diabetes), had the greatest event rate on placebo (36 percent) and the greatest benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      (relative risk 0.48 versus 0.86 for isolated high LDL) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"       \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      was also more apparent in carriers of the apo E4 allele, who have a nearly two-fold increased risk of dying [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/52\">",
"       52",
"      </a>",
"      ]. The excess mortality was abolished with simvastatin and the mortality risk was reduced to 0.33, while it was reduced to 0.66 among patients without the allele. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"       \"Inherited disorders of LDL-cholesterol metabolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This secondary prevention trial is a landmark study because it was designed with appropriate statistical power to demonstrate that cholesterol lowering therapy lowers morbidity and mortality from cardiovascular disease as well as all-cause mortality. The long-standing concern that cholesterol lowering therapy might increase noncardiovascular deaths (due to accident or suicide) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/55,56\">",
"     55,56",
"    </a>",
"    ] was shown to be incorrect in this trial, as were other unproven concerns regarding the potential hazards of cholesterol lowering interventions.",
"   </p>",
"   <p>",
"    Follow-up results from the 4S trial showed continuing survival benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/57\">",
"     57",
"    </a>",
"    ]. After the five-year placebo-controlled trial, patients from both arms of the study were treated with open-label",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    until the results of the trial were published; thereafter, decisions about lipid-lowering therapy were made by the patients and their providers. After 10 years, fewer patients initially assigned to the simvastatin group died (19.1 versus 21.3 percent), mainly due to a reduction in cardiovascular mortality (14.6 versus 15.6 percent). There was no significant difference in deaths from cancer (4.3 versus 5.1 percent, relative risk 0.80, 95% CI 0.60-1.08).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     LIPID trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LIPID study randomly assigned 9014 men and women with a recent myocardial infarction or unstable angina with serum cholesterol concentrations of 155 to 270",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4 to 7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/58\">",
"     58",
"    </a>",
"    ]. After a mean follow-up of 60 months, the study was terminated prematurely because, compared with placebo, pravastatin was associated with significant reductions in death from CHD (6.4 versus 8.3 percent, p&lt;0.001), total mortality (11 versus 14 percent, p&lt;0.001), stroke (20 percent relative decrease), need for bypass surgery (8.9 versus 11.3 percent), and fatal and nonfatal myocardial infarction (7.4 versus 10.1 percent) (",
"    <a class=\"graphic graphic_figure graphicRef53640 \" href=\"mobipreview.htm?35/14/36077\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    was primarily related to changes in lipid levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/59\">",
"     59",
"    </a>",
"    ] and was seen in all predefined subgroups, including those of any age, with acute myocardial infarction or unstable angina, and at any serum concentration of total cholesterol, LDL-C, HDL-C, or triglycerides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/58,60\">",
"     58,60",
"    </a>",
"    ]. The greatest absolute reduction in coronary events was seen in patients who were judged high risk based on age and gender, lipid levels, comorbid diseases, smoking, and history of prior cardiovascular event; the number needed to treat to prevent one event in low, medium, and high risk patients was 83, 45, and 24, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A post-hoc analysis of the LIPID study looked at the effects of therapy in a subgroup of 2073 patients with low LDL-C (140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.6",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or less) and low HDL-C (40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.0",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or less) who also had a triglyceride level of 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.4",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/62\">",
"     62",
"    </a>",
"    ]. Absolute and relative risk reductions for cardiovascular events and mortality were similar to those seen in the overall cohort. An analysis in a further subset of 536 patients with very low LDL-C (116",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.0",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or less) found similar point estimates of absolute and relative risk reductions, but the results did not achieve statistical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     TNT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Treating to New Targets (TNT) trial randomly assigned 10,001 patients with stable coronary heart disease to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    at a low dose (10 mg daily) with a goal LDL-C of 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or a high dose (80 mg daily) with a goal LDL-C of 75",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/63\">",
"     63",
"    </a>",
"    ]. Patients were required to have a baseline LDL-C between 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and 250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and, during an open label run-in period on atorvastatin, 10 mg daily were required to achieve and LDL-C below 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    primary end point of the trial was a major cardiovascular event, defined as death from CHD, nonfatal non-procedure-related MI, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The following findings were seen with high dose compared to low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    at a median follow-up of 4.9 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly lower mean serum LDL-C concentration (77 versus 101",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.0 versus 2.6",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      Significant reductions in the rate of the primary end point (8.7 versus 10.9 percent, hazard ratio [HR] 0.78, 95% CI 0.69-0.89) as well as MI (HR 0.78, CI 0.66-0.93), fatal or nonfatal stroke (HR 0.75, CI 0.59-0.96), and cardiovascular death (HR 0.80, CI 0.64-1.08).",
"     </li>",
"     <li>",
"      No reduction in overall mortality (HR 1.01, CI 0.85-1.19). Despite the reduction in cardiovascular deaths, there was a similar increase in noncardiovascular deaths in patients receiving high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (HR 1.25, CI 0.99-1.57). These noncardiovascular deaths were due to cancer (HR 1.13, CI 0.83-1.55) and from nontraumatic causes other than cancer (HR 1.35, CI 0.91-2.00).",
"     </li>",
"     <li>",
"      A greater likelihood of persistent elevations in serum liver aminotransferases (1.2 versus 0.2 percent) but no increase in myalgias or other muscle toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An analysis of patients ages 65 and over (n = 3809) in TNT found similar efficacy and safety results to those in the overall analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/64\">",
"     64",
"    </a>",
"    ]. These older patients had a significant reduction in the primary end point (10.3 versus 12.6 percent, HR 0.81, CI 0.67-0.98), but a nonsignificant increase in noncardiac mortality (5.1 versus 4.1 percent, HR 1.26, CI 0.93-1.70). There was also a small, nonsignificant increase in overall mortality (9.1 versus 8.5 percent, HR 1.08, CI 0.87-1.33) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     IDEAL trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study was an open label trial with blinded endpoint analysis that randomly assigned 8888 patients with a past history of acute MI to receive intensive lipid lowering therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg daily or standard lipid lowering therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    20 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/66\">",
"     66",
"    </a>",
"    ]. After 24 weeks, the dose of simvastatin could be increased to 40 mg daily if the total cholesterol concentration was greater than 190",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.0",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    at the end of the study 23 percent of patients were taking simvastatin 40 mg daily. The dose of atorvastatin could be decreased to 40 mg daily for adverse events; at the end of the study, 13 percent of patients were taking atorvastatin 40 mg daily.",
"   </p>",
"   <p>",
"    The primary endpoint of the trial was time to first occurrence of a major coronary event (coronary death, hospitalization for acute MI, or cardiac arrest). The following findings were seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    at a median follow-up of 4.8 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower LDL-C concentration (81 versus 104 mg",
"      <span class=\"nowrap\">",
"       /dL",
"      </span>",
"      [2.7 versus 2.1",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      A statistically nonsignificant reduction in the primary endpoint (9.3 versus 10.4 percent, hazard ratio [HR] 0.89, 95% CI 0.78-1.01).",
"     </li>",
"     <li>",
"      No effect on all-cause mortality (HR 0.98, CI 0.85-1.13), cardiovascular mortality (HR 1.03, CI 0.85-1.24) or noncardiovascular mortality (HR 0.92, CI 0.73-1.15).",
"     </li>",
"     <li>",
"      A reduction in a number of secondary endpoints including nonfatal myocardial infarction (6 versus 7.2 percent, HR 0.83, CI 0.71-0.98) and coronary revascularization (13.0 versus 16.6 percent, HR 0.77, CI 0.69-0.86).",
"     </li>",
"     <li>",
"      A higher rate of adverse events leading to discontinuation of the study drug (9.6 versus 4.2 percent) including myalgia (2.2 versus 1.1 percent); elevated aminotransferase levels were also more common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H719305722\">",
"    <span class=\"h3\">",
"     SEARCH trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) randomly assigned 12,064 patients with a prior history of MI to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    80 mg daily or simvastatin 20 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/67\">",
"     67",
"    </a>",
"    ]. The primary composite endpoint was major vascular events (coronary death, MI, stroke, or arterial revascularization). The following findings were seen with high dose compared with low dose simvastatin after a median follow-up of 6.7 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.35",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      lower LDL-C concentration",
"     </li>",
"     <li>",
"      A statistically nonsignificant reduction in the primary endpoint (24.5 versus 25.7 percent, risk ratio [RR] 0.94, 95% CI 0.88-1.01)",
"     </li>",
"     <li>",
"      No effect on all cause mortality (RR 0.99, CI 0.91-1.09), vascular mortality (RR 0.99, CI 0.88-1.11), or nonvascular mortality (RR 1.00, CI 0.87-1.15)",
"     </li>",
"     <li>",
"      A higher rate of creatine kinase elevations including those more than 40 times the upper limit of normal (0.4 versus 0.0 percent), incipient myopathy (1.4 versus 0.2 percent), definite myopathy without rhabdomyolysis (0.9 versus 0.0 percent), and rhabdomyolysis (0.1 versus 0.0 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A significant number of patients in the low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    arm of SEARCH took additional statin off protocol as more intensive LDL-C goals were promulgated, and this may have reduced the ability of SEARCH to find a benefit with more intensive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     BIP trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12933?source=see_link\">",
"     Bezafibrate",
"    </a>",
"    Infarction Prevention (BIP) trial randomized 3090 coronary patients with a prior MI and symptomatic coronary artery disease who had a total cholesterol of 180 to 250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.7 to 6.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    HDL &le;45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.16",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    triglycerides &le;300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and LDL cholesterol &le;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    to bezafibrate or placebo for five to seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/68\">",
"     68",
"    </a>",
"    ]. Although bezafibrate therapy resulted in an 18 percent increase in HDL, a 21 percent decrease in triglycerides, and a 6 percent decrease in LDL, the primary end point (fatal and nonfatal MI and sudden death) was not significantly different compared to placebo (13.6 versus 15 percent); however, there was a significant 40 percent reduction (13 versus 22.3 percent at 6.2 years) in the primary end point in the subset of patients with high triglyceride levels (&ge;200",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    especially in those who had an increase in HDL by &ge;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or a reduction in triglycerides by &ge;28",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef69300 \" href=\"mobipreview.htm?22/8/22669\">",
"     figure 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Patients with borderline high serum cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding trials have all evaluated patients with hypercholesterolemia. The effect of lipid lowering has also been evaluated in patients with borderline high serum cholesterol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     CARE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CARE (Cholesterol and Recurrent Events) trial found benefits with lipid-altering therapy among patients without markedly elevated lipid levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/69\">",
"     69",
"    </a>",
"    ]. This study involved 4159 patients with a history of a myocardial infarction in the previous two years who had average levels of total, LDL, and HDL cholesterol of 209",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    139",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and 39",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.4, 3.6, and 1.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    respectively. At five years, benefits with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    treatment (40 mg before sleep) compared to placebo included significant reductions in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combined end point of coronary death and nonfatal MI (10.2 versus 13.2 percent, p = 0.003) (",
"      <a class=\"graphic graphic_figure graphicRef82485 \" href=\"mobipreview.htm?23/30/24045\">",
"       figure 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The need for revascularization with CABG or PTCA (14.1 versus 18.8 percent, p&lt;0.001)",
"     </li>",
"     <li>",
"      The frequency of stroke (2.6 versus 3.8 percent, p = 0.03) and of stroke plus transient ischemic attacks (4.4 versus 6.0 percent, p = 0.02) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The combined end point among patients who underwent revascularization with CABG or PTCA prior to randomization (8.3 versus 12.4 percent, p = 0.001); the benefit was seen regardless of whether CABG or PTCA had been performed (",
"      <a class=\"graphic graphic_figure graphicRef55789 \" href=\"mobipreview.htm?28/8/28814\">",
"       figure 13",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/71\">",
"       71",
"      </a>",
"      ]. There was also a significant reduction in fatal and nonfatal MI (5.9 versus 9.2 percent) and in stroke (2.6 versus 4.1 percent) in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefits were seen only in patients with LDL-cholesterol levels above 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/72\">",
"     72",
"    </a>",
"    ]. In contrast to the results in 4S, the absolute or percentage reduction in LDL had little relationship to coronary events (",
"    <a class=\"graphic graphic_figure graphicRef77082 \" href=\"mobipreview.htm?16/35/16958\">",
"     figure 14",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/72\">",
"     72",
"    </a>",
"    ]. Benefits were more apparent among women (",
"    <a class=\"graphic graphic_figure graphicRef72888 \" href=\"mobipreview.htm?10/54/11118\">",
"     figure 15",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/73\">",
"     73",
"    </a>",
"    ], older patients (above age 60), and those with higher pretreatment levels of LDL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11258?source=see_link\">",
"     \"Management of coronary heart disease in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on the results, it was calculated that the number needed to treat over the duration of the study to prevent one event and one death is 33 and 125, respectively; the number needed to treat for one year to prevent one event and one death is 173 and 694, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Other trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subset analysis from CLAS, REGRESS, and 4S also showed benefit from cholesterol lowering in patients with clinical coronary disease who have borderline elevations in total and LDL cholesterol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/21,22,24,74\">",
"     21,22,24,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      REGRESS found that the delay in angiographic progression and clinical event reduction induced by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      occurred in patients at all lipid levels, including those in the lowest quintile with baseline LDL-cholesterol levels between 85 and 147",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2 to 3.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 4S study found that the reduction in major coronary events induced by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      was of an equivalent magnitude in subjects with total cholesterol levels in the lowest quartile (212 to 240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.5 to 6.24",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      when compared to those with higher levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, in a subset of patients from ALLHAT (Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial), lipid lowering with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    did not improve all-cause mortality or CHD events compared with usual care in patients with a history of CHD and an LDL-cholesterol of 100 to 129",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (or in patients without CHD who had an LDL-cholesterol of 120 to 189",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/75\">",
"     75",
"    </a>",
"    ]. However, there were some methodological issues with this study that may explain the negative results, as well as a high lack of adherence to statin therapy among the treated patients and considerable crossover in the usual care group. Thus, the major lesson from this study may be that in the primary care setting it is difficult to reach the levels of adherence and lipid lowering that occurred in many of the clinical trials described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Cost effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cost-effectiveness analysis, based upon the CARE trial, found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    was associated with an incremental cost of $16,000 to $32,000 per quality-adjusted life-year gained; cost-effectiveness was greater for patients more than 60 years of age or with pretreatment LDL-cholesterol above 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon data from the CARE trial, it was estimated that, in patients with average cholesterol levels treated with a statin for five years, there would be 150 preventable cardiovascular events per 1000 patients; among patients over 60 years of age, the number would be 207 per 1000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/77\">",
"     77",
"    </a>",
"    ]. In addition, 121 and 225 cardiovascular hospitalizations per 1000 patients, respectively, would be prevented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Primary and combined primary and secondary prevention",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Heart Protection Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Heart Protection Study (HPS) randomly assigned 20,536 subjects to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo: 33 percent had baseline LDL cholesterol &lt;116",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    25 percent had a level of 116 to 135",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3 to 3.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and 42 percent had levels &gt;135",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/78\">",
"     78",
"    </a>",
"    ]. Entry criteria included a history of cardiovascular disease (coronary cerebrovascular, or peripheral artery disease), diabetes mellitus, or treated hypertension. Thus, most patients were treated for secondary prevention.",
"   </p>",
"   <p>",
"    After an average follow-up of 5.5 years, the following significant benefits with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 13 percent reduction in all-cause mortality (12.9 versus 14.7 percent for placebo).",
"     </li>",
"     <li>",
"      An 18 percent reduction in deaths from heart disease or related blood vessel disease (5.7 versus 6.9 percent).",
"     </li>",
"     <li>",
"      A 24 percent reduction in major cardiovascular events (19.8 versus 25.2 percent) (",
"      <a class=\"graphic graphic_figure graphicRef81866 \" href=\"mobipreview.htm?13/44/14030\">",
"       figure 16",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A 25 percent reduction in the first event rate for stroke (4.3 versus 5.7 percent) reflecting a 28 percent decrease in ischemic strokes and no reduction in hemorrhagic strokes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/79\">",
"       79",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link&amp;anchor=H10#H10\">",
"       \"Secondary prevention of stroke: Risk factor reduction\", section on 'Dyslipidemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among 3982 diabetic patients without prior cardiovascular disease, a 28 percent reduction in the incidence of MI and stroke (14 versus 18.7 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The percent reduction in events was similar in the three tertiles of baseline LDL cholesterol&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef68116 \" href=\"mobipreview.htm?6/28/6592\">",
"     figure 17",
"    </a>",
"    ) and was also similar in patients with LDL cholesterol concentrations below 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    These nonrandomized, subgroup observations suggest that if there is a threshold below which lowering LDL cholesterol no longer reduces cardiovascular risk in patients with cardiovascular disease, it is apparently at a much lower concentration that is typically seen in Western populations. The benefit in patients with lower LDL cholesterol concentrations may reflect actions of statins other than lipid lowering (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/80\">",
"     80",
"    </a>",
"    ]. Of note, the LDL-C levels in HPS were measured values rather than the calculated values used in most earlier trials, observational studies, and clinical practice; measured LDL-C is typically lower than calculated LDL-C making the starting and target LDL-C levels in HPS appear somewhat lower than the values clinicians are typically familiar with.",
"   </p>",
"   <p>",
"    The relative benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    on all-cause mortality was also similar across various subgroups, including men and women, younger and older patients, and those with higher and lower baseline LDL-C concentrations (",
"    <a class=\"graphic graphic_figure graphicRef50534 \" href=\"mobipreview.htm?35/47/36592\">",
"     figure 18",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/81\">",
"     81",
"    </a>",
"    ]. A subsequent analysis showed that the relative benefit of simvastatin on major vascular events was also similar across a wide range of baseline C-reactive protein (CRP) concentrations and, in particular, in patients with a CRP below 1",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/82\">",
"     82",
"    </a>",
"    ]. In patients with a CRP below 1.6",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (the median CRP in the trial) and an LDL-C below 108",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.8",
"    <span class=\"nowrap\">",
"     mmol/L;",
"    </span>",
"    the median baseline LDL-C in the JUPITER trial (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'JUPITER trial'",
"    </a>",
"    )], simvastatin again showed typical benefit (risk ratio 0.73, 99% CI 0.52-1.04).",
"   </p>",
"   <p>",
"    The benefit of statins was independent of and additional to all other treatments (eg, antihypertensive therapy, beta blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , angiotensin converting enzyme inhibitors) (",
"    <a class=\"graphic graphic_figure graphicRef60445 \" href=\"mobipreview.htm?42/24/43407\">",
"     figure 19",
"    </a>",
"    ). There was no effect on the incidence of noncardiovascular deaths.",
"   </p>",
"   <p>",
"    These findings suggest that treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    for five years should prevent 70 to 100 people per 1000 from suffering a major vascular event. Furthermore, the results can probably be applied widely since the study population included a broad range of patients with varying underlying cardiovascular conditions, age, sex, and presenting lipid concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     CARDS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of statin therapy in patients with type 2 diabetes without known cardiovascular disease was studied in a trial of 2838 diabetic patients with a serum LDL concentration &le;160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.14",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    a fasting triglyceride concentration &le;600 (6.78",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and at least one of the following: retinopathy, albuminuria, current smoking, or hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/83\">",
"     83",
"    </a>",
"    ]. Patients were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    10 mg daily or placebo with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The trial was terminated two years earlier than expected (median duration of follow-up 3.9 years) because the predetermined stopping rule for efficacy had been met.",
"     </li>",
"     <li>",
"      The rate of cardiovascular events was reduced by 37 percent (95% CI -52 to -17) in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      group compared with placebo. Treatment would be expected to prevent 37 major vascular events per 1000 patients treated for four years.",
"     </li>",
"     <li>",
"      Analyzed separately, the rate of coronary heart disease events was reduced by 36 percent (95% CI -55 to -9), coronary revascularizations by 31 percent (95% CI -59 to 16), stroke by 48 percent (95% CI -69 to -11), and death by 27 percent (95% CI -48 to 1).",
"     </li>",
"     <li>",
"      Compared with placebo, the absolute reduction in events with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      was similar in patients with LDL-cholesterol concentrations above or below 120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (reduction from 9.5 to 6.1 percent versus reduction from 8.5 to 3.6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     FIELD trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     Fenofibrate",
"    </a>",
"    Intervention and Event Lowering in Diabetes (FIELD) trial randomly assigned 9795 patients ages 50 to 75 with type 2 diabetes (2131 with prior cardiovascular disease) to receive micronized fenofibrate 200 mg daily or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/84\">",
"     84",
"    </a>",
"    ]. Patients were required to have a total cholesterol concentration from 116 to 251",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.0 to 6.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    plus either a total cholesterol to HDL-C ratio of at least 4.0 or a triglyceride concentration from 89 to 443",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.0 to 5.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and to not be taking other lipid lowering therapy at study entry. There was a 16 week run-in phase that included four weeks of dietary modification, six weeks on placebo, and six weeks on fenofibrate.",
"   </p>",
"   <p>",
"    The primary endpoint of the study was initially coronary mortality. However, four years into the study the investigators performed a blinded analysis of the data and found that they would be unlikely to detect a difference in this endpoint and so changed the primary endpoint to include nonfatal myocardial infarction.",
"   </p>",
"   <p>",
"    After a median follow-up of five years, the following results were seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    compared with placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nonsignificant decrease in the modified primary outcome of coronary events (hazard ratio [HR] 0.89, 95% CI 0.75-1.06).",
"     </li>",
"     <li>",
"      A nonsignificant increase in the original primary outcome of coronary mortality (HR 1.19, CI 0.90-1.57).",
"     </li>",
"     <li>",
"      A nonsignificant increase in all-cause mortality (HR 1.11, 95% CI 0.95-1.29).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     Fenofibrate",
"    </a>",
"    appears to have been well tolerated both by patients who took it as monotherapy and by patients who initiated statin therapy during the study. However, there may have been a small increased risk of pancreatitis and venous thromboembolic disease among patients receiving fenofibrate. Myositis, rhabdomyolysis, and elevated creatine kinase levels all occurred in less than 1 percent of patients receiving fenofibrate; the three patients who developed rhabdomyolysis while receiving fenofibrate were not taking a statin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     ACCORD Lipid trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Action to Control Cardiovascular Risk in Diabetes lipid (ACCORD Lipid) trial randomly assigned 5518 patients with type 2 diabetes (ages 40 to 79 if they had clinical CVD; ages 55 to 79 if they had subclinical CVD or at least two additional cardiovascular risk factors) to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    160 mg daily or placebo; all patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the end of the study, LDL-C levels were similar in both groups, HDL-C levels were slightly higher in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    group (41.2 versus 40.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.07 versus 1.05",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    and triglyceride levels were lower in the fenofibrate group (147 versus 170",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.66 versus 1.92",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    After a mean follow-up of 4.7 years, there was no significant difference in the primary composite outcome of first occurrence of a major cardiovascular event (nonfatal MI, nonfatal stroke, or death from a cardiovascular cause) between the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    and placebo groups (2.24 versus 2.41",
"    <span class=\"nowrap\">",
"     events/year,",
"    </span>",
"    hazard ratio [HR] 0.92, 95% CI 0.79-1.08). There was also no significant difference between the groups in any of the components of the primary outcome or in death from any cause.",
"   </p>",
"   <p>",
"    A subgroup analysis suggested a differential effect in men and women that was statistically significant, with men benefiting from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    and women being harmed by fenofibrate, however other studies have not suggested such an effect. No differential effect was seen in patients with low or high triglycerides or low or high HDL-C levels, however patients with the combination of high triglycerides and low HDL-C levels showed a nonstatistically significant trend toward better outcomes with fenofibrate than patients without this lipid profile. Multiple subgroup analyses were performed and so both these subgroup results might have been due to chance.",
"   </p>",
"   <p>",
"    An analysis from a substudy of ACCORD, the ACCORD Eye Study, examined the effects of the interventions described above on progression of diabetic retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/86\">",
"     86",
"    </a>",
"    ]. Fewer patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    had composite events (progression by at least three steps on a diabetic retinopathy scale or development of proliferative retinopathy necessitating photocoagulation or vitrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/87\">",
"     87",
"    </a>",
"    ]; 6.5 versus 10.2 percent, odds ratio 0.60, 95% CI 0.42-0.87). The individual components of the composite were not initially reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/88\">",
"     88",
"    </a>",
"    ], and no such benefit was seen for moderate loss of vision (HR 0.95, CI 0.79-1.14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/89\">",
"     89",
"    </a>",
"    ]. Subsequently, the authors reported the components of the composite, showing that fewer patients treated with fenofibrate underwent photocoagulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitrectomy (1.9 versus 3.0 percent; statistical significance not reported) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     ASPEN trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ASPEN (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     Atorvastatin",
"    </a>",
"    Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus) randomly assigned 2410 patients ages 40 to 75 with type 2 diabetes (505 with prior MI or interventional procedure) to receive atorvastatin 10 mg daily or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/90\">",
"     90",
"    </a>",
"    ]. Entry criteria included an LDL-C below 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in patients without known CHD or an LDL-C below 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.6",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    in patients with known CHD). Mean LDL-C levels were approximately 113",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.92",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    at baseline in all groups. The primary endpoint was time to the occurrence of a first composite clinical event (cardiovascular death, nonfatal MI, coronary intervention, unstable angina, or resuscitated cardiac arrest).",
"   </p>",
"   <p>",
"    After a median follow-up of four years, there was no statistically significant reduction in the primary composite endpoint in all patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (13.7 versus 15 percent, hazard ratio [HR] 0.90, 95% CI 0.73-1.12), or in the subset of patients without prior MI or interventional procedure (10.4 versus 10.8 percent, HR 0.97, CI 0.74-1.28), or in the subset with prior MI or interventional procedure (26.2 versus 30.8 percent, HR 0.82, CI 0.59-1.15).",
"   </p>",
"   <p>",
"    More patients in the placebo arm took other lipid lowering therapy during the course of the study (27 versus 15 percent) and both arms of the study had relatively high dropout rates (42 and 33 percent in the placebo and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    arms, respectively). This, combined with the relatively low statistical power of the trial, likely contributed to the negative results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     MEGA trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MEGA trial randomly assigned 8214 Japanese men and postmenopausal women ages 40 to 70 and a total cholesterol concentration of 220 to 270",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.69 to 6.98",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to receive diet therapy alone or diet therapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    10 to 20 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/91\">",
"     91",
"    </a>",
"    ]. Patients could not have prior CHD or stroke, but could have diabetes. The study was open label, and there was significant differential dropout of patients after randomization with 100 more patients analyzed in the diet arm than in the pravastatin arm. The study was initially planned to last five years, but was then extended for an additional five years. The primary endpoint was first occurrence of CHD (fatal and nonfatal MI, angina, cardiac and sudden death, coronary revascularization).",
"   </p>",
"   <p>",
"    After a median follow-up of 5.3 years, fewer patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    had a primary CHD endpoint (3.3 versus 5.0 percent, hazard ratio [HR] 0.67, 95% CI 0.49-0.91). There was a nearly statistically significant reduction in all-cause mortality as well (2.7 versus 3.8 percent, HR 0.72, 95% CI 0.51-1.01).",
"   </p>",
"   <p>",
"    These results suggest that the relative benefits of statin therapy in an Asian population are similar to those seen in American and European populations, although the absolute benefits in this low-risk population were small. However, the large number of patients lost to analysis relative to the small number of events in this open label study raises some issues about the results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been several meta-analyses of clinical trials with statins in patients with CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/92-96\">",
"     92-96",
"    </a>",
"    ]. One meta-analysis of 17,617 patients in the 4S, CARE, and LIPID trials found that the reduction in the risk of major coronary events, cardiovascular mortality, and all-cause mortality was 30, 27, and 23 percent, respectively; there was no effect on noncardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/95\">",
"     95",
"    </a>",
"    ]. The risk reduction was similar for men and women and for elderly and middle-aged persons.",
"   </p>",
"   <p>",
"    A second meta-analysis of 34 trials involving approximately 25,000 subjects found that four years of cholesterol lowering therapy would prevent one death, one CHD death, and one cardiovascular death for every 110, 96, and 117 patients treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/94\">",
"     94",
"    </a>",
"    ]. Analysis of subgroups revealed that a survival benefit was seen in studies in which more than 50 percent of patients were survivors of myocardial infarction who had a total cholesterol reduction of more than 10 percent and who were treated for at least four years. Statins produced a greater reduction in the odds of death than other therapies.",
"   </p>",
"   <p>",
"    Similar findings were noted in an analysis of pooled data from three randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    involving 19,768 patients (CARE, LIPID, and WOSCOPS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/96\">",
"     96",
"    </a>",
"    ]. The benefits were similar in younger (&lt;65 years) and older (&ge;65 years) patients, men and women, smokers and nonsmokers, patients with and without diabetes and hypertension, and across the population ranges of total cholesterol, LDL cholesterol (125 to 212",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    3.2 to 5.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    HDL cholesterol, and triglycerides.",
"   </p>",
"   <p>",
"    An analysis of subgroups found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    therapy for five years would prevent one death for every 50 patients with a prior MI (95 percent confidence interval [CI] 30 to 135) and one death for every 54 patients with unstable angina (95% CI 35-200) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Early use of statins after an ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prevention trials have primarily evaluated the role of statin therapy initiated three to six months or longer after acute MI. As mentioned above, however, statins may decrease cardiovascular events by a number of mechanisms that can be important early after MI, including plaque stabilization, reversal of endothelial dysfunction, inhibition of monocyte recruitment, decreased thrombogenicity, and a reduction in inflammation (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    ). These findings have led to the investigation of earlier initiation of statin therapy during hospitalization for an acute coronary syndrome (MI or unstable angina).",
"   </p>",
"   <p>",
"    While observational trials and small randomized trials had come to differing conclusions about the effect of early initiation of a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/20,98-100\">",
"     20,98-100",
"    </a>",
"    ], the issue has now been addressed in several large randomized, controlled trials that are discussed below.",
"   </p>",
"   <p>",
"    A meta-analysis of placebo-controlled trials concluded that early initiation of statin therapy (within 14 days of an ACS) did not reduce death, MI, or stroke at 30 days or four months but did appear to decrease unstable angina at four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/101\">",
"     101",
"    </a>",
"    ]. This meta-analysis excluded the PROVE IT-TIMI 22 trial because this was a comparison of two different statins. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'PROVE IT-TIMI 22 trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical implications of these results and recommendations regarding early initiation of statin therapy in patients with an acute coronary syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33656?source=see_link\">",
"     \"Cholesterol lowering after an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     MIRACL trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MIRACL trial was a randomized, double-blind trial that reported benefits with early statin therapy, but not mortality benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/102\">",
"     102",
"    </a>",
"    ]. In this study, 3086 adults with unstable angina or non-Q-wave MI were randomly assigned to receive treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo between 24 and 96 hours after hospital admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary end point (nonfatal infarction, cardiac arrest with resuscitation, or recurrent symptomatic ischemia requiring hospitalization) was less frequent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (14.8 versus 17.4 percent for placebo, relative risk reduction 16 percent, 95% CI 0-30 percent); the benefit was primarily due to a 26 percent reduction in recurrent symptomatic ischemia requiring emergency hospitalization. Treatment with atorvastatin did not prevent death, resuscitated cardiac arrest, or MI, and did not reduce the need for revascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     PROVE IT-TIMI 22 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PROVE IT-TIMI 22 trial was a randomized trial that compared standard LDL-C lowering (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40 mg daily) with intensive LDL-C lowering (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg daily) in 4162 patients who had been hospitalized with an acute coronary syndrome within the preceding 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/103\">",
"     103",
"    </a>",
"    ]. Patients had to be stable and, if a percutaneous intervention was planned, were enrolled after that intervention; patients were required to have a baseline total cholesterol concentration of 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.21",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or less if not on prior therapy, or of 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.18",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or less if on lipid-lowering therapy at the time of the acute coronary syndrome; the median baseline LDL-C concentration was 106",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.74",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Enrollment was continued until 925 end point events occurred, and this led to an average follow-up of 24 months (range 18 to 36 months) at the time the study was concluded. Patients assigned to receive pravastatin had their dose increased to 80 mg daily if their LDL-C concentration exceeded 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.23",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    on two consecutive visits; this occurred in 8 percent of patients.",
"   </p>",
"   <p>",
"    The median LDL-C concentration was lower with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    (62 versus 96",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.60 versus 2.46",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    Among the 2985 patients who had not previously received statin therapy, median LDL-C levels fell more with atorvastatin (51 versus 22 percent), and among the 990 patients previously on statin therapy, LDL-C levels fell by an additional 32 percent with atorvastatin but were unchanged from baseline with pravastatin. Median HDL-C levels rose less with atorvastatin than pravastatin (6.5 versus 8.1 percent), and median C-reactive protein (CRP) concentrations (baseline 12.3",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    were lower during treatment with atorvastatin (1.3 versus 2.1",
"    <span class=\"nowrap\">",
"     mg/L).",
"    </span>",
"   </p>",
"   <p>",
"    The primary composite end point was death from any cause, myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization performed more than 30 days after randomization, and stroke. After two years, the rate of reaching the primary end point was lower in patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    (22.4 versus 26.3 percent; hazard ratio 0.84 [95% CI 0.74-0.95]). The benefit of atorvastatin was apparent as early as 30 days after randomization and was consistent over time (",
"    <a class=\"graphic graphic_table graphicRef78178 \" href=\"mobipreview.htm?14/49/15131\">",
"     table 3",
"    </a>",
"    ). Similar benefit or a trend toward benefit was seen in all the components of the primary end point with the exception of stroke (for which there were very few events, and so the power to detect a difference was small). The benefit of atorvastatin compared with pravastatin appeared to be greater in patients with a baseline LDL-C concentration of 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.23",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or greater, than in patients with lower levels (reduction in hazard ratio of 34 versus 7 percent, respectively).",
"   </p>",
"   <p>",
"    The residual differential effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    (after considering reductions in LDL-C) appeared to be largely explained by effects on CRP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/104\">",
"     104",
"    </a>",
"    ]. While there was only a weak correlation between reduction in CRP and reduction in LDL-C, adjusting for both the CRP achieved and the LDL achieved appeared to explain the benefits of atorvastatin compared with pravastatin with regard to the outcome of recurrent myocardial infarction or death from coronary causes past 30 days (hazard ratio 1.00, 95% CI 0.75-1.34). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rates of discontinuation of therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    were similar (22.8 versus 21.4 percent at one year; 30.4 versus 33.0 percent at two years). The rates of dose reduction for side effects or liver function abnormalities were also similar; however, more patients receiving atorvastatin had elevations in alanine aminotransferase of more than three times the upper limit of normal (3.3 versus 1.1 percent). Rates of myalgia were similar (3.3 versus 2.7 percent), and there were no cases of rhabdomyolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     FLORIDA trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FLORIDA trial was a randomized, placebo-controlled, double-blind study that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    80 mg daily with placebo in 540 patients with an acute myocardial infarction and serum cholesterol &lt;251",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After 12 months, there was no significant difference between the two groups in reaching the composite end point of either ischemia on ambulatory electrocardiographic monitoring or the occurrence of a major clinical event. The mean final LDL-C in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    (104",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.7",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    was much higher than the values achieved with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    in MIRACL and PROVE IT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     PACT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PACT trial was a randomized trial that compared treatment within 24 hours of an ACS with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    (20 mg early in the study and 40 mg for patients enrolled later) with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/106\">",
"     106",
"    </a>",
"    ]. The trial was stopped early (after 3408 patients were enrolled) because of difficulties with recruitment.",
"   </p>",
"   <p>",
"    There was no statistically significant reduction in the primary composite endpoint (death, recurrent MI, or readmission for unstable angina within 30 days) in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    compared with placebo (11.6 versus 12.4 percent, relative risk 0.94, 95% CI 0.72-1.13).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Phase Z of the A to Z trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase Z of the A to Z trial was a randomized trial that compared an aggressive statin strategy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    40 mg daily for one month followed by 80 mg daily thereafter) with a delayed conservative strategy (placebo for four months followed by simvastatin 20 mg thereafter) in 4497 patients with acute coronary syndrome who had an initial total cholesterol level &le;250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.48",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/107\">",
"     107",
"    </a>",
"    ]. The median follow-up was 721 days.",
"   </p>",
"   <p>",
"    In the conservative strategy arm, the LDL-C concentration increased during the four-month placebo period from 111",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.87",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to 124",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.21",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and then decreased to 77",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.99",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    four months after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    20 mg daily was initiated. In the aggressive strategy arm, the LDL-C concentration decreased to 68",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.76",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    after one month of simvastatin 40 mg daily and decreased further to 62",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.60",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    three months after the simvastatin dose had been increased to 80 mg daily. In the conservative strategy arm, C-reactive protein (CRP) concentration decreased from 20.4",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    at baseline to 2.5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    after one month (still during the placebo period) and had decreased to 1.8",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    after eight months (four months after initiation of simvastatin). In the aggressive strategy arm, CRP concentration decreased to 2.4",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    after one month of simvastatin 40 mg daily (not significantly different from that seen with placebo) and decreased further to 1.5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    after eight months (seven months after initiation of simvastatin 80 mg daily).",
"   </p>",
"   <p>",
"    A combined end point of cardiovascular death, myocardial infarction, readmission for acute coronary syndrome, and stroke occurred less frequently in the aggressive strategy arm but did not achieve statistical significance (14.4 versus 16.7 percent, hazard ratio [HR] 0.89, 95% CI 0.76-1.04). Similarly, death from any cause occurred less frequently in the aggressive strategy arm but did not achieve statistical significance (5.5 versus 6.7 percent, HR 0.79, 95% CI 0.61-1.02).",
"   </p>",
"   <p>",
"    The primary combined end point was not decreased in the aggressive strategy arm during the first four months of therapy (during which time the conservative strategy arm was receiving placebo) (HR 1.01, 95% CI 0.83-1.25), but it was decreased from four months to the end of the study (HR 0.75, 95% CI 0.60-0.95).",
"   </p>",
"   <p>",
"    More patients developed creatine kinase (CK) concentrations more than 10 times the upper limit of normal in the aggressive strategy arm (nine versus one patient), and three patients developed rhabdomyolysis while taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    80 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Patients with low LDL and low HDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with both low LDL-C and low HDL-C appear to get equivalent benefit from statin therapy to other patients treated for secondary prevention. Although not designed to look specifically at this question, as discussed above, a post-hoc analysis of a subset of patients from the LIPID study with low HDL-C and LDL-C levels found similar absolute and relative clinical benefits with treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    to those in the overall cohort (see",
"    <a class=\"local\" href=\"#H19\">",
"     'LIPID trial'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/62\">",
"     62",
"    </a>",
"    ]. Patients with low HDL-C (40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.0",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or less) who had low LDL-C (140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.6",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or less) or very low LDL-C (116",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.0",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or less) had similar increases in HDL-C levels compared with the entire cohort (6, 3, and 6 percent, respectively) and had similar decreases in LDL-C levels compared with the entire cohort (-29, -30, and -28 percent, respectively).",
"   </p>",
"   <p>",
"    Several studies have looked at raising HDL-C in patients with a low baseline serum concentration and found that such therapy may be effective for secondary prevention of CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     VA-HIT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VA-HIT trial included 2531 patients with an LDL-C &le;140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    an HDL-C &le;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and triglyceride levels &le;300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    who were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/108\">",
"     108",
"    </a>",
"    ]. At one year, the mean HDL-C level was 6 percent higher in the gemfibrozil group (34 versus 32",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for placebo or 0.9 versus 0.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the mean total cholesterol was 4 percent lower (170 versus 177",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 4.4 versus 4.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the mean triglyceride level was 31 percent lower (115 versus 166",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 1.3 versus 1.6",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    these differences persisted throughout the study. The mean LDL-C level was the same in both groups (113",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 2.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    At",
"    five years, the combined primary end point of cardiac death and nonfatal myocardial infarction occurred less in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    treated group (17 versus 22 percent for placebo), representing a relative risk reduction of 22 percent (",
"    <a class=\"graphic graphic_figure graphicRef71148 \" href=\"mobipreview.htm?39/52/40781\">",
"     figure 20",
"    </a>",
"    ). The risk reduction was similar for both components of the composite end point; the beneficial effect of gemfibrozil did not become apparent until two years after randomization. Patients taking gemfibrozil also had a lower stroke rate (4.6 versus 6 percent for placebo), a 59 percent decrease in transient ischemic attacks (1.7 versus 4.2 percent), and a 65 percent reduction in carotid endarterectomy (1.3 versus 3.5 percent); the reduction in stroke was evident after six to 12 months of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     AFREGS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AFREGS trial included 143 adults younger than age 76 with angiographically-evident CHD, an HDL-C below 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and an LDL-C below 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.1",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    exclusion criteria included a major cardiovascular event in the past six months, a left ventricular ejection fraction below 40 percent, and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/110\">",
"     110",
"    </a>",
"    ]. All patients were treated with aggressive lifestyle and dietary interventions and were randomly assigned to receive pharmacologic therapy or placebo. The pharmacologic therapy group was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    600 mg twice daily; starting in the third month, short-acting niacin 250 mg daily was added and titrated up to 3000 mg daily as tolerated; starting in the sixth month,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    was added and titrated up to a dose of 16 g daily as tolerated. Patients in both groups were given open-label cholestyramine if the LDL-C level exceeded 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    during the trial.",
"   </p>",
"   <p>",
"    The mean baseline HDL-C was 34",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The percentage increase in the HDL-C level was greater in the intervention group than in the control group (38 versus 2 percent). LDL-C levels decreased in the intervention group and increased in the control group (-22 versus 5 percent).",
"   </p>",
"   <p>",
"    The primary outcome of the trial was the percentage change in global coronary stenosis assessed by angiography. The absolute percentage of global coronary stenosis decreased by 0.75 percent in the intervention group and increased by 1.16 percent in the control group (p = 0.04). A combined cardiovascular outcome (hospitalization for angina; myocardial infarction; transient ischemic attack and stroke; PCI; CABG; and death) occurred less frequently in the intervention group (13 versus 26 percent).",
"   </p>",
"   <p>",
"    Nearly all patients in the intervention group experienced flushing from niacin, which likely lead to involuntary unblinding of the study. There were few \"hard\" endpoints of death or myocardial infarction, and so this unblinding could have biased the combined cardiovascular outcome. Three patients in the intervention group experienced splenic ruptures during colonoscopy to evaluate heme-positive stool. The colonoscopies were performed by three different operators in two different centers. There is no obvious biologic mechanism linking the pharmacologic therapy to splenic rupture; however, this is a rare complication of colonoscopy, and it is unclear why it should have occurred in 4 percent of the intervention group patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     HATS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HATS trial suggested that additional benefits may be observed in patients with low HDL-C by combining a statin (which not only lowers LDL-C but may have additional cardiovascular benefits beyond lipid lowering) with a drug that increases HDL-C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/111\">",
"     111",
"    </a>",
"    ]. This three year trial included 160 patients with clinical and angiographic evidence of CHD who had an HDL-C less than 35",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and an LDL-C less than 145",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.75",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/111\">",
"     111",
"    </a>",
"    ]. Patients were randomly assigned to one of four regimens:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    plus niacin; antioxidants; simvastatin plus niacin plus antioxidants; or placebo. The mean serum LDL-C and HDL-C concentrations were unaltered in the antioxidant and placebo groups, but changed substantially (-42 and +26 percent, respectively) in the simvastatin plus niacin group. Compared with placebo, patients receiving simvastatin plus niacin were significantly less likely to sustain a cardiovascular event (death, myocardial infarction, stroke, or revascularization) and experienced angiographic regression (compared with progression for the placebo group) of the most significant coronary stenosis.",
"   </p>",
"   <p>",
"    The magnitude of the reduction of clinical events with drug therapy (relative risk 0.1 to 0.4 compared with placebo) in this study was greater than that typically observed with studies of statins alone, suggesting that treatment designed to raise HDL-C provides additional protection beyond that attributable to simply lowering LDL-C. However, caution should be exercised when comparing results of different study populations. In addition, the study group was relatively small and the confidence intervals wide, suggesting that larger studies comparing combination therapies with statins alone may be warranted. Antioxidants did not provide any additional benefits in this study of secondary prevention (and even appeared to attenuate the positive effects of combination drug therapy), which is consistent with most other clinical trial data. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     ARBITER 6-HALTS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARBITER 6-HALTS was an open label randomized trial comparing extended release niacin (target dose 2000 mg at bedtime) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    (10 mg daily) in patients with CHD or a CHD risk equivalent who were on statin therapy and had an LDL-C below 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and an HDL-C below 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for men or 55",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/112\">",
"     112",
"    </a>",
"    ]. The primary endpoint was change in carotid intima media thickness (CIMT).",
"   </p>",
"   <p>",
"    LDL-C was reduced less by niacin than by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    (- 10.0 versus -17.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [-0.3 versus -0.5",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    while HDL-C was raised by niacin and reduced by ezetimibe (+7.5 versus -2.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [+0.2 versus -0.1",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    In 208 patients analyzed for this endpoint, niacin reduced CIMT compared with ezetimibe at both 8 and 14 months; the trial was stopped early based on this primary endpoint, an unusual decision given that the endpoint was not a clinical one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/113,114\">",
"     113,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There were fewer composite cardiovascular events (myocardial infarction, myocardial revascularization, acute coronary syndrome, death from CHD) in patients treated with niacin (2 of 160 versus 9 of 165; 1 versus 5 percent, p = 0.04). There was one death in the niacin arm and five deaths in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    arm.",
"   </p>",
"   <p>",
"    More patients treated with niacin withdrew from the study, withdrew for adverse effects (17 versus 3), and were less adherent to medication; flushing was reported by 36 percent of patients taking niacin.",
"   </p>",
"   <p>",
"    This trial called into question the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    and appeared to raise the likelihood that combination therapy with a statin plus niacin might improve outcomes compared with a statin alone. However, as discussed below, the AIM-TRIAL found no benefit of adding niacin to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    in a similar population (see",
"    <a class=\"local\" href=\"#H708622578\">",
"     'AIM-HIGH trial'",
"    </a>",
"    below). The lack of benefit in AIM-HIGH increases concerns that adding niacin to a statin may not improve outcomes and that one possible explanation for the results seen in ARBITER 6-HALTS could be that adding ezetimibe to a statin might actually worsen outcomes. Further trials of combination therapy with ezetimibe are underway that should also help clarify these issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H708622578\">",
"    <span class=\"h3\">",
"     AIM-HIGH trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIM-HIGH was a randomized trial comparing-extended release niacin (target dose 2000 mg per day) with placebo (100 to 200 mg of immediate release niacin) in 3414 patients with cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/115\">",
"     115",
"    </a>",
"    ]. All patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    40 to 80 mg daily with a goal of maintaining an LDL-C of 40 to 80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.03 to 2.07",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    10 mg daily could also be added if needed to achieve this goal. The primary endpoint was a composite of death from CHD, nonfatal MI, ischemic stroke, hospitalization for an acute coronary syndrome, and symptom driven coronary or cerebral revascularization.",
"   </p>",
"   <p>",
"    The trial was stopped early for futility after a mean follow-up of three years. At two years, treatment with niacin increased levels of HDL-C (25.0 versus 9.8 percent) and lowered levels of triglycerides (-28.6 versus -8.1 percent) and LDL-C (-12.0 versus -5.5 percent).",
"   </p>",
"   <p>",
"    There was no reduction in the rate of the primary endpoint with niacin (16.4 versus 16.2 percent, hazard ratio [HR] 1.02, 95% CI 0.87-1.21) or in all-cause mortality (5.6 versus 4.8 percent, HR 1.16, CI 0.87-1.56). There was a trend toward more ischemic strokes in the niacin group, which contributed to the decision to stop the trial early.",
"   </p>",
"   <p>",
"    More patients in the placebo arm received the higher 80 mg dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (24.7 versus 17.5 percent) and more were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    (21.5 versus 9.5 percent). This could have affected the study results, although neither high-dose simvastatin nor ezetimibe has been shown to add clinical benefit in similar populations, compared with moderate-dose simvastatin. Additionally, the elevation in HDL-C levels in the &ldquo;placebo&rdquo; arm (which received low dose niacin) was greater than expected and may have reduced the ability of the trial to detect a real benefit with niacin therapy. As discussed above, this trial may contribute to our understanding of the ARBITER 6-HALTS trial. (See",
"    <a class=\"local\" href=\"#H45\">",
"     'ARBITER 6-HALTS trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Patients with saphenous vein grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to beneficial effects in native vessels, lipid lowering also appears to be protective in saphenous vein grafts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Post Coronary Artery Bypass Graft Trial evaluated 1351 patients with LDL cholesterol levels between 130 and 175",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4 to 4.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and at least one patent vein graft documented on angiography performed one to 11 years after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/116\">",
"     116",
"    </a>",
"    ]. Patients were randomly assigned to receive aggressive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    and if needed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    to reduce LDL cholesterol to less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or moderate therapy which resulted in levels of approximately 134",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Patients also were randomly assigned to therapy with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (INR = 1.4) or placebo. Angiography was repeated an average of 4.3 years.",
"   </p>",
"   <p>",
"    The following benefits were noted with aggressive compared to moderate therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower percentage of grafts showing progression of atherosclerosis (27 versus 39 percent).",
"     </li>",
"     <li>",
"      A lower rate of revascularization (CABG or PTCA) (6.5 versus 9.2 percent).",
"     </li>",
"     <li>",
"      Less progression of atherosclerosis in the native left main coronary artery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/117\">",
"       117",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were no significant differences in cardiovascular outcomes among treatment groups. However, clinical outcomes were evaluated after a follow-up of 7.5 years; compared to moderate therapy, aggressive therapy was associated with a 30 percent reduction in revascularization procedures and 24 percent reduction in the composite end point of cardiovascular death, MI, stroke, CABG, or angioplasty (",
"    <a class=\"graphic graphic_figure graphicRef74401 \" href=\"mobipreview.htm?21/39/22142\">",
"     figure 21",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    had no effect on disease progression. However, during the extended 7.5 year follow-up, warfarin reduced deaths by 35 percent; deaths or MI by 31 percent; and the composite clinical end point of death, MI, stroke, CABG, or angioplasty by 17 percent when compared to placebo (",
"    <a class=\"graphic graphic_figure graphicRef60976 \" href=\"mobipreview.htm?17/58/18350\">",
"     figure 22",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isolated low HDL levels is also a risk factor for the development of coronary artery disease and may contribute to the development of vein graft disease. One study, LOCAT (Lopid Coronary Angiography Trial), randomized 395 post CABG patients with LDL cholesterol &le;175",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and HDL cholesterol concentration &le;42",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    (1200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/119\">",
"     119",
"    </a>",
"    ]. After an average of 32 months, patients receiving gemfibrozil had a slower rate of progression of native coronary artery atherosclerosis and a lower incidence of new lesions in the vein grafts (2 versus 14 percent) compared to the control group. Triglyceride rich lipoproteins, especially VLDL and intermediate density lipoproteins, were most predictive of new lesions in vein grafts; HDL3, but not HDL2, cholesterol was associated with protection against progression, especially disease in native coronary arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/120\">",
"     120",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Restenosis after angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the beneficial effect in atherosclerosis, there appears to be no role for lipid lowering with statins in the prevention of restenosis after angioplasty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/121\">",
"     121",
"    </a>",
"    ]. A possible exception is probucol, a modestly active lipid lowering agent that has antioxidant activity. Data from two studies suggest that probucol may reduce the incidence of restenosis. However, restenosis is now a much less frequent problem with the use of drug-eluting stents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Reduction in stroke and treatment after stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from early clinical trials suggested that lowering cholesterol did not reduce the risk of stroke; however, these studies did not involve the use of statins. A meta-analysis of trials using fibrates, resins, or diet for lipid lowering also showed no reduction in stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meta-analyses have been published of trials in which statins were given for primary or secondary prevention of coronary heart disease and data were reported on the incidence of fatal and nonfatal strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/93,122-124\">",
"     93,122-124",
"    </a>",
"    ]. Statin therapy was associated with a reduction in stroke; this benefit was mainly seen in the secondary prevention trials with no significant difference in the trials of primary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/123\">",
"     123",
"    </a>",
"    ]. Furthermore, the Heart Protection Study found a significant and substantial reduction in ischemic stroke with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    therapy (4.3 versus 5.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/78\">",
"     78",
"    </a>",
"    ]. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link&amp;anchor=H10#H10\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Dyslipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The SPARCL study (below) examined affects on cardiovascular outcomes in patients with a recent stroke or transient ischemic attack. Symptomatic carotid artery disease is a coronary risk equivalent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     SPARCL study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) study randomly assigned 4731 patients who had had a stroke or transient ischemic attack (TIA) within one to six months to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg daily or placebo. Patients were required to have no known CHD and to have a baseline LDL-C of 100 to 190",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6 to 4.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/125\">",
"     125",
"    </a>",
"    ]. Patients were excluded if they had a potential cardioembolic source of stroke (particularly atrial fibrillation). The primary endpoint was fatal and nonfatal stroke.",
"   </p>",
"   <p>",
"    After a median follow-up of 4.9 years, patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    had fewer strokes (11.2 versus 13.1 percent, adjusted hazard ratio [HR] 0.84, 95% CI 0.71-0.99). Patients also had a reduction in cardiovascular events (22.4 versus 29 percent, HR 0.74), and a statistically nonsignificant reduction in cardiovascular death (3.3 versus 4.1 percent, HR 0.78, CI 0.58-1.06), but there was no reduction in all-cause mortality (9.1 versus 8.9 percent, HR 1.00, CI 0.82-1.21).",
"   </p>",
"   <p>",
"    A post hoc analysis suggested that patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    had a reduced risk of ischemic stroke but an increased risk of hemorrhagic stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link&amp;anchor=H10#H10\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Dyslipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Lipid lowering versus coronary intervention",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9381721\">",
"    <span class=\"h3\">",
"     AVERT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AVERT (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     Atorvastatin",
"    </a>",
"    Versus Revascularization Treatment) trial compared the outcome of aggressive lipid-lowering with atorvastatin (80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to that of angioplasty in 341 patients with 1 or 2 vessel coronary artery disease and LDL-C levels &gt;115",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/126\">",
"     126",
"    </a>",
"    ]. After an 18 month follow-up, the reduction in mean LDL-C levels was greater in the atorvastatin group (140 to 77",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    versus 140 to 119",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in the angioplasty group). &nbsp;Patients treated with atorvastatin had a trend toward fewer composite endpoints (death, myocardial infarction, stroke, resuscitated cardiac arrest, revascularization, and hospitalization for worsening angina, 13 versus 21 percent for angioplasty), however this was not statistically significant; the atorvastatin group had a lower rate of bypass surgery (1.2 versus 5.1 percent) and hospitalization for worsening angina (6.7 versus 14.1 percent), and a significantly longer time to first ischemic event (",
"    <a class=\"graphic graphic_figure graphicRef61804 \" href=\"mobipreview.htm?24/55/25469\">",
"     figure 23",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Ischemic heart failure",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h3\">",
"     CORONA trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CORONA (Controlled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     Rosuvastatin",
"    </a>",
"    Multinational Trial in Heart Failure) trial compared rosuvastatin 10 mg daily with placebo in 5011 patients ages 60 and older with New York Heart Association class II, III, or IV ischemic systolic heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/38/43626/abstract/127\">",
"     127",
"    </a>",
"    ]. The primary composite outcome was death from cardiovascular causes, nonfatal MI, or nonfatal stroke.",
"   </p>",
"   <p>",
"    Compared with placebo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    reduced LDL levels (76 versus 138",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.96 versus 3.57",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    and also had beneficial effects on HDL-C and triglycerides. Despite this, no significant reduction was seen in the primary composite outcome (hazard ratio [HR] 0.92, 95% CI 0.83-1.02), coronary events (HR 0.92), cardiovascular mortality (HR 0.97) or all-cause mortality (HR 0.95).",
"   </p>",
"   <p>",
"    These results are surprising, since benefits would have been expected, particularly in the rates of coronary events. The explanation for the lack of benefit is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529651390\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of cholesterol lowering therapy have addressed both primary and secondary prevention. The results of trials that looked mainly at patients with known coronary heart disease (CHD) or coronary risk equivalents are addressed here. Clinical trials that looked mainly at patients without known CHD or coronary risk equivalents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary risk equivalents include (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Symptomatic carotid artery disease",
"     </li>",
"     <li>",
"      Peripheral artery disease",
"     </li>",
"     <li>",
"      Abdominal aortic aneurysm",
"     </li>",
"     <li>",
"      Chronic kidney disease",
"     </li>",
"     <li>",
"      Multiple risk factors that confer a 10-year risk of CHD &gt;20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical management of lipids in primary and secondary prevention is discussed in detail separately:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/1\">",
"      Ballantyne CM, Grundy SM, Oberman A, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 2000; 85:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/2\">",
"      Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/3\">",
"      Rosengren A, Hagman M, Wedel H, Wilhelmsen L. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in G&ouml;teborg, Sweden. Eur Heart J 1997; 18:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/4\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/5\">",
"      Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. N Engl J Med 1985; 312:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/6\">",
"      Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/7\">",
"      de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/8\">",
"      Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/9\">",
"      Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992; 86:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/10\">",
"      Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998; 280:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/11\">",
"      De Lorgeril M, Salen P, Martin JL, et al. Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments. J Am Coll Cardiol 1996; 28:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/12\">",
"      de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/13\">",
"      Kris-Etherton P, Eckel RH, Howard BV, et al. AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. Circulation 2001; 103:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/14\">",
"      Salonen R, Nyss&ouml;nen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995; 76:34C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/15\">",
"      Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/16\">",
"      Aengevaeren WR, Uijen GJ, Jukema JW, et al. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1997; 96:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/17\">",
"      Pitt B, Mancini GB, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995; 26:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/18\">",
"      Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/19\">",
"      Furberg CD, Byington RP, Crouse JR, Espeland MA. Pravastatin, lipids, and major coronary events. Am J Cardiol 1994; 73:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/20\">",
"      Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/21\">",
"      Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264:3013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/22\">",
"      Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996; 93:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/23\">",
"      Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/24\">",
"      Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91:2528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/25\">",
"      van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation 1996; 94:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/26\">",
"      de Groot E, Jukema JW, Montauban van Swijndregt AD, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998; 31:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/27\">",
"      Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/28\">",
"      Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/29\">",
"      Ericsson CG, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/30\">",
"      Ericsson CG, Nilsson J, Grip L, et al. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 1997; 80:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/31\">",
"      Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998; 32:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/32\">",
"      Ruotolo G, B&aring;venholm P, Brismar K, et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 2000; 35:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/33\">",
"      Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001; 104:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/34\">",
"      Sacks FM, Pasternak RC, Gibson CM, et al. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet 1994; 344:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/35\">",
"      Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/36\">",
"      Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/37\">",
"      Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/38\">",
"      Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/39\">",
"      Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/40\">",
"      Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009; 54:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/41\">",
"      Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/42\">",
"      Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/43\">",
"      Allen Maycock CA, Muhlestein JB, Horne BD, et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 2002; 40:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/44\">",
"      Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/45\">",
"      Salonen R, Nyyss&ouml;nen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/46\">",
"      Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/47\">",
"      Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 2000; 86:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/48\">",
"      Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/49\">",
"      Otterstad JE, Sleight P. The HOPE study: comparison with other trials of secondary prevention. Eur Heart J 2001; 22:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/50\">",
"      Pedersen TR, Kjekshus J, Py&ouml;r&auml;l&auml; K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/51\">",
"      Wilhelmsen L, Py&ouml;r&auml;l&auml; K, Wedel H, et al. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 2001; 22:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/52\">",
"      Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/53\">",
"      Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/54\">",
"      Miettinen TA, Py&ouml;r&auml;l&auml; K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96:4211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/55\">",
"      Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994; 308:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/56\">",
"      Ryman A. Cholesterol, violent death, and mental disorder. BMJ 1994; 309:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/57\">",
"      Strandberg TE, Py&ouml;r&auml;l&auml; K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/58\">",
"      Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/59\">",
"      Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002; 105:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/60\">",
"      Tonkin AM, Colquhoun D, Emberson J, et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet 2000; 356:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/61\">",
"      Marschner IC, Colquhoun D, Simes RJ, et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. J Am Coll Cardiol 2001; 38:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/62\">",
"      Colquhoun D, Keech A, Hunt D, et al. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Eur Heart J 2004; 25:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/63\">",
"      LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/64\">",
"      Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147:1.",
"     </a>",
"    </li>",
"    <li>",
"     Wenger, NK. Personal communication (July 9, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/66\">",
"      Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/67\">",
"      Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/68\">",
"      Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/69\">",
"      Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/70\">",
"      Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999; 99:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/71\">",
"      Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol 1999; 34:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/72\">",
"      Sacks FM, Moy&eacute; LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/73\">",
"      Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/74\">",
"      Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/75\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/76\">",
"      Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001; 141:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/77\">",
"      LaRosa JC. Prevention and treatment of coronary heart disease: who benefits? Circulation 2001; 104:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/78\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/79\">",
"      Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/80\">",
"      Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/81\">",
"      Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med 2005; 3:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/82\">",
"      Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 2011; 377:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/83\">",
"      Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/84\">",
"      Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/85\">",
"      ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/86\">",
"      ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/87\">",
"      Chew EY, Ambrosius WT, Danis RP. Retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/88\">",
"      Rind DM. Retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/89\">",
"      Chew EY, Ambrosius WT. Update of the ACCORD Eye Study. N Engl J Med 2011; 364:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/90\">",
"      Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/91\">",
"      Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/92\">",
"      Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/93\">",
"      Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/94\">",
"      Marchioli R, Marfisi RM, Carinci F, Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med 1996; 156:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/95\">",
"      LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/96\">",
"      Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000; 102:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/97\">",
"      Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J 2002; 23:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/98\">",
"      Stenestrand U, Wallentin L, Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/99\">",
"      Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002; 287:3087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/100\">",
"      Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000; 86:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/101\">",
"      Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006; 295:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/102\">",
"      Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/103\">",
"      Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/104\">",
"      Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/105\">",
"      Liem AH, van Boven AJ, Veeger NJ, et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002; 23:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/106\">",
"      Thompson PL, Meredith I, Amerena J, et al. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J 2004; 148:e2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/107\">",
"      de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/108\">",
"      Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/109\">",
"      Bloomfield Rubins H, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001; 103:2828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/110\">",
"      Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005; 142:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/111\">",
"      Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/112\">",
"      Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/113\">",
"      Blumenthal RS, Michos ED. The HALTS trial--halting atherosclerosis or halted too early? N Engl J Med 2009; 361:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/114\">",
"      Kastelein JJ, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med 2009; 361:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/115\">",
"      AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/116\">",
"      The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997; 336:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/117\">",
"      White CW, Gobel FL, Campeau L, et al. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation 2001; 104:2660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/118\">",
"      Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000; 102:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/119\">",
"      Frick MH, Syv&auml;nne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997; 96:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/120\">",
"      Syv&auml;nne M, Nieminen MS, Frick MH, et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998; 98:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/121\">",
"      Boccuzzi SJ, Weintraub WS, Kosinski AS, et al. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). Am J Cardiol 1998; 81:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/122\">",
"      Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 1998; 128:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/123\">",
"      Crouse JR 3rd, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/124\">",
"      Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/125\">",
"      Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/126\">",
"      Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/38/43626/abstract/127\">",
"      Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357:2248.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4559 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43626=[""].join("\n");
var outline_f42_38_43626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H529651390\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIFESTYLE MODIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanisms of improvement with lipid lowering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Improvement in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - CLAS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - FATS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - REGRESS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - LCAS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - BECAIT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - GAIN trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - HARP and SCAT trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - REVERSAL trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - ARBITER 2 study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - ASTEROID trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Oxford Niaspan study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H648157811\">",
"      - SATURN trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Improvement in clinical outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - 4S trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - LIPID trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - TNT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - IDEAL trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H719305722\">",
"      - SEARCH trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - BIP trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Patients with borderline high serum cholesterol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - CARE trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Other trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Cost effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Primary and combined primary and secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Heart Protection Study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - CARDS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - FIELD trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - ACCORD Lipid trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - ASPEN trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - MEGA trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Early use of statins after an ACS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - MIRACL trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - PROVE IT-TIMI 22 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - FLORIDA trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - PACT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Phase Z of the A to Z trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Patients with low LDL and low HDL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - VA-HIT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - AFREGS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - HATS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - ARBITER 6-HALTS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H708622578\">",
"      - AIM-HIGH trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Patients with saphenous vein grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Restenosis after angioplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Reduction in stroke and treatment after stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - SPARCL study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Lipid lowering versus coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9381721\">",
"      - AVERT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Ischemic heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      - CORONA trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H529651390\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4559\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4559|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/19/34109\" title=\"figure 1\">",
"      Plasma cholesterol and cardiovascular mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/27/10686\" title=\"figure 2\">",
"      Mediterranean diet and CAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/57/20381\" title=\"figure 3\">",
"      Pravastatin improves CHD risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/16/22798\" title=\"figure 4\">",
"      Regression CAD chol lowering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/22/17773\" title=\"figure 5\">",
"      Fluvastatin CHD progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/45/41693\" title=\"figure 6\">",
"      Fluvastatin event free survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/55/19325\" title=\"figure 7\">",
"      Simvastatin and CHD mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/34/25134\" title=\"figure 8\">",
"      Simvastatin major cardiac event",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40814\" title=\"figure 9\">",
"      Simvastatin and atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/14/36077\" title=\"figure 10\">",
"      Pravastatin cardiac mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/8/22669\" title=\"figure 11\">",
"      Bezafibrate high triglyceride",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/30/24045\" title=\"figure 12\">",
"      Pravastatin CARE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/8/28814\" title=\"figure 13\">",
"      Pravastatin events post revasc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/35/16958\" title=\"figure 14\">",
"      LDL reduction and events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/54/11118\" title=\"figure 15\">",
"      Pravastatin and MACE rates in men versus women CARE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/44/14030\" title=\"figure 16\">",
"      Statin benefits in HPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/28/6592\" title=\"figure 17\">",
"      Statin benefits by tertile HPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/47/36592\" title=\"figure 18\">",
"      HPS all-cause mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/24/43407\" title=\"figure 19\">",
"      Statin benefits by other Rx HPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/52/40781\" title=\"figure 20\">",
"      Gemfibrozil events low HDL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/39/22142\" title=\"figure 21\">",
"      Lipid lowering improves outcome after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/58/18350\" title=\"figure 22\">",
"      Low dose warfarin after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/55/25469\" title=\"figure 23\">",
"      Atorvastatin vs PTCA ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4559|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/20/333\" title=\"table 1\">",
"      Regression of atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/10/36012\" title=\"table 2\">",
"      CHD benefit of lipid lowering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/49/15131\" title=\"table 3\">",
"      PROVE IT prim endpoint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33656?source=related_link\">",
"      Cholesterol lowering after an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11258?source=related_link\">",
"      Management of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10760?source=related_link\">",
"      Treatment of dyslipidemia in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_38_43627="Dissociative PTSD vs hyperaroused PTSD";
var content_f42_38_43627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F59632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F59632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Typical differences between dissociative PTSD and hyperaroused PTSD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dissociative subtype of PTSD",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hyperaroused PTSD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etiology",
"       </td>",
"       <td>",
"        Likely to be more severe, chronic, repeated, usually childhood and adult trauma",
"       </td>",
"       <td>",
"        Likely to be later-occurring trauma and/or less cumulative trauma",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Likely response when presented with traumatic narrative or triggers",
"       </td>",
"       <td>",
"        Dissociation, numbing",
"       </td>",
"       <td>",
"        Terror",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased, blunted autonomic arousal",
"       </td>",
"       <td>",
"        Increased autonomic arousal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased heart rate",
"       </td>",
"       <td>",
"        Increased heart rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortisol release is delayed",
"       </td>",
"       <td>",
"        Rapidly increased cortisol level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased skin conductance",
"       </td>",
"       <td>",
"        Increased skin conductance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain areas activated that may over-control emotion and alter sense of self (eg, MPFC)",
"       </td>",
"       <td>",
"        Brain areas activated that may under-control emotion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PTSD: posttraumatic stress disorder; MPFC: medial prefrontal cortex.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Vermetten E, Dorahy MJ, Spiegel D. Traumatic Dissociation Neurobiology and Treatment, American Psychiatric Press, Washington DC, 2007.",
"       </li>",
"       <li>",
"        Brand B, Loewenstein RJ. Dissociative disorders: An overview of assessment, phenomenology and treatment, Psychiatric Times, 2010.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43627=[""].join("\n");
var outline_f42_38_43627=null;
var title_f42_38_43628="WHO pulmonary hypertension";
var content_f42_38_43628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical classification of pulmonary hypertension (Dana Point, 2008)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       1. Pulmonary arterial hypertension (PAH)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1.1. Idiopathic PAH",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1.2. Heritable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1.2.1. BMPR2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1.2.3. Unknown",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1.3. Drug- and toxin-induced",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1.4. Associated with",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1.4.1. Connective tissue diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1.4.2. HIV infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1.4.3. Portal hypertension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1.4.4. Congenital heart diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1.4.5. Schistosomiasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1.4.6. Chronic hemolytic anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1.5 Persistent pulmonary hypertension of the newborn",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1&prime;. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Pulmonary hypertension owing to left heart disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2.1. Systolic dysfunction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2.2. Diastolic dysfunction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2.3. Valvular disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Pulmonary hypertension owing to lung diseases and/or hypoxia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3.1. Chronic obstructive pulmonary disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3.2. Interstitial lung disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3.4. Sleep-disordered breathing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3.5. Alveolar hypoventilation disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3.6. Chronic exposure to high altitude",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3.7. Developmental abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Chronic thromboembolic pulmonary hypertension (CTEPH)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Pulmonary hypertension with unclear multifactorial mechanisms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5.1. Hematologic disorders: myeloproliferative disorders, splenectomy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALK1: activin receptor-like kinase type 1; BMPR2: bone morphogenetic protein receptor type 2; HIV: human immunodeficiency virus.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Simonneau, G, Robbins, IM, Beghetti, M, et al. Updated Clinical Classifications of Pulmonary Hypertension. J Am Coll Cardiol 2009; 54:S43. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43628=[""].join("\n");
var outline_f42_38_43628=null;
var title_f42_38_43629="Sudden weakness in children";
var content_f42_38_43629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Muscle weakness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 288px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SAH: subarachnoid hemorrhage; EDH: epidural hematoma; SDH: subdural hematoma.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Tsarouhas N, Decker JM. Weakness. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43629=[""].join("\n");
var outline_f42_38_43629=null;
var title_f42_38_43630="NE and survival ValHeFT";
var content_f42_38_43630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Plasma NE concentration predicts survival in patients with HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 405px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In an analysis from the Val-HeFT trial, patients with NYHA class II to III heart failure (HF) were stratified according to quartiles of plasma concentration of norepinephrine (NE). The mortality rates at two years after randomization were significantly higher in higher quartiles of plasma NE.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Anand IS, Fisher LD, Chiang YT, et al. Circulation 2003; 107:1278.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43630=[""].join("\n");
var outline_f42_38_43630=null;
var title_f42_38_43631="Prevention of dog ear deformity";
var content_f42_38_43631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Prevention of dog ear deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The obese or large breasted patient will often have redundant tissue, which can result in an unsightly and uncomfortable \"dog-ear\" deformity at the axillary end of the incision. A \"Y\" shaped incision can be used to excise excess skin and avoid this deformity. Instead of suturing the full length of the wound, the medial one-half to two-thirds of the wound is first sutured using a subcuticular suturing technique. The lateral tip of the incision is then approximated to the midline of the closure, excess skin is removed, and the final wound will be \"Y\" or \"fish-tail\" shaped with two \"arms\" facing towards the lateral side of the wound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_38_43631=[""].join("\n");
var outline_f42_38_43631=null;
